Experimental DNA vaccine against filariasis by Luo, Honglin
Experimental DNA Vaccine against Filariasis
Honglin Luo
A thesis presented for degree of Doctor of Philosophy













There are lots of people I would like to thank for all the supports that got me through the
most difficult challenge I have faced in my life yet.
First of all I would like to thank David W Taylor for the great guidance, support,
encouragement and effort throughout my study. Special thanks to Judith Allen for the support
and helpful advice. I also like to thank Simon Babayan for all the great help and guidance
during my three years project including the experimental skills, communications, way of
thinking, extraction of ideas, and so on. I would like to say I would not complete my project
on time without your great help, thank you all!
I gratefully acknowledge the financial support of EU (SCOOTT) and China Scholarship
Council.
This thesis would be less concerned without the collaborative and communicative
atmosphere fostered by colleagues in Allen lab as well as Rick Maizles group. Also thank
Mark Blaxter, David Gray, Andrew MacDonald lab for their supports.
I specially thank Dominik Ruckerl, Tara Sutherland, Karen Fairlie-clarke, Steve Jenkins,
Sheelagh Duncan, Nienke van der Werf, Matt, Kathryn Watt, Steve Redpath, Gaby
Lindergard, cellein, James, Janice Murray, Yvonne Harcus for your wonderful advice,
inspiration and circumspect help.
I am particularly grateful to Nick Gray for nice communication, wonderful organization and
great assistance and coordination and to Alison Fulton for providing adequate active
infective larvae.
IV
Thanks to my previous supervisor Weiyi Huang for your encouragement, inspiration and
kindly concern.
I would like to thank my family for endless love and support in China, I would never go
through it without your wholehearted dedication. Especially thank my lovely wife and son
for your encouragement and warm love. Thanks to respectable parents and parents-in law as
well as my sisters and their families- I love you all and this is dedicated to you all.




Filarial infections are major causes of morbidity in the tropics and sub-tropics, afflicting over
150 million people in about 80 countries, causing debilitating symptoms such as elephantiasis
(lymphatic filariasis), dermatitis and blindness (onchocerciasis or river blindness). Current
control of lymphatic filariais relies on mass drug treatment with diethylcarbamazine（DEC)
and albendazole while ivermectin is used against onchocerciasis. Repeat treatment is
frequently required and this highlights the possibility of development of drug resistance. In
addition, risk of adverse reactions following treatment excludes some patients from control
programmes. Such circumstances urgently call for the development of complementary control
measures such as vaccination.
DNA vaccines are novel type of subunit vaccine in which production of the immunizing
antigen is induced in host cells after introduction of a plasmid or recombinant viral vector
containing the gene that encodes the antigen. DNA vaccines are relatively simple and cheap
to produce and their stability makes them particularly suitable for use in remote regions that
lack the cold-chain storage facilities required of conventional vaccines. Filarial nematodes are
tissue-dwelling parasites that survive for many years in immunocompetent hosts. It is
proposed that this longevity is, in part, due to the capacity of the parasites to modulate
potentially lethal Th2 responses of their hosts. Consequently, the efficiency of a filarial
vaccine may depend on how well it circumvents filarial-driven immunosuppression.
To test this hypothesis, a series of DNA vaccines were developed and tested in the
Litomosoides sigmodontis-mouse model of filarial infections. The L. sigmodontis Abundant
Larval Transcript-1 (Ls-ALT) and Cysteine Protease Inhibitor (Ls-CPI) genes were cloned
and genetically engineered to ablate their immunomodulatory properties by deleting the
acid domain and by site mutation, respectively. In addition, the L. sigmodontis Venom
Allergen Homologue (Ls-VAH) and Thioredoxin Peroxidase (Ls-TPX) were used in their
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native forms as vaccine targets. To improve immunisation and antigen processing by the
host, these parasite genes were fused to a DNA sequence encoding an antibody that
specifically binds dendritic cell surface protein (αDEC205 single chain Fv). DNA plasmids
carrying mutated forms and/or anti-DEC205 were then co-administered with plasmids
encoding the Th2 promoting cytokine IL4, and/or antigen-presenting cell activating MIP1
and Flt3L.
Mice immunized with mutated forms (ADDALT and CPImu) of parasite antigens produced
more specific antibody post-challenge and showed strongly increased lymphocyte stimulation
above controls immunized with the native form. The immune response was further enhanced
when plasmids encoding IL4, MIP1, Flt3L and anti-DEC-205 forms were co-administered,
resulting in production of a Th2/IgG1 phenotype. Significant reduction of worm burden
(82.3%) was achieved by a cocktail vaccination which combined the ADDALT and CPImu
candidates. Mice immunized with Ls-VAH and Ls-TPX DNA carried by αDEC205 elicited
Th2-biased responses with up-regulated IgG1 and IgE antibodies as well as enhanced IL5,
IL4, and IL13 and diminished IFNγ production compared to controls. The immune responses 
were further driven towards the Th2/IgG1 phenotype when Ls-VAH and Ls-TPX were
injected with plasmids encoding ADDALT and CPImu and with the adjuvants Flt3L, MIP1
and IL4. This resulted in reduction in worm burden of 55.7% (cocktail vaccine containing




ADCC Antibody-dependent cellular cytotoxicity
ADDALT Acidic domain deleted ALT
AEP Asparaginyl endopeptidase
ALT Abundant Larval Transcript
ANOVA Analysis of variance
APC Antigen-presenting cell
APOC African Programme for Onchocerciasis Control
Asn Asparagine
ASP Ancylostoma secreted protein
Asp Aspartic acid
BLAST Basic local alignment search tool
BSA Bovine serum albumin
cAMP 3'-5'-cyclic adenosine monophosphate
cDNA Complementary deoxyribonucleic acid
CD4 Cluster of differentiation 4
CD8 Cluster of differentiation 8
CPI Cysteine proteases inhibitor
CPImu Mutant of CPI2
CRISP Cysteine rich secretory proteins
CTLA4 Cytotoxic T-lymphocyte antigen 4








EDTA Ethylene Diamine Tetraacetic Acid
ELISA Enzyme linked immuno-sorbent assay
EN Endemic normals
EP Electroporation
FACS Fluorescence-activated cell sorting
FcR Fc receptor
FCS Fetal calf serum
Flt3L Fms-like tyrosine kinase 3-ligand
FOXP3 Forkhead box p3
g gravitational force
GAGA3 GATA-binding factor 3
GITR Glucocorticoid-induced tolerance receptor
GLM Generalised linear models
GM-CSF Granulocyte macrophage colony stimulating factor















IL4R Interleukin 4 receptor alpha
IL2R Interleukin 2 receptor alpha
IL10R Interleukin 10 receptor
IPTG β-D-thiogalactopyranoside
IVC Individually ventilated cages
L3 Third larval stage
L4 Forth larval stage




MHC Major histocompatibility complex
Mins Minutes
MIP1 Macrophage inflammatory protein 1 alpha
MMLV Moloney Murine Leukemia Virus
mRNA Messager RNA
NKT Natural killer T cell
OVA Ovalbumin
OCP Onchocerciasis Control Programme
PAF Platelet activating factor
PBMC Peripheral blood mononuclear cells
PBS Phosphate-buffered saline
PCA Principal component analysis
PCL Pleural cavity lavage





RT-PCR Reverse transcriptase PCR
RUNX Runt-related transcription factor
s. c Subcutaneously
SDS Sodium dodecyl sulfate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
siRNA Small interfering RNA
SOC Super optimal broth with catabolite repression
SOCS1 Suppressor of cytokine signaling 1
SOD Superoxide dismutase
STAT Signal Transducer and Activator of Transcription
TAP Transporter associated with antigen processing
TBE Tris/Borate/EDTA
TBS Tris buffered saline
TE Tris/ EDTA
Th1 T helper cells 1
Th2 T helper cells 2
Th17 T helper cells 17
TGFβ Transforming growth factor beta
TLR Toll like receptor
TNF Tumor necrosis factor-alpha
TPX Thioredoxin peroxidase








CHAPTER 1-INTRODUCTION ........................................................................................................ 1
1.1 FILARIAL DISEASES AND TREATMENT........................................................................... 1
1.2 IMMUNOLOGICAL RESEARCH ON FILARIAL INFECTIONS............................................................ 7
1.3 VACCINATION AND DNA VACCINE ............................................................................................. 18
1.3.1 General vaccination............................................................................................................ 18
1.3.2 Mechanism of DNA vaccine presentation ........................................................................... 21
1.3.3 Roles of dendritic cells (DCs) in DNA-based immune induction........................................ 23
1.3.4 DNA vaccine delivery and electroporation ......................................................................... 25
1.3.5 Enhancement of efficiency of DNA Vaccines....................................................................... 26
1.3.6 Possibility of DNA vaccine research on filariae ................................................................. 29
1.4 VACCINE CANDIDATES OF FILARIAL NEMATODES ..................................................................... 30
1.4.1 Abundant Larval Transcript (ALT) ..................................................................................... 30
1.4.2 Cysteine Proteases and their Inhibitors (CPI) .................................................................... 31
1.4.3 Venom Allergen Homologue (VAH)..................................................................................... 33
1.4.4 Thioredoxin Peroxidase (TPX)............................................................................................ 33
1.5 THE L. SIGMODONTIS/ MICE RESEARCH MODEL ....................................................................... 35
1.6 DESIGNING A DNA VACCINE AGAINST FILARIAE....................................................................... 38
1.7 AIM OF PHD............................................................................................................................... 42
CHAPTER 2-MATERIALS AND METHODS ............................................................................... 43
2.1 MATERIALS................................................................................................................................ 43
2.1.1 Mice .................................................................................................................................... 43
2.1.2 Parasite life cycle maintenance .......................................................................................... 43
2.1.3 Parasite antigens preparation............................................................................................. 43
2.1.4 Buffers, solutions and media............................................................................................... 44
2.1.5 Bacterial host strains and plasmid vectors ......................................................................... 47
2.1.6 Primers for DNA amplification and sequencing ................................................................. 47
2.1.7 Kits...................................................................................................................................... 47
2.2 METHODS................................................................................................................................... 47
2.2.1 Methods of DNA analysis and manipulation....................................................................... 47
2.2.2 Methods for protein analysis............................................................................................... 55
2.2.3 In vitro lymph node cell culture .......................................................................................... 58
2.2.4 Cell proliferation assays ..................................................................................................... 58
2.2.5 Cytospin assay .................................................................................................................... 59
2.2.6 Enzyme linked immuno-sorbent assay (ELISA) .................................................................. 59
2.2.6.1 IgG assay ......................................................................................................................... 59
2.2.6.2 IgE determination ............................................................................................................ 60
2.2.6.3 Cytokine detection............................................................................................................ 60
2.2.7 Immunization and Necropsy................................................................................................ 61
2.2.8 Larval, adult and Microfilariae counting ........................................................................... 61
2.2.9 Flow cytometry ................................................................................................................... 62
2.3 STATISTICAL ANALYSES ............................................................................................................. 62
CHAPTER 3-ENHANCEMENT OF IMMUNOGENICITY AND VACCINE POTENTIAL OF
ALT AND CPI2 VIA MODIFICATION OF GENE STRUCTURE............................................... 64
3.1 INTRODUCTION.......................................................................................................................... 64
3.2 RESULTS..................................................................................................................................... 66
3.2.1 Isolation of ALT and CPI2 genes ........................................................................................ 66
3.2.2 Site-directed mutagenesis of Ls-CPI2 to Ls-CPImu............................................................ 71
3.2.3 Construction of plasmids .................................................................................................... 71
3.2.4 Protein expression in E. coli and purification of recombinant antigen............................... 74
3.2.5 Identification of ALT and CPI2 by Western blotting ........................................................... 76
3.2.6 Protein expression in COS7 cell and identification ............................................................ 76
3.2.7 Tissue distribution of ALT / CPI2 plasmids in mice ............................................................ 77
3.2.8 Stronger antibody responses were induced by DEC-ADDALT compared to control .......... 82
3.2.9 DEC-ADDALT provoked stronger Th2 antibodies.............................................................. 84
3.2.10 DEC-ADDALT elicited Th2-biased cytokines ................................................................... 86
3.2.11 Recruitment of total cells and eosinophils were decreased following vaccination with
DEC-ADDALT ............................................................................................................................. 87
3.2.12 Worm recovery was reduced but protection was not obtained following vaccination with
DEC-ADDALT ............................................................................................................................. 90
3.2.13 Immune responses induced by CPI2 was reversed by CPImu........................................... 90
3.2.14 DEC-CPImu vaccination induced a Th2 bias ................................................................... 93
3.2.15 CPImu restored the responses induced by CPI2 on the proliferation of lymph node cells in
vitro.............................................................................................................................................. 95
3.2.16 Combination of ADDALT and CPImu upregulated the levels of Th2 type antibodies ...... 97
3.2.17 IL5 and IL13 levels increased following combined vaccination ....................................... 99
3.2.18. Eosinophil numbers increased in the pleural cavity following combined immunization 101
3.2.19. Significant reduction of worm burden was achieved by combined vaccination............. 103
3.2.20 Immune determinants of protective immunity ................................................................. 104
3.3 DISCUSSION.............................................................................................................................. 106
3.3.1 Ls-ALT and Ls-CPI2 can be expressed in the adult stage of L. sigmodontis .................... 106
3.3.2 Extensive distribution and long time persistence of foreign DNA in host tissue ............... 107
3.3.3 Removal of immunomodulatory properties of Ls-ALT and Ls-CPI2 results in the
enhancement of immune responses ............................................................................................ 108
3.3.4 DCs are essential to the enhancement of DNA vaccination ............................................... 111
3.3.5 Th2-bias induced by Ls-ADDALT and Ls-CPImu DNA vaccinations................................112
3.3.6 IL10 produced by DNA vaccine did not induce inhibition of Th2-mediated protective
immunity .....................................................................................................................................113
3.3.7 Worm specific IgG1 and neutrophils, macrophages are correlated with worm killing ......113
CHAPTER 4-IMMUNE RESPONSES AGAINST FILARIAL INFECTION WERE
ENHANCED BY SINGLE VAH OR TPX VACCINATION .........................................................117
4.1 INTRODUCTION.........................................................................................................................117
4.2 RESULTS....................................................................................................................................118
4.2.1 Isolation of Ls-VAH and Ls-TPX genes..............................................................................118
4.2.2 Construction of plasmids .................................................................................................. 123
4.2.3 Protein expression in E. coli and purification................................................................... 125
4.2.4 Identification of VAH and TPX by Western blotting.......................................................... 127
4.2.6 Tissue distribution of VAH / TPX plasmids in mice........................................................... 128
4.2.7 Higher levels of Th1 and Th2 antibodies were evoked by DEC-VAH compared to control
................................................................................................................................................... 131
4.2.8 DEC-VAH induced significant quantities of IL 4, IL5 and IL13 in pleural cavity fluid .... 133
4.2.9 Vaccination with DEC-VAH resulted in decreased levels of IFN in the pleural cavity and
decreased IL10 production by lymph nodes............................................................................... 136
4.2.10 Increased Th2 cytokines and IFN were induced with stimulation of Ls-Ag in vitro by
DEC-VAH immunization............................................................................................................ 137
4.2.11 Elevated numbers of eosinophils, but not macrophages and neutrophils, were detected
following vaccination with DEC-VAH ....................................................................................... 139
4.2.12 Vaccination with DEC-VAH resulted in reduced worm burdens ..................................... 141
4.2.13 Th2-dominant antibodies were produced by DEC-TPX vaccination .............................. 142
4.2.14 IL5 and IL13 rather than IL4 in the pleural cavity fluid were enhanced by DEC-TPX
immunization.............................................................................................................................. 144
4.2.15 Increased IFN in the pleural cavity fluid was induced by TPX DNA vaccination......... 145
4.2.16 Levels of IL10 were no difference between primary infections and mice vaccinated with
DEC-TPX................................................................................................................................... 145
4.2.17. Lymph nodes cells produced more IL5, IL13 and IFN than IL4 and IL10 following
stimulation with Ls-Ag in vitro................................................................................................... 146
4.2.18 Lower numbers of eosinophils, macrophages and neutrophils were recruited in the pleural
cavity with DEC-TPX immunization .......................................................................................... 149
4.2.19 Adult worm recovery was significantly decreased in mice vaccinated with DEC-TPX when
compared to a primary infection................................................................................................ 151
4.3 DISCUSSION.............................................................................................................................. 152
4.3.1 Ls-VAH and Ls-TPX as candidates for a filarial DNA vaccine ........................................ 152
4.3.2 Immunization with Ls-VAH and Ls-TPX induces a predominant antibody response ........ 153
4.3.3 Vaccination with Ls-VAH not Ls-TPX induces a Th2-bias in cytokine responses ............. 154
4.3.4 IL10 should be taken into consideration when develop a DNA vaccine ........................... 154
4.3.5 Factors associated with protective responses induced by single DEC-VAH or DEC-TPX
vaccination................................................................................................................................. 155
CHAPTER 5-PARTIAL PROTECTION HAS BEEN ACHIEVED BY ADDALT, CPIMU AND
VAH OR TPX COCKTAIL VACCINATION ................................................................................ 157
5.1 INTRODUCTION........................................................................................................................ 157
5.2 RESULTS................................................................................................................................... 158
5.2.1 Bi- and Tri- rather than Tetra-vaccine induced higher production of IgG1 compared to
backbone plasmid ...................................................................................................................... 158
5.2.2 No significant difference on cytokine production by vaccinations .................................... 161
5.2.3 Significantly higher numbers of eosinophils were recruited in the pleural cavity by Tri- and
Tetra-vaccinations...................................................................................................................... 163
5.2.4 Cocktail vaccines induced significantly higher number of macrophages but not neutrophils
compared to the Single-vaccine ................................................................................................. 163
5.2.5 Significant reduction of worm burden but not microfilariae numbers was achieved by the
Tri-vaccine immunization........................................................................................................... 165
5.2.6 Both Tri-VAH and Tri-TPX induced protective responses................................................. 166
5.3 DISCUSSION.............................................................................................................................. 171
5.3.1 Cocktail vaccination is a promising approach for a more efficacious vaccine against
filarial infection ......................................................................................................................... 171
5.3.2 Ratio and quantity of components in cocktail vaccine may impact protective responses . 172
5.3.3 Cytokine production of cocktail vaccination..................................................................... 173
CHAPTER 6- GENERAL DISCUSSION ...................................................................................... 174
6.1 SUMMARY OF EXPERIMENTAL RESULTS .................................................................................. 174
6.2 DISCUSSION.............................................................................................................................. 175





1.1 Filarial diseases and treatment
Filariasis is the name given to a number of parasitic infections caused by filarial nematodes
belong to the superfamily Filaroidia (Anderson RM, and May RM, 1992; Thomas BN, 2000).
Eight filarial nematodes commonly infect humans (Table 1.1), cause a wide range of
pathologies and can be generally classified into three groups: lymphatic filariasis,
subcutaneous filariasis, and serous cavity filariasis.
Lymphatic filariasis is associated with the lymphatic system in which adult worms live and
their physical obstruction of lymph flow can induce elephantiasis. The three principle species
responsible for this disease are Wuchereria bancrofti, Brugia malayi and Brugia timori.
Subcutaneous filariasis is associated with three major parasites: Loa loa, Mansonella
streptocerca and Onchocerca volvulus. Adult worms of these species live the subcutaneous
tissue of the skin. Serous cavity filariasis is caused by the worms of Mansonella perstans and
Mansonella ozzardi. Their adult worms live in body cavities and can cause angioedema,
pruritus, fever and serous cavities pain. All worms above distribute widely over the world
and they can cause severe diseases in humans and animals (Table 1.1).
The most common human filariasises are lymphatic filariasis and onchocerciasis. They have
similar life cycles, which consist of five developmental stages (L1, L2, L3, L4 and adult).
After the male and female worms mate, the female gives birth to L1 (normally called
microfilariae, Mf), which are ingested by the vector (mosquitoes in lymphatic filariasis;
Simulium. spp in onchocerciasis) during a blood meal. The Mf moult and develop into the L2
and then L3 (infective) in the vector. The vector transmits the iL3 into the dermis layer of the
skin. After about one year of development in the host, the larvae moult through two more
stages and mature into adult to complete the full life cycle (Fig 1.1).
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In the filaria life cycle, the infective larva (iL3) is a vulnerable stage of the parasite in the
mammalian host in light of its size as well as biological requirements. It moults within about
7-10 days into L4. The potential of L3 larvae on induction of protective immunity against L3
challenge has been studied in both experimental and human filariasis. L3s have been found
to secrete some important antigens which can elicit immune responses (Bleiss W et al. , 2002;
Day KP et al , 1991b; Devaney E, Osborne J, 2000; Eisenbeiss WF et al., 1994; King CL,
Nutman TB, 1991; Rajan TV et al., 2002). However, targeting of other stages should not be
neglected in the understanding of antifilarial immunity. Distinct reactivities against adult
male worm antigens have also been identified in endemic normal humans (Turaga PS et al.,
2000), and it had been shown that putative immune responses could also be induced by Mf
(Boussinesq M, 1991).
Filarial diseases have major social and economic impacts. In lymphatic filariasis, W.
bancrofti counts for about 90% of about 120 million worldwide and B. malayi accounts for
the rest and is mainly distributed in Southeast Asia. B. timori is found only in southeastern
Indonesia. Onchocerciasis also affects widely and cause serious disease. It affects about 37
million people in 34 countries and is abundant in Africa, although there is small population
in southern and Central America and the Yemen. (Addiss, 1998; Richards FO et al., 1998;
Saeftel M et al., 2003).
Current control strategies mainly rely on mass drug treatment and a great deal of large scale
international initiatives have been launched by WHO and the World Bank and supported by
various charities with the goal of global elimination of filarial infections. These include:
Global Alliance to Eliminate Lymphatic Filariasis (GAELF, http://www.filariasis.org/);
Onchocerciasis Control Programme (OCP, ended in 2002,
http://www.who.int/blindness/partnerships/onchocerciasis_OCP/en/); African Programme for
Onchocerciasis Control (APOC, http://www.who.int/blindness/partnerships/APOC/en/), and
Onchocerciasis Elimination Program for Americas (OEPA,
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http://www.who.int/blindness/partnerships/onchocerciasis_oepa/en/). These programmes rely
on a very limited number of drugs comprising diethylcarbamazine（DEC), albendazole and
ivermectin.
In the case of lymphatic filariasis in Africa, ivermectin in combination with albendazole are
used to control disease, while outside Africa it is a combination of DEC and albendazole
(Table 1.2). DEC (6 mg/kg) kills adult worms while the combination with albendazole
(400mg) likely to reduce the number of circulating Mf than DEC alone for longer periods.
However, DEC cannot be used in Africa where is onchocerciasis co-endemic because of the
risk of severe adverse reactions resulting from rapid death of great numbers of Mf in the skin
and eyes inducing systemic inflammation that likely to be related to the release of Wolbachia
(Cross HF et al., 2001; Keiser PB et al., 2002).
For control of onchocerciasis, annual or bi-annual treatment with ivermectin is under-use.
Ivermectin kills Mf, however prolonged use can decrease fecundity despite adult worms are
not killed (Basáñez MG et al., 2008). However, in areas of Africa where the eye worm L. loa
and O. volvulus is co-endemic, ivermectin cannot be used because of the risk of adverse
reactions associated with death of L. loa Mf in and consequential neurological sequelae
(Gardon J et al., 1997; Twum-Danso NA, 2003). Furthermore, there is evidence of
emergence of filarial resistance to ivermectin in humans and animals (Osei-Atweneboana
MY et al., 2007). These constraints accelerated the search for new antifilarial drugs. In this
regard, the observations that many filarial nematodes including Brugia. pahangi, Dirofilaria.
immitis, B. malayi, W. bancrofti and O. volvulus are the hosts of the endosymbiont bacteria of
Wolbachia (Table1. 3, Bandi C et al., 1999; Hoerauf A et al., 2001; Townson S et al., 2000;
Rao R, 2002; Smith HL, 2000) provide us considerable prospects for alternate therapy
through the use of antibiotics which target Wolbachia. This method may result in the adult
worms and / or Mf killings. A study by Langworthy NG (2000) showed that oxytetracycline
is macrofilaricidal effective for O. ochengi. Turner JD et al (2010) showed doxycycline
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treatment was well tolerated by the onchocerciasis individuals. Similar results have been
described by Hoerauf A et al (2000, 2001).
However, tetracyclines cannot be used on pregnant women or children who are below the
age of 9 (Hoerauf A et al., 2008). These constraints leave a proportion of subjects living in
onchocerciasis endemic regions at risk from infection with O. volvulus. Such circumstances
urgently need development of complementary measures to control filarial diseases. Taking
together, these observations highlight the need of a safe and effective vaccine to prevent
filariasis.
Fig. 1.1 Life cycle of filariae (Cited from http:// www. dpd. cdc. gov/dpdx)
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Table 1.2 Recommended treatment strategies for mass drug administration (MDA),





























Hydrocoele: doxycyline 200 mg
per day, 6 weeks;
Tropical pulmonary
eosinophilia: doxycyline 200
mg per day, 4 weeks plus
ivermectin, 150g/kg twice a
year; Onchocerciasis:
Ivermectin, 150g/kg twice a
year until transmission stops;
doxycyline 200 mg per day, 4
weeks plus ivermectin,
150g/kg twice a year
Table 1.3 Distribution of Wolbachia spp in filarial and other nematodes
Nematodes with Wolbachia spp
(Taylor MJ, Hoerauf A 1999; Taylor MJ
et al., 2005)
Nematodes without Wolbachia spp
(Bordenstein SR et al., 2003; Duron O,
Gavotte L. 2007; McNulty SN et al., 2010 )
B. malayi Onchocerca flexuosa
Wu. bancrofti Setaria equine
O. volvulus Acanthocheilonema viteae
Onchocerca fasciata Dipetalonema setariosum
B. pahangi Caenorhabditis elegans
Litomosoides sigmodontis L. loa
M. ozzardi
- 7 -
1.2 Immunological research on filarial infections
In the past decades, immunological knowledge of protection against filariasis has been
progressed. This provides clues to develop vaccines which also should be considered with
any pathology associated with infection and the potential risk that this pathology may be
induced by vaccination.
In 1987, Duke described the observation that even in hyper-endemic areas, there were still a
small number of persons (1-5% of the population) who had no clinically and
parasitologically sign of filarial infection (Word Health Organization, 1987), suggesting
protective immunity can be induced following natural exposure. Analysis of Mf prevalence
in Cameroon also revealed that not all persons living in endemic areas were infected with the
filariae (Boussinesq M et al., 1997) (Fig 1.2).
Similar observations were made in cattles with the parasite Onchocerca. ochengi. Tchakouté
VL et al (2006)carried out longitudinal studies under conditions of either natural exposures
or experimental infections in order to find out whether protective immunity against
onchocerciasis exists. Results showed that cattles who were with putative immunity were
less susceptible to heavy field challenge than age matched groups and naïve controls.
Furthermore, melarsomine*-treated and patently infected cattles were fully susceptible. Also
cattles immunized with iL3s were completely protected against experimental challenge, and
this immunization also achieved against the prevention of severe and prolonged field
challenge.
Two early studies of filariasis (Jachowski LA et al., 1951; Leeuwin RS, 1962 ) showed that
many individuals with microfilariamia moved from W. bancrofti endemic areas to
nonendemic areas were never developed to chronic disease afterwards, indicating insistence
might be induced when conditions were changed. Day KP (1991a) proposed a concept of
“endemic normal”to describe the individuals who are Mf and symptoms or history of
disease free despite life-long exposure to infection are processed. In support, Freedman DO
* Melarsomine is an arsenic-based drug that is effective against to microfilariae and adult
heartworms and also can be used to treat some other nematodes.
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et al (1989) identified 7 out of 459 amicrofilaremic adult people as endemic normals who
were living in Mauke, Cool Islands. Furthermore, Steel C et al (1996) provided evidence that
protective immunity to lymphatic filariasis existed and it might be mediated by T cells.
Evidence of protective immunity also comes from onchocerciasis. Ward DJ et al (1988)
described differences of parasite-specific T cell subpopulations between infected and
putative immune individuals. Results demonstrated that these differences might be correlated
with the development and maintainance of protective immunity to O. volvulus infection.
Nutman TB et al (1991) compared antibody specificity in onchocerciasis patients to define
potential antigens of antibody responses using sera from 12 persons without onchocerciasis
and 16 people with O. volvulus infection. They found there were no differences in antigen
recognition using O. volvulus adult antigens between the putative immune individuals and
infected subjects. However, IgG from the putative immune individuals preferentially
recognized 45- to 50-kDa and 22-kDa L3 antigen when O. lienalis L3 antigens were used.
Therefore, based on the evidence from human and cattle studies, protective immune
responses do exist and might be associated with Th2 responses. This is supported by work
with experimental models that demonstrate the Th2 immune responses are dominant during
filarial infections. Early experiments of B. pahangi in cats provided clear evidence of
Fig. 1.2 The Mf prevalence (mean of Mf load per person) examed by Boussinesq in the
community of 25 north Cameroonian villages (Boussinesq M, 1991, 1997) (sample sizes: 19
to 460 per village). The markers correspond to the age- and sex-adjusted Mf prevalence in
the community using the whole sample (sizes:4576 people) as the reference (Figure is










acquired resistance against reinfection with L3s, and this resistance mainly targeted to L3
larvae, with destruction of the majority in 1 day post infection (Denham DA et al., 1983 ),
suggesting protective immune responses can be induced by L3 larvae. Subcutaneous
infection of BALB/c mice with B. pahangi L3 (Osborne J et al., 1996 ) resulted in
production of a strong Th2 response characterized by increased IL4, IL5, and IL10 and
parasite-specific IgG1 and IgE. Similarly, Th2 cytokines IL4, IL5, IL10 and IL13 were
grown up in gerbils after a primary subcutaneous infection with B. pahangi. Also a peak of
peripheral eosinophilia was presented at 4 weeks after infection in these animals (Chirgwin
SR et al., 2005). Osborne J and Devaney E (1998) described that in the draining lymph node
of L3- but not Mf-infected mice IL4 transcription 4 days post infection (p.i) peaked, at this
stage, IL4 was the only detectable cytokine. In contrast, high mRNA levels of IFN were
induced by Mf at day 4 p.i. without production of IL4 or IL10. Bancroft AJ et al (1994)
described a strong Th2 bias protective immune response to a challenge infection was induced
by immunization subcutaneously (s.c.) with iL3s of B. pahangi in BALB/c mice and this
resulted in a 75-100% parasite burden reduction 6 days post challenge. Furthermore,
Paciorkowski N et al (2003) found that B cells in pleural cavity were required for clearance
of primary and challenge infections with B. pahangi L3s and the early productions of
Th2-type cytokines.
Th2 biased immune responses can also be induced in other experimental models. For
example, studies on D. immitis showed that microfilariaemic dogs had high level of IL4 and
IL10 in contrast to their marginal expression in amicrofilariemic dogs. It was also showed
that Mf positive status was associated with high level of IgG1 against worm antigens
(Morchón R et al., 2007 ). Marcos-Atxutegi C et al (2003) showed that the Th2 type
responses provided protection against D. immitis larval challenge. High levels of IFN, IL4,
IgG1 and IgE were produced in BALB/c mice inoculated with soluble antigens from D.
immitis L3s or its adult worms. The cytokine response was similar to other filarial infections,
with responses biased towards Th2. Moreover, Tezuka H et al (2003) evaluated the ability of
a D. immitis protein, which presents as 15-kDa monomer and 30-kDa dimmer, to induce
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Th1/Th2 responses. Results indicated that the monomer rather than the dimer protein had a
greater capability to stimulate IgE and was associated with both B cell activation and IL4
production.
Studies using the L. sigmodontis mouse model provided further evidence that Th2 immune
responses contribute to protection against filarial infection. During chronic and potent
infections of L. sigmodontis, susceptible BALB/c mice showed a strong Th2 response with
high levels of IL4, IL5 and IL10 58 days post infection while in resistant B10.D2 mice had
no none (Maréchal P et al., 1997). Additionally, evidence of eosinophils on killing of
helminths by eosinophil peroxidase (EPO) and major basic protein (MBP) has been shown to
be part of the defense mechanism against filarial nematodes, with support that lack of EPO
or MBP impaired the defense ability against murine filarial infection (Specht S et al., 2006 ).
More evidence of Th2 responses induced by nematode infection comes from work with: 1),
B. malayi in BALB/c mice. For instance, acceleration of live parasites elimination was found
in mice immunized with soluble microfilarial antigens. Results also showed the clearance of
Mf was associated with local eosinophilia and increased serum IgE levels. Th2 cytokines in
response to B. malayi antigens were produced by CD4+ cells from the site of parasite
challenge (Pearlman E et al.,1993). 2), Intestinal Trichinella spiralis and Nippostrongylus
brasiliensis in rodents. Studies have shown that Th2 rather than Th1 responses mediated
resistance to the nematodes. Also Th2 cytokines were associated with worm killing and
specific cellular responses by study using neutralizing antibodies and genetically engineered
mice (Mahida YR, 2003).
Development of Th2 responses may also be a consequence of immunomodulation by the
parasites (Tawill S et al., 2004). For example, Th2 responses in mice could be driven by the
excreted/ secreted antigens from N. brasiliensis without requirement of infection (Holland
MJ et al.,2000). Th2 differentiation could be triggered by the A. viteae secreted
phosphorylcholine-bearing protein ES-62 (Whelan M et al., 2000). Carbohydrates also
mediated the induction of Th2 responses, with the examples of soluble extracts from B.
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malayi and schistosome soluble egg antigen (SEA) (Pearce EJ, MacDonald AS, 2002; Tawill
S et al., 2004). Similarly, proteins such as proteases could also be Th2-trigers (Sokol CL et
al., 2007). According to Lawrence RA et al (1994), Th2 cell differentiation could be driven
by adult females rather than Mf. The Th2-biased responses induced in mice implanted with B.
malayi might be driven by alternatively activated macrophage (Loke P, et al., 2000;
Rodríguez-Sosa M, et al., 2002). Also T h2 responses with the high production of IL4, IL5,
IL6, IL9 and IL13 followed by IgG, IgE could be induced by Eosinophils and mast cells
which are early sources of IL4 (Maizels RM et al., 2004 ).
However, the conventional Th1/Th2 dichotomy does not explain all the clinical and
parasitological manifestations caused by filarial infections. In the case of onchocerciasis, the
asymptomatic individuals harbor abundant Mf in tissue but no overt responses to their
presence (Mackenzie CD et al., 1985). Hyper-responsive individuals with pathology were
classified into another group characterised with Mf-negative (some patients are symptomatic
microfilaridermic) but pathology-positive. In this sense, the presence of Mf appears
necessary for the pathology resulted from the death of Mf in tissue (Connor DH et al., 1985;
Mackenzie CD et al., 1985). In contrast, individuals suffering from severe skin pathology
(Sowda) showed reduced Mf in the skin, increased cell-mediated responses and elevated
IgE and IgG (Brattig NW et al., 1987; Lucius R et al., 1986).
Similar clinical manifestations have also been observed in lymphatic filariasis in humans
(Mahanty S et al., 1996; Ottesen EA et al., 1977; Sasisekhar B et al., 2005; Steel C et al.,
1994) and animal models with the presence of lymphocytes in the bloodstream (Harnett W,
Harnett MM, 2008; Taylor MD et al., 2006). Studies in onchocerciasis have shown that
hypo-responsive individuals have high levels of IgG4, IgE and reduced levels of IFN
whereas hyper-responsive individuals have high levels of IgG1, 2, 3 and elevated IFN,
indicating that more complicated mechanisms apart from both Th1 and Th2 responses may
be involved (King CL et al., 1993; Maizels RM et al., 1995).
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The Th1/Th2 paradigm has been used as a framework of examination of immune responses
in humans and mice for many years, however, criticism for over-simplifying the real
complexity of infections in vivo was rising (Allen JE, Maizels RM, 1997; Maizels RM et
al.,1999) (Table 1.4, Fig. 1.3, 1.4). The discovery of regulatory T cells (Tregs) makes the
picture of immune response much clearer. There are two types of CD4+ Tregs, ‘natural’Tregs
(nTregs) and induced Tregs (iTregs). nTregs develop in the thymus, while iTregs develop
from CD4+ T cells following antigenic stimulation under different circumstances in the
periphery (Workman CJ et al., 2009). There are three Treg phenotypes, Tr1, Th3 and
CD4+CD25+ cells. Tr1 is induced by IL10 (Groux H, 1997; Vieira PL, 2004), while Th3 is
induced by TGF (Weiner HL, 2001). CD4+CD25+ cells (nTregs) were first described by
Sakkguchi in 1995 (Sakaguchi S, 1995) then fork head box p3 (Foxp3) was found to be
expressed by both nTregs and iTregs in humans and mice (Fontenot JD, 2005; Sakaguchi S ,
2004). Although there are many markers of Tregs (Table 1. 5), the Foxp3 is more generally
accepted as the marker of nTreg development and functions even there are reports showed
that not all Foxp3+ human T cells are suppressive (Ziegler SF, 2006). Indeed, it has been
shown that regulatory capacity is needed when conventional T cells are induced to express
Foxp3 via retroviral transduction in vivo and in vitro (Fontenot JD et al., 2003; Hori S et al.,
2003).
Tregs can suppress both Th1 and Th2 activities (Fig. 1.3) and affect the outcome of infection
with protozoan (Belkaid Y et al., 2002; Hisaeda H et al., 2004), viral (Iwashiro M et al.,
2001) and bacterial (Kullberg MC et al., 2002; McGuirk P et al., 2002). The precise
mechanisms of Treg cell function have not been clear. Significant progress has however been
made in identification of their roles in filariasis in the past years. Although Foxp3 has proved
to be an invaluable marker of mouse Treg cells, expression of Foxp3 alone is not enough for
regulatory function. Doetze A et al (2000) found that O. volvulus (Ov)-specific
hypo-responsiveness was mediated by IL10 and TGF. Significantly greater IL10 produced
by the PBMC from individuals with generalized onchocerciasis (GEO) could be reversed by
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anti-IL10 and anti-TGF antibodies treatment. Satoguina J et al (2002) showed that although
patients who had little dermatitis demonstrated millions of onchocerca worms in the skin,
Tr1 cells could be obtained and could induce an increased CTLA-4 after stimulation and
inhibit other T cells. In L. sigmodontis model, Treg function (Fontenot JD et al., 2003), the
increased IL10 and TGFβare associated with an early increase of Foxp3 mRNA in the
draining lymph nodes. Moreover, the levels of CTLA-4 and GITR increase despite IL5
decreases during infections. It has been demonstrated that removal of Tregs activities could
reverse hypo-responsiveness and lead to filarial parasite clearance by anti-CD25 and-GITR
treatment(Taylor MD et al., 2007), furthermore, the protective immunity in vivo was
inhibited by the CTLA-4 and CD4+CD25+ regulatory T cells. Recent research showed that
the early recruitment of nTregs determined outcome of filarial L3 infection (Taylor MD et al.,
2009).
Recent researches suggested more factors are involved in Treg functions. Collison LW et al
(2007) IL35 might be specifically produced by Treg cells and required for maximal
suppressive activity of Tregs. Studies from Bopp T et al (2007) showed that nTreg
cell-mediated suppression and membrane traverse via gap junctions are associated with
cyclic adenosine monophosphate (cAMP). Huang AY et al (1996) showed that Tregs
populations are marked by lymphocyte activation gene 3 (LAG-3). Studies from Kitoh A et
al (2009) indicated that in vivo Treg cell inhibition and optimal expression of FoxP3 gene are
mediated by the Runt-related transcription factors (Runx1)-core-binding factor-beta (Cbf)
heterodimer. Additionally, data from Klunker S et al (2009) showed that TGF-induced
Foxp3 expression during iTreg cell differentiation is linked by Runx transcription factors.
Further, the Eos gene plays an essential role in Foxp3-dependent gene silence of Tregs.
Silencing of Eos in Tregs gets rid of the suppressive abilities to immune responses (Fan Pan
et al., 2009).
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Fig. 1.4 Relationship between Treg, Th1 and Th2 response
Fig. 1.3 Th1/Th2 paradigm and differentiation pathway. Th2 and Th1 responses































Table 1.5 Molecular markers associated with Th1, Th2, Th17 and Tregs. (Cells associated
with these responses are not concern in present study)
Response Molecules Function Expression References
Th1 IFN activates macrophages, CTLs and
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Tregs; B cells Reviewed in
(Xu L et al.,
2010)
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Moreover, Th2 responses can be also induced by irradiated L3 vaccination. For instance, a
study on L. sigmodontis- BALB/c mice model showed the high levels of specific IgM and
IgG subclasses (IgG1, IgG2a and IgG3), high specific IL5 from spleen cells in vitro and a
high number of eosinophils in subcutaneous tissue contribute to protection (Le Goff L et al.,
2000). Another study showed a significant but partial protection up to 5 months post
vaccination with iL3s was achieved. However, this immunity did not extend to the next life
stages (Babayan SA et al., 2006 ). More importantly, iL3 vaccination in L. sigmodontis
-BALB/c mice model showed a type 2 bias immune response and maintained its efficacy
even repeated parasite challenges were given (Hübner MP et al., 2010).
Th2 biased responses can also provide protection against O. volvulus in mice based on the
following facts. a) IL5 instead of IFN was detected in diffusion chambers from vaccinated
mice (Lange AM et al., 1994). b) Levels of IL4 and IL5 increased when spleen cell cultures
were stimulated wih O. volvulus antigen (Taylor MJ et al., 1994). c) Significantly decreased
protective responses of iL3 vaccination were demonstrated by treatment witheither ant- IL5
or -IL4 mAb. and d) No protection was obtained by immunization in IL4 defect mice
(Johnson EH et al., 1998).
Similar observations were made by Girod N et al (2003) in BALB/c mice immunized with
iL3 of Necator americanus. Further support comes from the work of Ricardo T et al (2006)
on dogs that showed high level of antibodies, strong PBMC proliferation to L3 antigens and
production of IL4 were evoked by iL3vaccination. Similar observations have been obtained
from experiments with A. viteae in Meriones unguiculatus, Mastomys coucha and
Mesocricetus auratus (Schrempf-Eppstrin B et al., 1997), L. loa in Mandrillus sphinx (Akue
JP et al., 2003; Ungeheuer M et al., 2000), Nematodirus battus in lambs (Winter MD et al.,
2000 )and Ancylostoma caninum in dogs (Boag PR et al., 2003; Fujiwara RT et al., 2006 ),
mice and hamsters (Jian X et al., 2006 ).
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1.3 Vaccination and DNA vaccine
1.3.1 General vaccination
Success vaccinations against infectious diseases have been achieved for over 200 years.
Indeed, vaccination is considered to be the most cost-effective method to prevent human
disease and reduce animal suffering and economic losses. However, even with these
successes on vaccination, infectious diseases are still economical significant on reduction of
productivity and animal death. The discovery of biotechnologies, genomics, proteomics
together with understanding of immune responses to pathogens and pathogenesis provide us
excellent opportunities to develop more efficient and safer vaccines.
Although vaccination has became commonplace against many bacterial and viral infections
(Table 1. 6), development of vaccines against helminth infection has been very slow. Indeed,
the only commercially available vaccine against helminth infection is that used for
Dictyocaulus viviparus, the cattle lungworm. This vaccine comprised iL3 larvae and could
obtain 95% reduction in adult worm burdens when calves were vaccinated with 1000 iL3
larvae and challenged orally with 3000 to 4000 larvae (Bain RK, Urquhart GM, 1988).
The capacity of iL3 to evoke protective immunity has also been demonstrated in the
hookworm (N. americanus and A. caninum) in mice and hamsters (Jian X et al., 2006), as
well as A. viteae in three rodents (M. unguiculatus, M. coucha, and M. auratus
(Schrempf-Eppstrin B et al., 1997)
In the case of L. sigmodontis in mice, more than 50% protection was induced by three
inoculations with 25 iL3s after challenge infection. Th2 responses contributed to this
protective immunity and the enhanced L3 killing in vaccinated challenged mice appeared to
be associated to eosinophils (Abraham D et al., 2002; Le Goff L et al., 2000; Maréchal P et
al., 1997; Storey DM, Al-Mukhtar AS, 1982). An important feature of immune responses
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stimulated by L. sigmodontis is the key role played by Treg cells (Dittrich AM et al., 2008;
Taylor MD et al., 2007). This is a critical observation for the design of vaccines and
furthermore, responses parallel those seen in human onchocerciasis (Table 1.5).
However, although the use of iL3 larvae in veterinary medicine demonstrated the efficacy
and feasibility of iL3 vaccines, it is impossible that such vaccines would be either practical
or acceptable for human use, because of the impossibility of producing enough L3s and the
lack of acceptability by the public. The consequence is a focus on development of dead
vaccines, although use of attenuated viruses or bacteria as the carrier and delivery systems
remain as options.
There are two main approaches for development of dead vaccines including recombinant
protein and DNA vaccination. In the case of recombinant protein, the hepatitis B (Zhu FC et
al., 2010) and human papilloma virus ( HPV, Albarran Y et al., 2007) vaccines have
demonstrated their efficacy. In the case of eukaryote parasites, recombinant vaccines against
the animal stage ofEchinococcus spp (Heath DD et al., 2003), Taenia ovis (Rothel JS et al.,
1997) and ticks (Prudencio CR et al., 2010 ) have also been developed. Moreover, the
malaria RTS vaccine against Plasmodium falciparum showed promise after phase II trials in
children ( Sacarlal J et al., 2008; Barbosa A et al., 2009 ; Lell B et al., 2009).
DNA vaccines, although few are registered for commercial use, exhibit many advantages.
First, humoral and cellular immune responses can be achieved in animal models at low
dosages of DNA. In addition, they are safer than live attenuated vaccines (Meeusen EN et al.,
2007). Finally, DNA vaccines are more stable than conventional vaccines, this significantly
enhances vaccine storage and mobility (Table1.6).
DNA vaccine development against eukaryote parasites is progressing. DNA-based
vaccinations have been reported against Trypanosoma cruzi (Limon-Flores AY et al.,2010),
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Toxoplasma gondii (Li B et al., 2010), Schistosoma japonicum (Zhu Y et al.,2010),
Leishmania (Ahmed SB et al., 2009) and B. malayi (Ramachandran S et al., 2004;
Thirugnanam S et al., 2007). Moreover, “prime-boost”strategies have been applied in
malaria with some success. The mice that were primed with plasmid DNA which encodes
Plasmodium yoelii circumsporozoite surface protein (PyCSP) were boosted with a
recombinant vaccinia virus encoding the same protein, and significantly higher levels of
antibodies, IFNγ production and CTL activities than the mice that were immunized and
boosted with plasmid DNA alone were obtained (Sedegah M et al., 1998). This protective
responses can be further augmented by a prime of a mixtureof plasmids encoding PyCSP and
murine GM-CSF and a boost with recombinant vaccinia virus (Sedegah M et al., 2000). An
effective prime-boost strategy for the Plasmodium. knowlesi model has also been
demonstrated (Rogers Wo et al., 2001). Rhesus monkeys were primed with a DNA vaccine
consisting the merozoite surface protein 1 (PkMSP1p42), the apical merozoite surface
protein 1 (PkAMA1), sporozoite surface protein 2 (PkSSP2) and circumsporozoite surface
protein (PkCSP), then were boosted with a recombinant canarypox virus encoding all these
four antigens. All these immunized monkeys developed IFN-inducing T cell responses
against peptides from PkCSP as well as humoral responses against sporozoites and infected
erythrocytes. Moreover, “prime-boost”vaccination regimens against P. falciparum which
involve recombinant simian adenoviruses and plasmid DNA have recently been assessed as
priming regents in Adenovirus-MVA regimens in both phase I and phase IIa trials in United
Kingdom. These regimens showed better immunogenicities and efficacies than earlier
vaccinia virus Ankara regimens ( Moorthy VS et al., 2004;Gilbert SC et al., 2006; Hutchings
CL et al., 2005;Webster DP et al., 2005;Hill AV et al., 2010).
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Table 1. 6. Comparison of several types of vaccines (Modified from Meeusen EN et al.,
2007).
1.3.2 Mechanism of DNA vaccine presentation
DNA vaccines were first invented by Wolff and colleagues in 1990 (Wolff JA et al., 1990),
Type of
vaccine
Commercial products Advantages Disadvantages
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and were developed from “failed”gene therapy experiments (Tang D et al., 1992). DNA
vaccines are based on the possibility of induction of both humoral and cellular immunities
against antigens. DNA-based immunization is also an attractive strategy in the prevention of
infectious diseases.
DNA vaccines are made up of a small circular plasmid which has been genetically
engineered to produce one or multiple specific antigens from a pathogen. DNA vaccines are
commonly delivered by simple intramuscular injection (i.m), in muscular tissue the
expressed proteins form depots of antigens and stimulate both MHC II and MHC I-restricted
antigen presentation pathways. In the case of MHC I-restricted cytotoxic T lymphocytes
(CTLs), they may be induced by directly transfected somatic cells (keratinocytes, myocytes
or any MHC II-negative cells) or by professional antigen-presention cells (APCs), or by a
cross-priming method (Donnelly JJ et al.,1997; Sharma AK, Khuller GK, 2001). The process
might be as follows: when the DNA vaccine reaches cell nucleus, the transcription is started
then translation of the encoded protein is processed on cytosolic ribosomes. The synthesized
proteins are processed and released in the proteosome complex. Then they are transported to
the endoplasmic reticulum via the membrane transporter complex TAP-1 and TAP-2.
Afterwards, the transported peptides are bound to MHC I /MHC II molecules which locate
inside the endoplasmic reticulum (Huang AY et al., 1996; Rock KL, Goldberg AL, 1999).
Then, these bound peptides migrate to the cytoplasmic membrane and are present to the
CD8+/CD4+ T cells (Huygen K, 2005) (Fig. 1.5).
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1.3.3 Roles of dendritic cells (DCs) in DNA-based immune induction
It has been well documented that APCs are the key stimulators of immunity and functions
because they build immunological bridges between somatic cells and T cells. They can also
interact with antigens in the site of delivery and secondary lymphoid organs. DCs have been
identified to distribute in all the lymphoid and connective tissues. They can present antigens
to naïve T cells within secondary lymphoid tissues. Also DCs are potent activators of naïve
T cells and play three distinct roles in priming the immune system to DNA vaccine antigen:
1), MHC II-restricted presentation of antigen, 2), MHC I-restricted presentation, and 3),























MHC I-restricted “cross-presentation”of vaccine antigen. It is likely that each role is
essential in DNA vaccination and it is not enough for one of them to elicit potent humoral
and cellular responses.
The first function of DCs in immunity induction relies on their phagocytic ability to capture
and process secreted vaccine antigen expressed by plasmid-transfected cells. When DCs
receive the proper signal, they induce and up-regulate co-stimulatory molecules such as B7
and then interact with antigen-specific Th cells. These Th cells secrete Th2 cytokines in
subsequent pathways. Although antigen secretion from DNA vaccine might aid to increase
the humoral response, it might not induce CTLs, and thereby this function of DCs cannot act
independently of the other two roles in the induction of immunity.
An additional mechanism of immunity induction depends on the transfection of DCs at the
site of administration. A small amount of APCs express, process, and present the vaccine
antigen then migrate to draining lymph nodes (DLN) in which they interact with naïve T
cells. Casares S et al (1997) showed A/PR/8/34 influenza peptide encoded plasmid DNA has
been isolated and identified directly from DCs in the local lymph nodes and skin following
i.m injection. Condon C et al (1996) described that green fluorescent protein
(GFP)-expressing Langerhans cells (LCs) were identified in DLN after GFP-encoding
plasmid injection using gene gun, this supports the idea that skin LCs are directly transfected.
Chattergoon MA et al (1998) have shown that DCs can be directly transfected and migrate to
the regional lymph nodes, and can be found in the blood stream following i.m injection.
When CD4+ T cells are activated in this manner, they can migrate to the spleen (Akbari O et
al., 1999b).
The final mechanism of DC immune induction is associated with the “cross-presentation”of
vaccine antigen to T cells in a MHC I-restricted manner. Ulmer JB et al (Ulmer JB, 1996;
Ulmer JB, 1997) reported that the stably transfected myoblasts chimeric mice had the
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capability to induce protective antibody and CTL responses. These responses are restricted to
the MHC of the APCs from bone morrow, and are distinguished from the immune responses
induced by plasmid vaccination alone. Also successful cross-priming of antigens needs a
“danger”signal or a pro-inflammatory condition which is produced by opsonization and
cellular apoptosis.
Therefore, strategies to optimize antigen presentation by dendritic cells might be a rational
effective approach to DNA vaccine design.
1.3.4 DNA vaccine delivery and electroporation
Various strategies have been tested to overcome early weak performances of DNA
vaccination in primates. These approaches included particle-mediated delivery and gene gun.
However, these are only advantageous with low doses of DNA (Fuller DH et al., 2006). For
the i.m route, a main reason for the weak performance in large animals has now been
uncovered by the application of electroporation. It is already clear that the volume of
injection is crucial in this approach. Methods used to enhance the efficiency of DNA
delivery can be classified into three general types: mechanical, chemical and biological
method. Needle injection, gene gun and needle-free jet injection are the main mechanical
DNA delivery approaches. Needle injection needs much more DNA than gene gun, while
needle-free jet injection is more practical in laboratory animals than in clinical humans and
livestock animals.
In the case of chemical approaches, there are five general types of delivery systems. 1), DNA
mixed with cationic polymers including poly-L-lysine, protamine sulfate, polyethyleneimine,
chitosan, polyethylene glycol, poly-(D, L-lactide-co-glycolide). 2), DNA with artificial
cationic lipids or lipopolyamines. 3), DNA with artificial anionic lipids through electrostatic
interaction mediated by Na+ and K+ ions. 4), DNA with proteins or peptides. 5), DNA
dendrimers with marginal degree of polydispersity.
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The biological approaches are mainly based on the viral carrier system. This system is relied
on recombinant viral vectors either from weakened viruses such as poliovirus, vaccinia,
hepatitis B virus and measles virus or from other viruses such asadeno-associated virus
(AAV), alphavirus, human adenovirus (HAdV), vesicular stomatitis virus (VSV) and
poxviruses. These virally vectored vaccines can induce effective specific immune responses
against both expressed antigens and the viral capsid. They are generally conducted as the
second vaccination after DNA priming in a prime-boost strategy ( Cui Z et al., 2003; Merdan
T et al., 2002; Otten G et al., 2004; Mumper RJ, Cui Z, 2003; Bessis N et al., 2004).
A more promising approach is electroporation (EP). This device produces electrical
stimulation of muscle by a pulse generator and can be applied immediately after i.m injection
of the DNA plasmid (Aihara H, 1998; Mir LM, 1999; Mathiesen I, 1999). This procedure
enhances antigen expression by enhancing efficiency of transfection which can lead to local
tissue injury and inflammation (Ahlen G, 2007) and consequently result in remarkably
enhanced humoral and cellular immune responses (Babiuk S, 2002; Tollefsen S, 2002;
Widera G, 2000; Marc D et al., 2000). Importantly, EP reverses the failure of low-volume
i.m injection on immune responses induction in mice and increases responses in larger
animals. A combination of DNA priming with EP boost could induce higher antibody
responses in comparison with responses that are induced by protein in complete Freund
adjuvant, and also it can produce CTL responses. However, besides the transfection
efficiency, an effective candidate may be the most critical factor affecting the DNA vaccine
development.
1.3.5 Enhancement of efficiency of DNA Vaccines
Vaccine immunogenicity can be managed by factors which can attract APCs, enhance the
uptake of plasmid DNA or provide additional co-stimulation. In these ways, immune
responses can be directed toward a Th1 or Th2 response via different cytokine expression
and distinct T cell activations. The injection of DNA vaccines with adjuvants encoding
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cytokine can modulate the differentiation and expansion of Th1 and Th2 cytokines. For
instance, Kim JJ and Sin JI ( Sin JI et al., 1999b;Kim JJ et al., 1998a; Sin JI et al., 1999c)
described that the co-administration of IL12 encoded plasmid can direct the immune
response toward a Th1. Also the HIV-1 vaccine co-administration with plasmids encoding
IL12, IL18 and IFN could augment the level of antigen-specific proliferation in mice and
rhesus macaques (Kim JJ et al., 1999a). Kim JJ et al (1999b) showed that elevated levels of
antigen-specific antibodies were correlated to IL4, IL10 co-administration and the
chemokine macrophage-inflammatory protein-1 (MIP1, Boyer JD et al., 1999) within an
HIV-1 vaccine. In addition, treatment of TNF could significantly enhance CTL responses
and antigen-specific Th cell proliferation (Kim JJ et al., 1998b). Table 1.7 provides some
examples of enhancement of different immune responses by cytokines and other molecules
( Chow YH et al., 1998; Pan CH et al., 1999;Babiuk LA et al., 2003; Dale CJ et al., 2004;
Garmory HS et al., 2005; Gurunathan S et al., 2000; Liu MA et al., 2006; Sumida SM et al.,
2004; Munks MW et al., 2004).
Table 1.7 Cytokines or adjuvants help to enhance certain immune responses
Another way to enhance immune responses to DNA vaccines is associated with the addition
of heterologous gene sequences encoding localization or secretory signals. Thus the cellular
localization of heterologous antigen might be essential to manage the immune response. For
example, stimulation with antigen secreted instead of localized on the cell membrane or
within the cell induced higher titers of antigen-specific antibody in mice (Gurunathan S et al.,
Intended response Cytokines/ adjuvants
APC activation CpG, CD40L, MIP1α, Flt3L
CTL response IL1, IL2, IL12, IL15, IL18,GM-CSF, IFNγ, CD40L, ICAM1, LFA3
IgG2a (mice) IL1, IL2, IL7, IL12, GM-CSF, IFNγ, CD40L
IgG1 (mice) IL4, IL7, IL10, TGFβ
IFNγ-cellular
response





2000; Locher CP et al., 2002). Additionally, accelerated cytoplasmic antigen degradation
and improved efficiency of MHC I antigen presentation were induced when ubiquitin
sequence was fused with the antigen-encoding gen (Garmory HS et al., 2005). CTL and B
cell responses against the viral antigen were increased when antigen was fused with the
heat-shock protein (hsp)70-binding viral J-domain (Reimann J and Schirmbeck R, 2004).
While MHC class II responses were enhanced by fusing the antigen with the endosomal /
lysosomal sorting signal sequence (derived from lysosome--associated membrane protein
type 1; LAMP-1) (Kim TW et al., 2003).
An alternative approach to augment DNA vaccine efficiency involves immunization with
various combinations of recombinant virus, DNA vaccines and/or protein in prime-boost
strategy. There are two types of prime-boost strategies, homologous and heterologous
prime-boost. Among homologous prime-boost approaches, the DNA-prime-protein-boost
approach uses recombinant protein antigens used in DNA prime immunization ( Wang S et
al., 2008;Wang R et al., 2004; Lu Y et al., 2009).
Another DNA-prime-viral vector-boost approach focuses on the induction of T-cell immune
responses. More immunogenic and protective effects than the DNA vaccine alone have
been shown by DNA-priming and recombinant vaccinia boosting strategy in a mouse
malaria model (Sedegah M et al., 1998). Furthermore, complete protection in the same
model has been obtained by boosting with the recombinant modified vaccinia virus Ankara
(De ǵano P et al., 1999; Schneider J et al., 1999). A similar manner is being exploited on
viral vectors developed from fowpox (Kelleher AD et al., 2006) and recombinant vesicular
stomatitis virus (Egan MA et al., 2005).
The heterologous ‘prime-boost”vaccination approach stimulates stronger expansion of
antigen specific T cells by using different priming and boosting vectors (Schneider J et al.,
1999; Walczak M et al., 2010). Compared to homologous prime-boost approach with the
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same DNA vaccine, boosting a primary response with a heterologous vector could induce
4-10-fold higher T cell responses (Estcourt MJ et al., 2002; Degano P et al., 1999).
1.3.6 Possibility of DNA vaccine research on filariae
The most important factors that may determine the feasibility of development of a DNA
vaccine against filariasis will be the identification of excellent parasite antigens and a clear
understanding of the mechanisms of protective immunity. In the filarial life cycle, the L3 is a
vulnerable stage of the parasite in the mammalian host in light of its sizes, numbers and
migratory pathways. Several researchers have tried to address development of protective
immunity against L3 stage both in experimental and human filariasis ( Day KP et al., 1991b;
Devaney E, Osborne J, 2000; Eisenbeiss WF et al., 1994; Bleiss W et al., 2002; Helmy H et
al., 2000; Rajan TV et al., 2002). Antibodies against the surface of L3 in human have been
shown to be important to anti-larval immunity (Day KP et al., 1991b; Rajan TV et al., 2002).
Protective immunity against larvae in host impacted by antibody-dependent cytotoxicity
involving macrophages and eosinophils has been observed in experimental animals after
vaccination with iL3s (Devaney E, Osborne J, 2000; Bleiss W et al., 2002; Eisenbeiss WF et
al., 1994; Rajan TV et al., 2002). The observation that IgM and IgG2 are the major L3
surface-reactive antibodies in human sera indicates the possibility that carbohydrate
determinants may play a role in anti-larvae immunity. This is supported by the observation
that significantly higher IgG2 antibodies to parasite carbohydrates are found in infection-free
patients in endemic regions compared to infected humans (Mohanty MC et al., 2001).
Furthermore, gerbils are deficient in antibodies to T-independent carbohydrates antigens
(Mohanty MC, Ravindran B, 2002). All the above indicate that the surface constituents of L3
may be crucial in protective immunity.
However, targeting stages other than L3 should not be discounted in the understanding of
antifilarial immunity because distinct reactivities against adult male worm antigen have also
been identified in putative immune humans (Turaga PS et al., 2000). Importantly, adult
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worms may be a main source of immuno-modulatory molecules (Harnett W, Harnett MM,
2006). The clearance of circulating Mf in infected animals were positively associated with
circulating antibodies (Ravindran B et al., 2000), however an inverse relationship was also
observed in both brugian and bancroftian filariasis (Ravindran B et al., 1990; McGreevy PB
et al., 1980). Moreover, as stated in the section 1.2, pathology in onchocerciasis is related to
the death of Mf , which is mediated by Th2 immune responses. Thus the possibility of
conflict between stimulating protection and exacerbation of disease must be taken into
consideration. Additionally, control of Mf might be indirectly associated with the
anti-fecundity instead of the antibody. Therefore, the focus should be put on anti-larvae and
-adult instead of -Mf immunity
1.4 Vaccine candidates of filarial nematodes
Identification of vaccine candidates plays a key role in development of vaccines. Strategies
to identify vaccine antigens in filariasis relied on serum antibodies to define antigens with
comparison uninfected subjects with infected patients or by using sera from animals
vaccinated with iL3s, or by molecular biological approaches to analyze and define new
genes. Various candidates have been studied including the Abundant Larval Transcript (ALT),
Venom Allergen Homologue (VAH), Cysteine Proteases and their Inhibitors (CPI), and
Thioredoxin Peroxidase (TPX) (Table 1. 8).
1.4.1 Abundant Larval Transcript (ALT)
The ALT gene was first described from B. malayi (Gregory WF et al., 1997) and it accounts
for up to 5% of total transcript at the time when L3s invade the hosts. ALT is associated with
two highly expressed genes, ALT-1 and ALT-2 (79% identity), which are homologous to an
abundant gene from L3 of the D. immitis (Di-20/22L, Frank GR et al., 1995), O. volvulus
(Ov-ALT-1, Joseph GT et al., 1998) and A.viteae (Pogonka T et al., 1999). The secreted
larval acidic protein (SLAP) produced by O. volvulus larvae (Bianco AE et al., 1990; Bianco
AE et al., 1995) has also been shown to be a member of the ALT family (Gregory WF et al.,
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2000) and is an orthologous to ALT in brugia (Wu Y et al, 2004).
These ALT proteins are considered to be attractive vaccine antigens for three reasons: 1) they
are L3 specific and abundant but also expressed in L2 (Wu Y et al, 2004); 2) they are
abundantly expressed and secreted; and 3) they have no homologues in the mammalian host.
Gregory WF and colleagues (Gregory WF et al., 2000) found a high frequency of IgG1 and
IgG3 antibodies to ALT-1 and -2 in B. malayi- infected human and the response was different
from the response to adult antigens which are targeted by IgG4. Ramachandran S et al (2004)
found that 72% endemic normal individuals possessed antibodies against recombinant ALT-2
in endemic areas. This observation may suggest that the protective immunity might be
associated with a response to this protein. When ALT-2 was tested in a jird model using
either recombinant protein or DNA vaccine, significant protection (75% for protein and 57%
for DNA vaccine, respectively, Thirugnanam S, 2007) was observed when compared to a
control or adjuvant alone. This protection also indicates that this vaccine is a promising
candidate for further development.
However, experiments also suggest that ALT proteins can modulate host immunity.
Gomez-Escobar N et al (2005) described a transfection strategy to express these products in
Leishmania mexicana by in vitro in macrophages and in vivo infection in mice. Results
showed expression of ALT proteins instead of a truncated mutant led to 3-fold higher
parasite burden in vitro, and ALT-transfected parasites caused severe disease in vivo and
fewer mice eliminated infection. Furthermore, ALT-transfected parasites showed more
resistance to worm killing induced by macrophages.
1.4.2 Cysteine Proteases and their Inhibitors (CPI)
CPIs or cystatins were first identified from O. volvulus L3s and adult stages (Lustigman S et
al, 1991) then were found in B. malayi L3s (Gregory WF et al., 1997). In these parasites
three forms have been identified, Bm-CPI-1 is both secreted and located on the surface of L3
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although expression stopped after just 2 days post infection in mammalian hosts. Bm-CPI-1
may be a target for antibody-mediated immune responses because of the L3 surface location.
Bm-CPI-3 has also been identified and is expressed by L3s. Both of them were studied less
than Bm-CPI-2, which is expressed throughout the full life cycle. Bm-CPI-2 has been shown
to inhibit antigen presentation through MHC II (Manoury B et al., 2001; Murray J et al.,
2005) and may modulate the host’s immune response to the parasite. Bm-CPI-2 has been
found bi-functional by comparing with vertebrate cystatins (Murray J et al., 2005) with one
to block papain-like proteases and one to suppress a legumain such as asparaginyl
endopeptidase (AEP). Site-directed mutagenesis on Bm-CPI-2 at Asn-77 (the residue
associated with AEP inhibition) to Asp and Lys showed 10-fold decreased activity in AEP
inhibition, respectively, whereas blocking of papain-like proteases showed only a small
degree reduction.
Cystatin homologues have been found in other filariae such as onchocystatin (including
Ov-CPI-1, Ov-CPI-2) from O. volvulus (Lustigman S et al., 1996). They have been shown to
modulate T cell and macrophage activities and thus contribute to the hypo-responsiveness in
onchocerciasis patients (Schönemeyer A, et al., 2001), moreover, it has been shown partial
protection in its unmodified form with alum adjuvant (Abraham D et al, 2001). A cystatin
from A. viteae (Av-CPI) was reported to be highly secreted by female adult worms. its
recombinant protein is able to inhibit proliferative responses and increase IL10 production,
again indicating an immuno-modulatory function (Hartmann S et al., 1997).
An immuno-modulatory role for cystatins is also suggested by works on L. sigmodontis. The
level of nitric oxide (NO) was reduced while TNFαwas increased when C57BL/6 mice were
simultaneously inoculated with L. sigmodontis Mf and given recombinant Ls-CPI (Ls cystatin)
protein via micro-osmotic pumps (Pfaff AW et al., 2002). In addition, antigen-specific
proliferative responses of spleen cells to Mf were decreased, despite antibody production was not
inhibited. Produce protective immunity was not obtained by vaccination of BALB/c mice with
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Ls-CPI but the number of vaccinated mice that became microfilariamic (potent) was reduced
(Pfaff AW et al., 2002).
1.4.3 Venom Allergen Homologue (VAH)
VAH family of proteins or Ancylostoma secreted protein (ASP) produced by infective L3 are
cysteine rich secretory proteins (CRISP). Several homologues of CRISP have been reported
from nematodes such as A. caninum (Hawdon JM et al., 1996), Haemonchus contortus
(Rehman A, Jasmer DP, 1998), Ancylostoma duodenale (Bin Z et al., 1999), C. elegans,
Ascaris, N.americanus (Daub J, 2000), O. volvulus (MacDonald AJ et al., 2004), Toxocara
canis (Tetteh KK, 1999), and Strongyloides (Hawdon JM et al., 1999). Some experiments
have suggested that VAH is a potential vaccine candidate. For example, 80% protection was
obtained by vaccination with Hc-24 after challenge with H. contortus in sheep (Schallig HD,
van Leeuwen MA, 1997), and ASP-1-immunized mice showed up to 80% reduction of worm
burden with comparison to controls (Ghosh K et al., 1996; Sen L et al., 2000).
Murray J et al (2001) observed that more than 95% of microfilaraemic subjects are
antibodies positive against Bm-VAL-1 with high levels of IgG3 and IgG4. Anand SB et al
(2007) suggested EN individuals produced W. bancrofti VAH (Wb-VAH)-specific IgG1,
IgG2 and IgG3 whereas patients with chronic pathology mainly generated IgG3.
Ancylostoma secreted proteins (ASP) have also been well documented on protective immune
responses induction against hookworm infections in mice, hamsters and humans (Sen L et al.,
2000; Goud GN et al.,2004; Bethonya JM et al.,2008)
1.4.4 Thioredoxin Peroxidase (TPX)
TPX is a member of the thiol-specific antioxidant (TSA) family which has been described
from prokaryotes and eukaryotes. This family was originally described from yeast (Kim IH ,
1989; Kim K et al., 1988) as a 27 kDa ‘protector’protein which was able to protect other
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proteins from oxidative damage. This protein was also able to reduce H2O2 and alkyl
hydroperoxides (Chae H et al., 1994). The TPX gene (s) has been found in O. volvulus and B.
malayi. In O. volvulus, the Ov-TPX-2 cDNA represents about 2.5% of the total cDNAs from
the L3 cDNA library (Wenhong Lu et al., 1998) and encodes a 22 kDa native protein found
in both L3 and adult stages. In larvae, Ov-TPX-2 protein is mainly localized to the
hypodermis and cuticle. In adult worms, the primary sites are the uterine epithelium and
intestine (Lu W et al., 1998). The B. malayi Bm-TPX-1, locates in the cells of the
hypodermis/ lateral chord in adults, was only 60% identical to putative TPX proteins from O.
volvulus and C. elegans and is also different to Bm-TPX-2. The distribution of this protein in
the parasite suggests that Bm-TPX-1 may play an important role in countering radicals
produced within cells (Ghosh I et al., 1998).
TPX is also found in Fasciola hepatica, in which it appears to induce recruitment and
alternative activation of macrophages (Donnelly S et al., 2005) and it is also found in
schistosome eggs (Williams DL et al., 2001). The native TPX-1 protein elicited significant
greater proliferation and up-regulation of IFN, IL2, IL4 and IL5 in CD4+ cells from infected
CBA and C57BL/6 mice. By comparison, recombinant TPX-1 elicited a smaller Th1-biased
response, with significant production of IFN and IL2 (Williams DL et al., 2001). A
comparative study of the physiological roles of three peroxidases (NADH peroxidase, alkyl
hydroperoxide reductase and thiol peroxidase) in oxidative stress responses suggested that
TPX is the most important antioxidant for protecting the cells from the phagocyte
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1.5 The L. sigmodontis/ mice research model
A major constraint of filarial diseases research and vaccine development has been the lack of
great animal models in which the parasite can go through full life cycles. Early animal
models include O. volvulus in mice, A. viteae in gerbils and B. malayi in mice and gerbils,
but all these models have limitations. For example, although O. volvulus can survive in mice
after surgical implantation, it cannot produce Mf in the pleural cavity (Lustigman S et al.,
2003). Similarly, Brugia species are found to have an incomplete life cycle in mice.
Although B. malayi and A. viteae can reach potent stage with Mf in mongolian gerbils
(Meriones unguiculatus), lack of research reagents limit the immunological investigations
( Lawrence R, Devaney E, 2001; Abraham D et al., 2002).
Major progresses have been made in two animal models. O. ochengi in cattle is a good
model for onchocerciasis research based on the merits that it is the closest known relative of
O. volvulus and it is also transmitted by the blackfly, Simulium damnosum (Trees AJ et al.,
2000). Nodule formation caused by O. ochengi resembles that caused by O. volvulus and is
Table 1. 8. Vaccine candidates of filariae
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convenient for immunological analysis. However, it does not cause evident pathology in
cattle (Allen JE et al., 2008).
Another excellent model is the L. sigmodontis- lab mouse model. The report by Petit G et al
(1992) described that L. sigmodontis was able to produce potent infections in BALB/c mice.
This was a major breakthrough in filarial research because this raises a possibility to carry
out detailed immunological researches for the first time. L. sigmodontis development in
different mouse strains is listed in table 1.9. However, not all BALB/c mice infected with L.
sigmodontis can develop potent infections. The one constraint of the L. sigmodontis mouse
model is that there is little or no pathology associated with the infection nor the clinical signs
which are normally associated with onchocerciasis or lymphatic filariasis. This, in part, can
be attributed to the different anatomical compartments occupied by adult worms (thoracic
cavity) and Mf (blood) (Table. 1.10).
Table 1.9 Maturation of L sigmodontis in different mouse strains (from Petit G et al
(1992))
Mouse strains Haplotypes Susceptible Resistant Patency
BALB/c H-2d yes no yes
BALB/K H-2k et Less than BALB/c yes no
BALB/B H-2b Less than BALB/c yes no
B10 H-2b no yes no
B10Br H-2k et no yes no
B10D2 H-2d no yes no
CBA/Ca H-2k et Adult found no
CBA/HN H-2b Adult found no
C3H/HeN H-2k Adult found no
DBA/2N H-2d Adult found no
Note: Male CBA/HN and C3H/HeN were more susceptible to infection than female mice.
Inverse phenomenon was observed with strains BALB/c; and, no host sex effect was seen in
DBA/D2N.
The life cycle of L. sigmodontis in the mouse is summarized in Fig 1.5. Females give birth to
Mf 8 weeks after infection, then the Mf migrate to the blood from where they can be
ingested by blood-feeding arthropods. In the laboratory the mite, Ornithonyssus bacoti, is
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used as a vector. Ingested Mf then moult to L2 5-6 days post ingestion and to L3 8 days post
ingestion. L3s become infective to the vertebrate host 1 day after the L2/L3 moult (Diagne et
al., 1989). Infective L3s are inoculated to the vertebrate host when mites feed. The L4
moults 7-8 days post infection when the parasites are located in the pleural cavity. The final
moult to adult occurs 28-35 days post infection. Mf can be detected in circulation 55-60 days
post infection.
Table 1. 10. General features of the biology of O. volvulus, O. ochengi, and L.
sigmodontis (cited from Allen JE et al., 2008)
Filariae Vector Time to
patency
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1.6 Designing a DNA vaccine against filariae
To design an effective vaccine against filarial nematodes, the necessity to know the history
of such vaccine development is required. Since 1950s, a vaccine against D. viviparous
consisting of iL3s had been applied successfully to control bronchitis. Such success excited
scientists to develop vaccines against filarial nematodes in terms of the similar principle and
procedure. Many irradiated vaccines had been examed in the past decades and showed quite
high protections (from 70% to 100%, Wong MM et al, 1974; Abraham D et al, 2002; Grieve
RB et al, 1998). Even the protective immunity induced by iL3 vaccination was found to be
Th2 bias (Taylor MJ et al., 1994; Johnson EH et al., 1998; Lange AM et al., 1994), which
was essential to attack the filarial nematodes (see 1.2). However, the iL3 vaccine has its
weakness: it could never be used on humans because of safety concerns and the limited
acceptance mentally. Also, iL3 vaccine was unstable, it was not feasible for global
distribution. Moreover, this vaccine must be given annually which is labour-intensive.
Fig. 1.5 Life cycle of L. sigmodontis (courtesy of Simon Babayan). O. bacoti mite is used
to maintain the life cycle of L. sigmodontis during L1 to L3. BALB/c mouse is infected
with infective L3 and can reach patency in 55-60 days after infection.
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A more reasonable approach for vaccination would be the use of recombinant antigens. The
first step to develop a recombinant vaccine is the identification of candidates. On B. malayi,
Maizels RM et al (2001) developed three approaches to identify immune evasion genes
which might be the candidates for a novel vaccine. First strategy aimed to characterize
surface or secreted antigens, in which Bm-CPI2, a member of the cystain, had been digged
out. It had been tested as a recombinant vaccine and showed a promise effect (see 1.4), in
parallel, a serpin, Bm-SPN2, had also been found. The second route they used was based on
the hypotheses that filarial nematodes might encode homologues of cytokines from
mammalian hosts. They found that the Bm-TGH2, which is a homologue of TGFβ, could
bind to TGFβreceptors. Likewise, the Bm-MIF had been shown high similarity to the
proteins from mammalian host in both structure and function. The third method was to select
abundant mRNA from the key points of its life cycle. By this way, Bm-ALT and Bm-VAL-l
had been hunted. These candidates had been examined by their recombinant forms in animal
models and showed different protective immunity-inducing features (see 1.2, 1.4). In the
case of O. volvulus, a program to develop a recombinant vaccine was the Edna McConnell
Clark Foundation`s (EMCF) Oncho Task Force`s network (Cook JA et al., 2001). They
tested 44 recombinant antigens in 12 laboratories. Among them, 14 antigens had the
capabilities to induce partial but significant protections with the adjuvants of alum or FCA
(Lustigman S et al, 2002). Further, Ov7, Ov64 and OvB8 recombinant proteins were
individually tested in mice for their protective features. Significant reductions of parasite
survival were obtained with adjuvant alum instead of FCA, suggesting the protective
immunity induced would be Th2 instead of Th1 responses (Kenney JS et al, 1989; Yip HC et
al, 1999; Forsthuber T et al, 1996). However, fructose-1, 6-biphosphate aldolase functioned
with the addition of FCA not alum (McCarthy JS et al, 2002). A more recent field trial
vaccination in cattle- O. chengi system in West Africa was performed by using 8
recombinant antigens which were expressed in O. chengi. These antigens were administrated
with either FCA or alum individually, results showed 58% reduction of parasite infections
(Makepeace BL et al., 2009). Although the recombinant vaccines have been success in some
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laboratory animal models and field trials, the expression of nematode proteins in prokaryote
bacterial E. coli which has different bio-machine to eukaryote, may lead to the production of
proteins with abnormal secondary or tertiary structures or lack of post-translational
modifications. Consequently, their absence of bio-activities may impair their functions in
host cells. Despite new expression systems such as yeast, insect cell and mammal expression
systems, which improve the activity of post-translational modifications greatly, have been
applied extensively on protein expressions, the expressed proteins in these systems cannot
act as native proteins or proteins expressed in host cells (Y Gao, 2000). Moreover, as stated
above, some identified antigens induce Th1 whereas others stimulate a Th2 response, the
direction of protective immunity cannot be managed when recombinant proteins are used.
Therefore, an alternative strategy is needed to mimic the function of native protein and to
direct the protective immunity that the administrated vaccine is designed to induce.
The DNA vaccine is a novel type of vaccine which has many advantages over the traditional
vaccine as stated in section 1.3. The point that DNA vaccine can express carried gene by
using the bio-machine system in host cells naturally and the expressed protein is more close
to its native form in secondary or tertiary structure is noteworthy. Because this is what the
recombinant protein produced in E. coli or other protein expression system cannot provide.
In addition, the immunity the vaccine requires to induce can be managed by encoding
different cytokine adjuvants (see 1.3.5), this fortune makes DNA vaccine more feasible and
easy managed. As a support, DNA vaccine had been shown promise on controlling infective
disease and even two commercial products had been allowed to distribute (see 1.3). However,
till now, most experiments were performed on laboratory experimental animals instead of
primates or even big animals. The major reason was associated with the low efficiency that
the DNA vaccine induced. However, this weakness has been overcome by the use of
electroporation (see 1.3.4), which significantly improves the DNA efficiency in big animals
and reduces the amount of DNA.
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However, to design a DNA vaccine must understand the details of protective immunity that a
vaccine should induce. It is generally accepted that infection with helminths is associated
with Th2 responses characterized by increased IL4, IL5 and IL13. This can be seen in both
natural and experimental infections with platyhelminths (including schistosomes) and
nematodes (including filarial parasites) (see 1.2). However, the Th1 responses cannot be
ignored (see 1.2). Moreover, evident conflicting data on the role of Th1 versus Th2 responses
in protective immunity in lymphatic filariasis and onchocerciasis may be a manifestation of
the complexity of the filarial life cycle (see 1.2). This arouses more recognition of Tregs.
Apparently, the balance of Th1/ Th2 highlights the need for a thorough understanding of the

















Fig 1.6 Network of immune responses associated with worm killing. Th2 cytokines
including IL4, IL5, IL13 are associated with worm and Mf killing. Th2 cytokines may
engage the B cells to produce antibodies including IgG1, IgG2a, IgE to inhibit the worm and
Mf development. Eosinophils and neutrophils are also involved in worm expulsion by
degranuation or encapsulation around the worms. Worms can trigger Tregs to downregulate
Th1, Th2 and other effectors. Treg also can regulate response to avoid severe pathology.
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1.7 Aim of PhD
A long term objective is the development of a vaccine against onchocerciasis and lymphatic
filariasis. The aim of the present work in this thesis is to provide proof of principle for use of
a DNA vaccine against filariasis. Considering filarial infections persist long life time in host,
a hypothesis was proposed that this may due to the filariae-triggered Treg responses and the
existence of parasite-derived immuno-modulations. To develop an effective DNA vaccine
regimen against filariasis that can circumvent immune regulation and immuno-modulation, L.
sigmodontis/mice model will be used to test the selected filarial antigens including Acidic
Domain Deleted Abundant Larval Transcript (ADDALT), Mutated Cysteine Proteases and
their Inhibitors (CPImu), Venom Allergen Homologue (VAH), Thioredoxin Peroxidase
(TPX). Also electroporation will be used to enhance the efficiency of DNA vaccines
following the injection of DNA plasmids. Cytokines/ chemokines macrophage inflammatory
protein 1 alpha (MIP1), fms-like tyrosine kinase 3-ligand (Flt3L), and interleukin 4 (IL4)
will be used as adjuvants. All these are intended to test selected antigens for their abilities to
evoke protective immune responses.
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Chapter 2-Materials and Methods
2.1 Materials
2.1.1 Mice
BALB/c mice were used for all experiments. These animals were either bred in house in the
Ann Walker Facility, University of Edinburgh or purchased from Harlan-UK (Bicester, UK).
All mice were between 6 and 8 weeks old at the beginning of the experiment and were
euthanized with Vetelar/ Domitor before necropsy. They were housed in
individually ventilated cages (IVC) and were given sterilized food and water. All procedures
conformed to the Animals (Scientific Procedures) Act 1986, United Kingdom
2.1.2 Parasite life cycle maintenance
The filarial parasite L. sigmodontis was maintained in house by Alison Fulton. 1-3 C57BL/6
or BALB/c baby mice were put into each colony flask containing mites (O. bacoti). Within
18 hours the baby mice were removed from the colony flasks and 450 female mites per flask
were collected and put into a new colony flask for 1 week’s incubation at 37°C and 70%
humidity. After one week, the flasks with non-infected mites were put on infected jirds (M.
unguiculatus) carrying Mf in the blood stream and kept at 37°C and 70% humidity overnight.
The infected mites from infected jirds were collected into autoclaved tubes (50 mites per
tube) and incubated at 37°C and 70% humidity for 12 days to obtain the infective larvae.
Infective larvae were collected by dissecting the mites, then the L3s were put in RPMI 1640
medium for inoculation in room temperature after counting and were ready for experimental
use.
2.1.3 Parasite antigens preparation
For parasite antigen preparation, adult L. sigmodontis worms were collected from BALB/c
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mice (see 2.1.2) and homogenization (without protease inhibitors) of mixed sex worms
using a ground-glass homogeniser in PBS on ice was carried out. The homogenate was
centrifuged at 10,000×g for 20 minutes and the resultant supernatant fluid was passed
through a 0.22 m filter before determination of protein concentration using the Bradford
protein assay. The assays were read at 595 nm and concentration of antigen preparations
were determined by reference to the standard curve of 2-fold dilutions of bovine serum
albumen (BSA) at a starting concentration of 2mg/ml. The antigen preparations were stored
at -20°C.
2.1.4 Buffers, solutions and media
Carbonate buffer for ELISA coating: two solutions were prepared: A, 8.5g NaHCO3 in 1 liter
distilled water; and B, 10.6g Na2CO3 in 1 liter distilled water. Then add 45.3 ml A plus 18.2
ml B, make up to 1 liter with distilled water, and adjust the pH to 9.6.
Luria-Bertani broth (LB) for bacterial culture: 10 g tryptone, 5 g yeast extract, 5 g NaCl,
distilled water to 1 liter, sterilized by autoclaving (121°C, 1.5 pounds per square inch (psi),
for 30 minutes)
LB-agar: 1.5% Difco agar in LB, sterilized by autoclaving (121°C, 1.5 psi, for 30 minutes)
10PBS: 8.0 g NaCl, 2 g KCl, 11.5 g Na2HPO4, 2 g KH2PO4, distilled water to 1 liter, pH 7.5,
sterilized by autoclaving (121°C, 1.5 psi, for 30 minutes).
.
10TBE: 121.0 g Tris base, 61.8 g boric acid, 18.6 g EDTA, distilled water to 1 liter, pH 8.0.
TBS: 8.75 g NaCl, 2.42 g Tris base, distilled water to 1 liter, pH adjusted to 7.4 with HCl.
50TE: 60 g Tris base, 100 ml 0.5 M EDTA, distilled water to 1 liter, pH 8.0.
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S.O.C broth: 20 g bacto tryptone, 5 g yeast extract, 10 ml 1M NaCl, 2.5 ml 1M KCl were
mixed in 970 ml distilled water and sterilized by autoclaving (121°C, 1.5 psi, for 30 minutes),
the broth was completed by addition of 10 ml 1M MgCl2, 10 ml 1M MgSO4, 10 ml 2M
glucose (all these regents were filtered by passage through 0.22 m filter).
1% or 2 % agarose gel: 1g or 2g agarose was added into 100 ml 0.5TBE buffer and
dissolved at 100°C for 15 minutes in microwave oven, with addition of 5μl 10 mg/ml
ethidium bromide (EB) and the mixture was poured into the gel mould and allowed to set for
15-30 minutes before use.
SDS Gel: ready to use precast NuPAGE 4-12% Bis-Tris gels (1.0 mm10 well, cat no.
Np0321 Box) were purchased from Invitrogen.
Complete RPMI1640: RPMI1640 media was purchased from Gibco, UK (cat no 42401018)
and before use the following were added into 500 ml: 2 mM glutamine; 10 mM
2-hydroxyethyl (Hepes), 10% fetal calf serum (FCS), 100 U/ml penicillin,100 µg
streptomycin.
Protein purification buffer: 4 buffers were used to purify His-Tag recombinant proteins
within AKTA system including Charge Buffer, Strip Buffer, Binding Buffer and Elution
Buffer.
His-Tag protein affinity purification Charge Buffer Stock (8 ): 400mM NiSO4.
1Charge Buffer: add 25 ml 8  Charge Buffer Stock in 175 ml distilled water.
His-Tag protein affinity purification Strip Buffer Stock (8 ): 400 mM EDTA, 2 M NaCl and
80 mM Tris HCl, pH7.9.
1 Strip Buffer: add 25 ml 8 Strip Buffer Stock into 175 ml distilled water.
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His-Tag protein affinity purification Stock solutions for Binding Buffer Stock: 4 M NaCl:
234 g in 1 liter distilled water.
4 M Imidazole: 136.2 g in 500 ml distilled water.
0.2 M Na2HPO4: 28.4 g in 1 liter distilled water.
0.2 M NaH2PO4: 13.6 g in 500 ml distilled water.
0.2 M Sodium Phosphate: 40.5 ml of 0.2 M Na2HPO4 and 9.5 ml of 0.2 M NaH2PO4, pH7.4.
1 Binding Buffer: 100 ml of 0.2 M Sodium Phosphate, 125 ml of 4 M NaCl, 2.5 ml of 4 M
Imidazole, made up to 1 liter distilled water before use.
His-Tag protein affinity purification 1Elution Buffer: 20 ml of 0.2 M Sodium Phosphate, 25
ml of 4 M NaCl, 25 ml of 4 M imidazole, made up to 200 ml distilled water then added 6 M
urea before use.
Western blotting Transfer buffer: NuPAGE Transfer Buffer (20, cat no. NP0006-1) was
supplied by Invitrogen and 20 fold diluted prior to use with distilled water.
SDS running buffer: NuPAGE MES SDS running buffer (20, cat no. NP0002) was supplied
by Invitrogen and 20 fold diluted prior to use with distilled water.
SDS Gel Stain solution: dissolve 0.4 g of Coomassie blue R350 in 200 ml of 4 % (v/v)
methanol in water with stirring as needed. Filter the solution to remove any insoluble
material. Add 200 ml of 20 % (v/v) acetic acid in water. The final concentration is 0.1 %
(w/v) Coomassie blue R350, 20 % (v/v) methanol, and 10 % (v/v) acetic acid.
SDS Gel destain solution: add 500 ml of high performance liquid chromatograohy
(HPLC)-grade methanol to 300 ml of water. Add 100 ml of acetic acid, after mixing, adjust
the total volume to 1000 ml with water.
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SDS Gel Storage solution: add 25 ml of acetic acid to 400 ml of water. After mixing, adjust
the final volume to 500 ml with water.
2.1.5 Bacterial host strains and plasmid vectors
Bacterial strains and vectors used in experiments are listed in Appendix 1. All vectors were
kept at -20°C and strains were kept at -80°C (see appendix 1).
2.1.6 Primers for DNA amplification and sequencing
All primers used for DNA amplification by PCR and DNA sequencing were synthesized by
the Invitrogen company, and all primers are included in the tables (see Appendix 2.1, 2.2).
2.1.7 Kits
Kits were purchased for plasmid extraction, PCR product purification and gel extraction
including QIAprep spin Miniprep kit (Cat no.2714), QIAGEN plasmid Maxi kit (Cat no.
12162), QIAquick PCR purification kit (Cat no. 28104) and QIA quick Gel Extraction kit
(Cat no. 28704). All kits were obtained from QIAGEN, UK.
2.2 Methods
2.2.1 Methods of DNA analysis and manipulation
2.2.1.1 RNA extraction
For the isolation of total RNA, worms or tissue samples were removed from the gerbils or
mice (see 2.1.2) and COS7 cells obtained from cell cultures were also used as source of
mRNA for specific experiments (see 3.2.5 and 4.2.5). All samples were stored in 1 ml
RNALater (Ambion) or Trizol (Invitrogen) at -80°C. Before processing, the samples were
incubated for 5 minutes at room temperature, and once the sample was completely thawed,
150 μl chloroform per 800 μl sample was added, shaken vigorously by using a shaker for 15
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seconds and incubated further for 2-3 minutes at room temperature, followed by
centrifugation at 10,000 g for 20 minutes at 4°C. The aqueous phase was transferred to a new
tube and 1 ml of isopropanol containing 0.5 μl glycogen was added and the mixture was
vigorously shaken for 15 seconds. After incubation for 10 minutes at room temperature, the
samples were centrifuged at 10,000 g for 20 minutes at 4°C. The supernatant fluid was
removed and RNA pellet resuspended in 1 ml 75% ethanol. The RNA was recovered by
centrifugation at 10000 g for 20 minutes at 4°C and after removal of the supernatant fluid,
the RNA pellet was allowed to dry at room temperature. To the dried RNA pellet, 20μl dethyl
pyrocarbonate (DEPC) water was added and the sample was incubated at 60°C for 10
minutes to dissolve. RNA was stored at -80°C until to use.
2.2.1.2 First strand cDNA synthesis
1 μl of RNA was used to synthesize the first strand cDNA. The total reaction volumes were
20 μl and composed of : 1 mM of dNTP (Promega), 0.5 μg oligo dT (Promega), 1U RNase
inhibitor (Promega) and 500 U MMLV reverse transcriptase (Stratagene) in 1 reaction
buffer (Stratagene). The reaction mixture was incubated at 20°C for 10 minutes followed by
37°C incubation for 1 hour and 99°C for 5 minutes. The cDNA was stored at -80°C.
2.2.1.3 Standard PCR reactions
Standard PCR reactions were performed in a reaction mixture containing: 1-2 μl cDNA, 0.5
μM each primer, 0.25 mM dNTP, 1×PCR reaction buffer (QIAGEN) and 2.5 U Taq
polymerase (QIAGEN) in a total volume 20 or 50 μl (depended on how much products
required). The reaction conditions were as follows: 94°C for 5 minutes or 10 minutes (if the
templates were bacterial clones), then 30 cycles of 30-60 seconds at 94°C, 30-90 seconds at
55°C and 30-90 seconds at 72°C (depending on the size of the product to be attained), an
additional 10 minutes at 72°C were required to extend target PCR products. All PCR
products were examined by gel electrophoresis (0.8-1% agarose, in 0.5 TBE buffer, 120 V
for 40-50 minutes) and visualized with 5μl ethidium bromide (EB) per 100 ml agarose
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solution followed by image capture performed on the Gel Image system (Bio-Rad).
2.2.1.4 Real-time PCR
Relative quantification of genes of interest was detected by real-time PCR using a
LightCycler machine (Roche Molecular Biochemicals). Initially, a positive control was
determined by preliminary real-time PCR, identifying a reaction is considered to be a
positive control with a good standard amplication curve. In each reaction the positive control
sample of cDNA was 6 fold diluted from initial 1:10 dilution and was used as a standard
curve to estimate the expression levels of genes. PCR amplifications were performed in 10 μl
containing 3 μl cDNA, 1.4 μl SYBR Green I Master distilled H2O (Promega), 0.3 μl forward
and reverse primer each, and 5 μl SYBR Green I Master (Promega). The reaction was carried
out under the following conditions: 30 seconds denaturation at 95°C, 5 seconds annealing of
primers at 60°C and 20 seconds elongation at 72°C for 60 cycles. The amplication efficacy
was measured and data were recorded automatically. .
2.2.1.5 DNA isolation and purification
DNA isolation and purification was carried out according to the manufacturer’s instructions
of the QIA quick Gel Extraction kit. Gel electrophoresis (in 0.5 TBE buffer, 120 V for
40-50 minutes) was performed to visualize the target gene fragment band, which was the
excised from the agarose gel with a clean, sharp scalpel. The gel slice was weighed in a
colorless tube, and Buffer QG was added in a ratio of 1 to 3 weight to volume. The gel was
incubated at 50°C for 10 minutes. After the gel slice had dissolved completely, 1 gel volume
of isopropanol was added to the sample and mixed. The sample was applied to a QIAquick
2ml spin column in a provided 2 ml collection tube. To bind DNA, apply the sample to the
QIAquick column and centrifuged for 1 minute at 10,000 g. Unbound material was removed
by addition of 0.75 ml of Buffer QG to the QIAquick column and centrifuged for 1 minute at
10,000 g. The QIAquick column was transferred into a clean 1.5 ml microcentrifuge tube
and bound DNA eluted through addition of 50 μl of Buffer EB (10mM Tris-Cl, pH 8.5) and
- 50 -
centrifuged for 1 minute at 10,000 g. Purified DNA was stored at -20°C.
2.2.1.6 Plasmid construction
All plasmids used in experiments were constructed by using the “digestion-ligation”method
(Fig 2.1) and are listed in Appendix 3. Recombinant plasmids of pDEC-OVA and its
corresponding control pISO-OVA (Nchinda G et al., 2008) were a kind gift from the
Laboratory of Cellular Physiology and Immunology, the Rockefeller University. The
constructions of pDEC-OVA and its control pISO-OVA are illustrated in Fig 2.2. The
constructions of pSiEOS and pSiEOSSC are illustrated in Appendix 4, and constructions of












Fig 2.2 Schematic of construction of ALT, ADDALT, CPI2, CPImu, VAH and
TPX plasmids.
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2.2.1.7 Gene site directed mutation
Mutation of the CPI2 gene was carried out according to the manual of the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, Cat no.200519). Two complimentary
oligonucleotides containing the desired mutation of asn66 to lys66 (Fig 2.3) flanked by
unmodified nucleotide sequence were synthesized. Then the reaction was prepared as
follows: 5 l of 10×reaction buffer, 1l (5-50 ng) of dsDNA of CPI2, 1 μl (125 ng) of
forward primer , 1 μl (125 ng) of reverse primer, 1 μl of dNTP mix, and distilled water to a
final volume of 50 μl, then 1 μl of PfuTurbo DNA polymerase (2.5 U/μl) was added. The
conditions were as follows: 95°C for 30 seconds followed by 16 cycles of 95°C for 30
Fig 2.2 Construction strategy of pDEC-OVA and the control pISO-OVA, and
interaction between parasite antigens and DCs via DEC205 receptor. The “Target
protein”represents OVA gene or any parasite gene which is required for the DNA
vaccine. Antibody scDEC represents single chain anti-DEC205 antibody, which can
specifically interact with DEC205 receptor locate on the surface of DCs. The scDEC205
was constructed by fusion of heavy- and light-chain variable regions of monoclonal
antibody NLDC145 to DEC205 into a pcDNA3.1 vector. The scCont antibody is the
isotype of scDEC205 but cannot bind to DCs.
Promoter DEC-H DEC-L Target ProteinscDEC









seconds, 55°C for 60 seconds, 68°C for 12 minutes. Then the reaction was placed on ice for
2 minutes to cool the reaction to ≤37°C. 1 μl of the Dpn I restriction enzyme (10 U/μl) was
added directly to each amplification reaction. Gently and thoroughly mix each reaction
mixture by pipetting the solution up and down several times. The reaction mixtures were
spun in a microcentrifuge for 1 minute and immediately incubated at 37°C for 1 hour to
digest the parental supercoiled dsDNA. Then the transformation protocol (see 2.2.1.8) was
performed.
Fig 2.3 Schematic of CPI2 gene site direct mutation from Asn66 (N) to Lys66 (K).
2.2.1.8 Transformation of competent E. coli
The following procedure was used to transform host bacterial cells with all recombinant
plasmids: The vial(s) containing the ligation reaction(s) or plasmid was centrifuged and
placed on ice. 50 μl One Shot® Top10 or JM109 cells were used as hosts for the recombinant
plasmids. For each ligation/transformation, 2 l of each ligation reactions or plasmids were
directly added and mixed gently into 50 μl competent cells and held on ice for 30 minutes.
The suspension was then incubated for exactly 30 seconds at 42°C in a water bath before
being returned to an ice bath. 250 μl of pre-warmed S.O.C medium were added to the
bacterial suspension which was incubated in a shaker at 37°C for exactly 1 hour. After this
incubation period, 100 μl of the transformed cell suspension was applied to LB agar plates
which were then inverted and incubated at 37°C. Following overnight incubation individual
colonies were selected for analysis by agarose gel electrophoresis (0.8-1% agarose, in 0.5
TBE buffer, 120 V for 40-50 minutes). Colonies containing the required plasmid were grown






2.2.1.9 Small scale preparation of plasmid DNA
Small scale plasmid preparation was carried out according to the manufacturer’s instructions
of the QIAprep spin Miniprep kit. Transformed E. coli cells that harbor the plasmids of
interest were grown in LB containing antibiotic (50 g ml-1 ampicillin for pcDNA3.1-
plasmids or 10 g ml-1 kanamycin for pET- expression plasmids) at 37°C for 16 hours in a
shaking incubator. Bacteria from 10 ml of cultures were collected by centrifugation for 5
minutes at 10,000 g. The pelleted bacterial cells were resuspended in 250 l of Buffer P1 and
then 250 l of Buffer P2 were added and mixed by gentle inversion of the tube 4-6 times.
Then, 350 l of Buffer N3 were added and again mixed by gentle inversion 4-6 times. The
culture was then centrifuged for 10 minutes at maximum speed in tabletop microcentrifuge
and the supernatant fluid obtained (about 850 l) applied to the QIAprep column. Unbound
material was removed from the QIAprep column by centrifugal (1 minute at 10,000 g on a
microcentrifuge) washing with 750l Buffer PE. The QIAprep column was then placed in a
clean 1.5 ml microcentrifuge tube, and the bound DNA was eluted by addition of 50 l
buffer EB (10mM Tris-CL, pH 8.5). The columns were allowed to stand for 2 minutes before
eluted DNA was recovered by centrifugation for 1 minute. Eluted plasmid DNA was stored
at -20°C.
2.2.1.10 Sequencing and analysis of double-stranded plasmid DNA
Plasmid DNA was prepared for sequencing according to the instructions of BigDye®
XTerminator™ Purification Kit (Applied Biosystems). To 2 μl DNA templates were added: 3
μl distilled water; 2 μl 5×sequencing buffer (Bigdye terminator); 1μl sequencing primer
(usually T7 and/ or BGH, for pcDNA3.1-, pDEC- and pISO- plasmids; T7 and/ or T7
terminator for pET- plasmids); Bigdye solution 2 μl (total volume 10μl). Reactions were
performed through 25 cycles of 95°C for 30 seconds, 50°C for 20 seconds, and 60°C for 4
minutes, and stopped by cooling to 4°C or placing on ice.
Samples were sent to a specialist unit at the University of Edinburgh (The GenePool) for
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sequencing. Sequence editing was carried out with the DNASTAR's Lasergene sequence
analysis software, run on Windows XP. Sequence alignments were performed using
MegAlign program in DNASTAR's Lasergene. Sequences were extracted from the NCBI
database. Sequence comparisons with the national center of biotechnology information
(NCBI) database were performed using BLAST NCBI online program.
2.2.1.11 Large scale purification of plasmid DNA
Cultures were initiated by addition of 50 l E. coli carrying target plasmids into 500 ml of
LB broth containing 50 μg ml-1 ampicillin, and the suspension incubated at 37°C for 16 hours.
After this period the culture was centrifuged (6000 g, 30 minutes) at 4°C and the supernatant
fluid discarded. The bacterial pellet was resuspended in 10 ml Buffer P1 to which was then
added 10 ml Buffer P2. The suspension fluid was mixed thoroughly by vigorously inverting
the sealed tube 4-6 times and then incubated at room temperature (15–25°C) for 5 minutes.
Then, 10 ml of chilled Buffer P3 was added, mixed immediately and thoroughly by
vigorously inverting the tube 4-6 times, and the suspension fluid was incubated on ice for 20
minutes. The suspension fluid was then centrifuged at ≥20,000 g for 30 minutes at 4°C and
the supernatant fluid containing plasmid DNA recovered. This supernatant fluid was further
clarified by a second centrifugation at ≥20,000 g for 15 minutes at 4°C.
For purification of the plasmid DNA from the supernatant fluid, a QIAGEN-tip 500 column
was equilibrated by washing, under gravity, with 10 ml Buffer QBT. The supernatant fluid
containing the plasmids was then run through the QIAGEN-tip column under gravity. The
column was then washed with 2 30 ml Buffer QC. Next, the DNA was eluted with 15 ml
Buffer QF. The eluted fluid was collected into a 50 ml tube in which the DNA was
precipitated by addition of 10.5 ml (or 0.7 volumes) isopropanol at room-temperature.
Precipitated plasmid DNA was recovered by centrifugation at ≥15,000 g for 30 minutes at
4°C. The DNA pellet was then washed with 5 ml 70% ethanol at room-temperature and
again collected by centrifugation at ≥15,000 g for 10 minutes. The washed pellet was then
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air-dried for 5-10 minutes before being redissolved in TE buffer, pH 8.0. The yield of DNA
was determined by UV spectrophotometry at 260 nm and quantitative analysis on an agarose
gel. All plasmids were stored at -20°C.
2.2.2 Methods for protein analysis
2.2.2.1 Protein expression
2.2.2.1.1 Recombinant protein expression in E.coli
The recombinant of pET21b-(ALT/CPI2/VAH/TPX), pET29c-(ALT/CPI2/VAH/TPX),
pET24a –(ALT/CPI2/VAH/TPX) and pET30a-(ALT/CPI2/VAH/TPX) containing a T7 tag at
the N terminus and His tag at the C terminus (Appendix 5) were produced in bacteria
BL21(DE3) (Novagen, UK). The transformed bacteria were cultured at 37°C until the
absorbance at 600 nm reached 0.6, then expression of recombinant protein was induced by
the addition of isopropyl β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM.
The bacteria were then recovered by centrifugation at 6000 g for 30 minutes. The pellets
were weighed and then resuspended in His-tag binding buffer at a concentration of 1 gram of
cells per 5 ml buffer. They were then incubated for 20 minutes at room temperature and
resuspended in 50 ml of ice-cold His-binding buffer (20 mM sodium phosphate, 0.5 M NaCl,
10 mM imidazole) at a concentration of 1 gram of cells per 5 ml buffer, followed by
sonication on ice with 30 cycles (30 seconds on, 30 seconds off) at 23 KHz (MSE sonicator).
The sonicate was clarified by centrifugation at 6000 g for 30 minutes. The supernatant fluid
was collected before running the purification program 3 on AKTA system in Rick Lab. All
buffers (1 Charge Buffer, 1 Strip Buffer, 1 Binding Buffer and 1 Elution Buffer) were
prepared and connected to the right pipeline separately. The presence of recombinant protein
was determined by SDS-PAGE and Western blotting. Protein concentration was determined
by the Bradford method using protein assay dye reagent (Bio-Rad) with calibration using
bovine serum albumin (Sigma-Aldrich) serial dilution starting with 2mg/ml concentration
(see 2.2.2.4). Purified fractions were then dialyzed against phosphate buffered saline (PBS)
for 2 days with 2 replacements of PBS and aliquoted at -20°C.
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2.2.2.1.2 Protein expression in COS7 cell
Recombinant proteins were also produced using the eukaryote COS7 expression system. The
COS7 cells were obtained from Sigma, UK and maintained by passage as follows: complete
RPMI1640, distilled PBS and trypsin were prepared and warmed at 37°C before operation.
Cells were checked under a microscope, until confluence was about 95% and the cells were
healthy. The cells were gently washed with 7 ml PBS followed by the addition of 2 ml
trypsin enzyme, then incubated at 37°C for 5 minutes. Cells were transferred from the flask
to a tube and 0.2 ml cell liquid per 30 ml medium was added. Cells were incubated at 37°C
for 24-72 hours for use of plasmid expression in vitro.
Two reaction mixtures were prepared in Eppendorf tubes for each transfection. In tube 1,
1.25 g plasmid DNA was mixed with 500 l Opti-MEM I (Invitrogen). In tube 2, 2l
lipofectamine was added to 500 l Opti-MEM I. After 5 minutes, the DNA and
lipofectamine solutions were mixed in a single Eppendorf tube and allowed to react further.
After a further 20 minutes, the entire 1000 l transfection mixture was added to the 3 ml
COS7 cell cultures (in RMPI 1640 containing 10% FCS), which were then incubated for 5
hours at 37 °C. After this period, the cells were washed twice by centrifugation at 1100 g for
1 min with PBS. They were then resuspended in 3 ml RPMI 1640 (without FCS or
antibiotics) and incubated for a further 48 hours at 37°C. The culture supernatant fluid
containing expressed recombinant protein was collected by centrifugation at 1100 g for 5
minutes. The protein concentration was determined by the Bradford method using protein
assay dye reagent (Bio-Rad), and then stored at -80°C.
This procedure was also used to prepare recombinant proteins from: pcDNA3.1-ALT,
pcDNA3.1-ADDALT, pDEC-ADDALT, pISO-ADDALT, pcDNA3.1-CPI2,
pcDNA3.1-CPImu, pcDNA3.1-VAH, pcDNA3.1-TPX, pDEC-CPI2, pDEC-CPImu,
pDEC-VAH, pDEC-TPX, pISO-CPI2, pISO-CPImu, pISO-VAH, and pISO-TPX.
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2.2.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Commercial kits (Invitrogen, UK) were used for SDS-PAGE. The manufacture’s instructions
were followed throughout. Protein samples (including recombinant proteins ALT, CPI2,
VAH and TPX) were mixed with an equal volume of 2 SDS-PAGE sample buffer
(Invitrogen, UK) and boiled for 10 minutes before being applied to the gels. Electrophoresis
was performed at 200 volts (constant voltage) for 1 hour using the MiniPROTEIN system
(Bio-Rad). Gels were stained for 10 minutes with Coomassie blue solution and destained 5
times for about 1 hour using SDS Gel destain solution before transfer directly on to the
nitrocellulose filters for Western blotting.
2.2.2.3 Western blotting
Proteins were transferred from the gel to cellulose nitrate membranes for Western blotting by
electrophoresis at 30 volts for 1 hour. After transfer the membranes were washed twice for
10 minutes with 15 ml 1 TBS and then incubated for 1 hour in 5% skimmed milk in TBS to
block all remaining protein binding sites. This was followed by two washes of 20 minutes
with 1 TBSTT (4 ml Triton-x, 1 ml Tween-20 in 1 litre TBS) and a single wash for 10
minutes with 15 ml 1×TBS. The membrane was then incubated with either His-Tag
monoclonal antibody (Novagen, UK) or polyclonal antisera against individual recombinant
proteins (ALT, CPI2, VAH and TPX) from mice diluted in 5% skimmed milk in TBS
blocking buffer. After 1 hour incubation, the membrane was washed twice for 20 minutes in
1 TBSTT, then for 10 minutes with 1TBS. The membrane was then incubated with goat
anti-mouse IgG alkaline phosphatase conjugate (Invitrogen, UK) diluted (1:5000) in
blocking buffer for 8 hours. The membrane was washed 5 5 minutes with 1TBSTT and
then incubated with the substrate (specify) Chemi Glow (luminol/enhancer solution: stable
peroxide buffer =1: 1) (Alpha, USA) until the color developed and then the reaction stopped
by absorption the rest of substrates. The results were recorded using the Gel Image system
(Bio-Rad).
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2.2.2.4 Determination of protein concentration
The protein concentration was determined by Coomassie (Bradford) Protein Assay (Pierce)
on dialyzed samples. The assay was performed in duplicate with the dialysis buffer as a
control, 8 serial dilutions of (top concentration of 2 mg ml -1) BSA as the standard, and the
plate was read at 540 nm.
2.2.3 In vitro lymph node cell culture
Lymph nodes recovered from mice and washed in RPMI 1640 were crushed between two
pieces of autoclaved filcotex/ Nitex plate and then diced with scissors in 500 l of RPMI
1640 in a petri dish. The larger pieces of lymph node were allowed to settle and then the
supernatant fluid collected and transferred to a 15 ml Falcon tube with RPMI 1640 added to
a volume of 5 ml. Cells were spun down at 1100 g for 5 minutes, followed by resuspension
in 5 ml RPMI 1640. Cells were counted and resuspended at 5×106/ml. 3 ml of RBC Lysis
Buffer (Sigma) were added and mixed well after discarding the supernatant. After a further 4
minutes, 10 ml of RPMI 1640 were added and the cells were spun down at 1100 g for 5
minutes, followed by a finally resuspension in 10 ml RPMI 1640. Cells were counted and
resuspended at 107/ml. Each well of 96 well plates was dispensed with cells 100 l of cells
(5×105/well). Cultures were incubated at 37°C in 5% CO2 incubator.
2.2.4 Cell proliferation assays
For in vitro cell proliferation, lymph node cells were cultured in triplicate with L. sigmodontis
antigen (final concentration 10 g/ml), RPMI 1640 and anti-CD3 (final concentration 1 g/ml) in
a final volume of 200 l. Cultures were incubated at 37℃ in 5% CO2 for 48 hours followed by
addition of 10% of total volume Alamar Blue (Invitrogen, UK) and incubated for another 24
hours. Plates were read at 540 nm for proliferation. Then the plates were spun down at 1100 g for
2 minutes, and the supernatant fluid was harvested carefully by avoiding the cells. The
supernatant fluid was kept at -20℃ for further cytokines analyses.
- 59 -
2.2.5 Cytospin assay
Cytocentrifuge preparations from 200 l cells (see 2.2.7) from the pleural cavity (2106
cells/ml) in PBS were made using a Shandon Cytospin or Cytospin 4 (Thermo) at 200 g for 5
minutes. The slides were dried at room temperature overnight, then the slides were stained
with Diff-Quick (Dade) according to the manufacturer’s instructions. Briefly, Quick-Diff
FIX was added to the slides 10 times, 1 second each followed by Quick-Diff RED 6 times,1
second each and Quick-Diff BLUE 10 times ,1 second each. Once the slides had dried, DPX
mountant for histology (Sigma) was used to seal the slides with small cover slips. The cell
numbers and types were determined by microscopic examination of at least 300 cells per
slide.
2.2.6 Enzyme linked immuno-sorbent assay (ELISA)
2.2.6.1 IgG assay
Specific anti-L. sigmodontis IgG1 and IgG2a responses were measured by indirect ELISA
against whole soluble extract coated at 10 mg/ml, and anti-LsALT1, anti-LsCPI2, anti-VAH
or anti-TPX antibodies against the respective recombinant proteins coated at 50 µl per well
at 5 mg/ml by indirect ELISA. Briefly, after antigen coating, plates were blocked with 200 μl
PBS + BSA 4% per well. After washing with TBST solution, 50 μl of serially diluted serum
were added (starting at 1: 400, serial dilution 1:2) when measuring titres, or at 1/800 when
O.D. were used, and incubated overnight. Biotinylated detection antibody diluted in
PBS+BSA 1% (IgG1: 1/6000 (goat anti mouse, Adsorbed Southern Biotech, Cat no 1070-05),
IgG2a:1/4000 (goat anti mouse, Adsorbed Southern Biotech, Cat no 1080-05) was added for
2h at room temperature, and wells were incubated in 50%TMB-50% H2O2 (KPL) and
stopped with addition of 25 µl of 1 mM H2SO4 when the blanks developed blue. Plates were
read at 450 nm within 10 minutes of acid addition. Antibody titres were determined as the
highest dilution factor for which O.D. values exceeded 3 standard deviations above control
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wells on the same plate.
2.2.6.2 IgE determination
Total IgE production throughout all experiments was measured by sandwich ELISA. 96
wells plates were coated with IgE capture antibody (rat anti mouse, clone R35-72, BD
Pharmingen, Cat No. 553413) diluted in carbonate buffer at 2μg/ml. After 4 times wash with
TBST, plates were blocked with 100μl per well 5% skimmed milk carbonate buffer, and
incubated with serum samples (1:100) or standards (purified mouse IgE, BD Pharmingen,
Cat no. 557079, top standard concentration at 5μg/ml, diluted serially 1:2) at 37°C for 2
hours. 50µl per well detection biotinylated antibody (rat anti mouse IgE, BD Pharmingen,
Cat no. 553419) was added after washing at 2μg/ ml in 0.5% FCS-TBST after which 100μl
Extravidin Peroxidase (1/8000, cat: E2886, Sigma, UK) and incubated at 37°C for 30
minutes, then 100μl TMB substrate per well were added after 5 times plates wash. The
reaction was stopped with 50μl 1 mM H2SO4 per well, and plates were read in a
spectrophotometer at 450nm.
2.2.6.3 Cytokine detection
Cytokines of IL4, IL5, IL10, IFNγ and IL13 were detected by sandwich ELISA as follows.
96 wells plates were coated at 50 µl/well with capture antibody [all cytokines were tested
with ELISA kits, IL4 kit (cat: KMC0041, Invitrogen UK); IL5 kit (cat: CMC0053,
Invitrogen UK); IL10 kit (cat: CMC0103, Invitrogen UK); IL13 kit (cat: CMC2223,
Invitrogen UK); IFNγ kit (cat: CMC4033, Invitrogen UK), respectively in carbonate buffer 
(the dilution factor was 1:500 for IL4, IL10, IFN and 1: 250 for IL5 and IL13)]. Plates were
incubated at 4°C overnight. Plates were lavaged 3 times with TBST followed by incubation
in PBS + 4%BSA (200µl / well) for 2 hours at room temperature in the dark. Then 50 µl /
well 2-fold diluted standard (top concentration: IL4 at 8 ng/ml, IL5, IL10, IL13 at 10 ng/ml,
IFN at 50 ng/ml diluted with PBS-BSA 1% for IL4, IL5, IL10, IFN, and dulbecco's
modified eagle medium (DMEM) -5% FCS for IL13) was added in duplicate after wash,
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followed by the addition of 50 µl / well sera samples, and then incubated at 4°C overnight.
Plates were lavaged 3 times and incubated in biotinylated antibody (final dilution: IL4, IL5,
IFN at 1 µg/ml , IL13 and IL10 at 2 µg/ml, dilution buffer for IL4, IL5, IFN and IL10 was
PBS-BSA 1%, for IL13, TBST- 5% FCS) for 1 hour at room temperature followed by 30
minutes incubation in AMDEX streptavidin-peroxidase (cat: E2886, Sigma, UK) with
dilution 1: 6000 in PBS-1%BSA (IL13 in TBST-5% FCS) after lavaging 3 times. 50 l/well
TMB (cat: 002023, Invitrogen UK) was added and incubated in dark at room temperature.
When blue was intense only in upper standard wells, the reaction was blocked by addition of
20 µl per well H2SO4 at 1 mM. Plates were read at 450 nm.
2.2.7 Immunization and Necropsy
For immunization, female BALB/c mice, 6-8 weeks old, were divided into groups of 6
animals. Each mouse was vaccinated by inoculation of 40 µg plasmid plus adjuvant (pIL4 or
pIL4+pFlt3L+pMIP1) into the tibialis muscle. After vaccination, electroporation (ECM 830,
BTX, Harvard Apparatus) was performed with parameters of 100 v/cm, 8 pulses, 20.4
miliseconds per pulse length and 460 miliseconds interval between pulses. Challenge
infections of 25, 30 or 40 L3s were administered 4 weeks after the second dose. The time
interval between boots was 4 weeks. Necropsy was performed 10 days or 60 days post
challenge as follows: the mice were euthanized with Vetelar/ Domitor and the thoracic
lavage cells were obtained by thorough washing of the pleural cavity with total 10 ml cool
PBS. The supernatant fluid was separated and kept for cytokines detection and cytospin
procedures. Worms were pooled into one tube and fixed with final 70% ethyl alcohol. The
mediastinal and parathymic lymph node in thoracic cavity were removed for cell culture.
2.2.8 Larval, adult and Microfilariae counting
Worms were counted for measurement of protection. Intact worms were counted under
microscope one by one. For the microfilariae counting, tube containing 30 μl mouse heart
blood per 200 ml FACS lysing solution (cat no 349202, Becton Dickinson ) was centrifuged,
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then 120 μl supernatant fluid was dropped out. The rest pellet and solution in the tube was
smeared onto slide and the Mf were counted. Protection rate was calculated based on the
worms recovered from primary infection and vaccinated challenge group, respectively. The
formula is: protection %= (average of primary infection-average of vaccinated challenge)/
average of primary infection 100%.
2.2.9 Flow cytometry
Spleen cell suspensions were prepared for flow cytometry at 1106 cells per well in
supplemented RPMI 1640 medium, then were incubated at 4℃ for 5 minutes in CD16/32
blocking buffer (5g/ml in 1:20 2% mouse serum with FACS buffer: PBS plus 0.5%BSA
and 0.05% sodium azide, mainly to reduce the unspecific bounding by block the FcRs on the
antibodies), followed by staining for 30 minutes at 4℃ in dark with antibodies at the
appropriate dilution as determined by titration. The antibodies were generally directly
fluorochrome conjugated or biotinylated. The antibodies included anti-F4/80-FITC (1:100);
anti-SiglecF-PE (1:100); anti-CD4-PCP(1:100); anti-CD5-FITC (1:100); anti-B220-PCP
(1;100); anti-CD25-PE (1:100) and anti-Foxp3-FITC (1:100), as well as the appropriate
isotype control antibodies (IgG2a, К-FITC, IgG2a, К-PE, IgG2a, К- biotinylated). The cells
were then washed 3 times in FACS buffers before acquisition and analysis.
2.3 Statistical analyses
For assessing the statistical difference between two groups, Mann Whitney U test which
compares medians instead of means was used. When the P-values were less than 0.05,
differences between groups were considered significant. The mean +/- SE is shown unless
otherwise stated. All graphs were prepared using PRISM (version 4.0, GraphPad Software,
Berkeley, CA). For the analysis of contributors of protection, differences between mouse
groups were analyzed with generalized linear models (GLM) or regression linear model.
When the P-values were less than 0.05, differences between groups were considered
significant. The non parametric Kruskal-Wallis rank sum test followed by Dunn’s test for
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multiple comparisons were applied for parasite counts for which a post-hoc test was required.
A principal component analysis (PCA) was performed to reduce large numbers of
immunological measurements into fewer independent components. Briefly, data was scaled
to null mean and unit standard deviation, the broken stick model was then used to select
interpretable principal components, the biological interpretations of which were based on the
size of individual rotations.
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Chapter 3-Enhancement of immunogenicity and vaccine
potential of ALT and CPI2 via modification of gene
structure
3.1 Introduction
Infections with filarial nematodes are still major causes of public health in tropical and
subtropical areas. About 150-200 millions people in more than 80 countries are infected with
onchocerciasis and lymphatic filariasis. This situation has already been shown to be
associated with the capability of most helminths to modulate or suppress the host’s immune
system in such a way to tolerate the parasites for a long life span.
How do helminths inhibit host immune attack and prolong their survival? The answers still
remain unclear because of the involvement of factors from hosts, parasites and environments.
However, after decades of research, scientists have obtained some explanations. The
observation of lymphocyte hypo-responsiveness which showed that lymphocytes isolated
from infected people failed to respond to worm antigens (Ottesen EA et al., 1977), indicating
the existence of immuno-suppression caused by parasites, this hypothesis was supported by
similar findings in rodent models of filariasis (Weiss N using Dipetalonema. viteae 1978).
Presently, the common view is that the suppression from filarial infection is associated with
the presence of Mf in the bloodstream (Weller PF, 1978; Dalesandro DA, 1976; Lammie PJ,
Katz SP, 1983a; Lammie PJ, Katz SP, 1983b; O`Connor RA et al., 2000; O`Connor RA et al.,
2003) and other stages especially the infective larva stage ( King CL, 2001; Semnani RT et
al., 2004; Babu S et al., 2006) .
Helminths infections are found to have the ability to modulate immunity in both humans and
animal models. Helminth induced T-cell hypo-responsiveness is partially caused by the
modulation of dendritic cells (DCs) and macrophages. For example, activation of DCs can be
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modulated by CD4+ natural killer cells produced during schistosome infection (Speziali E et
al, 2010). Production of Tr1 cells from human DCs was modulated by TLR2-dependent
mechanism through a schistosomes-originated glycolipid. Moreover, T cell suppression
could be modulated by schistosome infection (Olds GR, Ellner JJ, 1984).
Studies on mouse models using filarial parasites have shown that CD4+ antigen specific T
cell proliferations could be inhibited by helminth-induced alternatively activated
macrophages which contributed to the protection of host from infection (Siracusa MC et al,
2008). In addition, granulocytes including eosinophils, mast cells, neutrophils and basophils,
which were regarded as effectors, are now found to play a role as immuno-modulators
(Cadman ET, Lawrence RA, 2010)
Helminth parasites can induce CD4+CD25+ regulator T cells and other types of regulatory T
cells (for instance Tr1, CD4+Foxp3+ cells) which can control Th2 responses and pathology
and influence helminth survival. IL10, which is produced by iTreg cells and non-T cells,
plays an important role in regulation of pathology during infection. In addition, the Foxp3
Treg cells also play a key role in the down-regulation of immune responses ( Mahanty S,
Nutman TB, 1995; Bluestone JA, Abbas AK, 2003; Mittrucker HW, Kaufmann SH, 2004;
Satogunia J et al., 2005).
A significant number of worm-derived molecules with immuno-modulatory prosperities have
been examed including carbohydrates [i.e.lacto-N-fucopentaose III, GalNAc (Fuc1-2
Fuc1-3) GlcNAc] (Thomas PG, Harn DA Jr, 2004), lipids and lipid-associated moieties (i.e.
Schistosome-derived lyso-phosphatidylserine) which has the ability to induce Tr1 (Van der
Kleij D et al., 2002); nucleic acids which can activate DCs and C-type lectins (DC-SIGN)
(Meyer S et al., 2005) which can interact with worms leading to the changes in
immunological phenotype; the excretory/secretory proteins, for example, cystatins, which
play a role in interfering with antigen presentation by monocytes (Hartmann S, Lucius R,
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2003) and polyproteins, which cause polyclonal antibody from B cells with stimulation of
IL4 (Tezuka H et al., 2002).
The present study has focused on two proteins, ALT and CPI2, which have been reported to
induce protective immune responses when used as vaccine candidates. More importantly,
they were reported to inhibit the immune responses as mentioned in Chapter 1
(Gomez-Escobar et al., 2005; Murray J et al., 2005; Manoury et al., 2001). The results
presented are aimed at the capabilities of ALT and CPI2 to evoke protective responses after
removal of their immunomodulatory properties.
3.2 Results
3.2.1 Isolation of ALT and CPI2 genes
ALT and CPI2 gene sequences from L. sigmodontis were downloaded from GeneBank
(http://www.ncbi.nlm.nih.gov/). The RT-PCR and standard PCR techniques were used to
isolate ALT and CPI2 genes from L. sigmodontis L3 larvae stage and adult worm using
ALT-specific and CPI2-specific primers, respectively (see primer table in chapter 2).
Electrophoresis shows that the right size of amplicon of ALT (444bp), ADDALT (306 bp)
and CPI2 (543 bp) were obtained (Fig 3.1). The sequences obtained were analyzed using the
MegAlign program in DNASTAR Lasergene 7.1 software to check their authenticities and
the results are shown in Fig 3.2 and 3.3. Alignments with B. malayi ALT1 (U57547), ALT2
(U84723) and W. bancrofti (AF084553) show that Ls-ALT1 includes a variable acidic
domain (aa 22-67). The programs of BLASTn using nucleotide sequence and BLASTp using
amino acid sequences were used to identify the isolated Ls-ALT gene. BLASTn showed the
isolate shares high similarities with Bm-ALT2 gene (XM-001896791) and L. sigmodontis
abundant larval transcript-1 (ALT1) (DQ451171) (identities = 79% and 100%, respectively).
BLASTp result showed the isolate shares high similarity (e value = 5e-80) with abundant
larval transcript-1 protein (ABE02808), and belongs to the Chromadorea ALT superfamily,
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suggesting the correct gene of ALT had been obtained.
In the case of CPI2, the BLASTn result showed the isolate shares high identities (99%) with
L. sigmodontis Ls-cystatin precursor (AF229173), and the BLASTp results showed it shares
high similarity (e value=5e-66) with Ls-cystatin precursor (AAF35896) and belongs to CY
superfamily. The alignments with B. malayi (Bm-CPI-1, U80972), Bm-CPI-2 (AF015263),
O. volvulus (Ov-CPI-1 AF177194; Ov-CPI-2, P22085), L. sigmodontis (Ls-CPI, AF229173),
A. viteae (Av-CP, L43053), N. brasiliensis (Nb-CPI, AB050883), H. contortus (Hc-CPI,
AF035945) and Chicken cystatin C (P01038) showed that conserved features SND, QVVAG
and PW motifs are all present in Ls-CPI-1 and Ls-CPI-2, suggesting the correct gene of CPI
had been obtained. Interestingly, the SND motif, reported to be present in Bm-CPI-2, not in
Bm-CPI-1, was found in both the Ls-CPI-1 and Ls-CPI-2 genes.
Fig. 3.1 Electrophoresis of RT- PCR amplification of ALT, ADDALT and CPI2 in
0.5% TBE solution at 120 V for 40 minutes. Adult worms from jird were used as source
of mRNA. (A) PCR products of ALT. M. 100 bp ladder marker; 1, 2 ALT; (B). PCR
products of ADDALT. M. 100 bp ladder marker; 1, ADDALT; (C) PCR products of CPI2.
M. 100 bp ladder marker; 1, 2 CPI2;
543 bp
C M 1 2
444bp












Fig. 3.2. Analysis of Ls-ALT protein using DNASTAR Lasergene 7.1 software. (A)
Alignment of sequence of L.sigmodontis ALT-1 compared to B. malayi ALT , ALT2 and W.
bancrofti. The intron position in W. bancrofti has not been determined. (B) Sequence distance
result of alignment of ALT proteins. Clustal W in program MegAlign was used to determine
alignment. Ls-ALT, A. viteae ALT, B. malayi ALT, ALT2 and W. bancrofti, Ov-ALT-2 and





Fig.3.3 Comparison of L. sigmodontis and other cystatin sequences. (A) Sequence
alignment of L. sigmodontis and other metazoan cystatins. The proposed AEP-binding loop
residues (numbered 66–68) are outlined in red boxes. The cystatin-specific flexible loop,
QVVAG in Ls-CPI-1 and Ls-CPI-2, is also shown. Accession numbers for cDNA or protein
sequences are as follows: B.malayi –Bm-CPI-1; Bm-CPI-2; O.volvulus –Ov-CPI-1;
Ov-CPI-2; L. sigmodontis–Ls-CPI; A. viteae–Av-CPI; N. brasiliensis –Nb-CPI; H. contortus
–Hc-CPI; Chicken cystatin C. (B) Sequence distance result of alignment of ALT proteins.
Clustal W in MegAlign program was used to construct alignment. B. malayi –Bm-CPI-1;
Bm-CPI-2; O. volvulus –Ov-CPI-1; Ov-CPI-2; L.sigmodontis–Ls-CPI-2, A. viteae –Av-CPI;
N. brasiliensis –Nb-CPI; Chicken cystatin C were applied to process. (C). Outline of the











3.2.2 Site-directed mutagenesis of Ls-CPI2 to Ls-CPImu
A site-directed mutagenesis of Ls-CPI2 gene which is the substitution of Asn66 with Lys66
was performed, this mutation was named Ls-CPImu (Fig. 3. 4). PCR identification and DNA
sequencing showed it was mutated into Lys66 successfully. The DpnI enzyme was used to
distinguish the methylate and unmethylated DNA.
3.2.3 Construction of plasmids
PCR products of ALT, ADDALT and CPI2 for pcDNA3.1- construction were ligated into
pcDNATM3.1Directional TOPO expression vector (5514 bp backbone length) according to
the kit instruction. The pDEC205- plasmids contain the antibody scDEC205 which targets
DEC205 receptor of DCs. Antibody pISO- plasmids were constructed as controls. Before the
ligation into vectors, pDEC205-OVA (OVA gene size 1167bp) and pISO-OVA were double
digested with NotI/ XbaI enzymes (Fig.3.5). Then, NotI/ XbaI-digested PCR products of
ADDALT, CPI2 and CPImu were ligated into digested pDEC205- and pISO- to replace the
OVA gene on the vector, respectively. Clones were confirmed by PCR using T7 and BGH
primers, respectively (Fig. 3.6). Expression plasmids of pET29c-CPI2 and pET21b-ALT







Fig.3.4 Agarose electrophoresis of site-directed mutagenesis of Ls-CPI2 in 0.5%
TBE solution at 120 V for 40 minutes. (A) PCR amplification of pcDNA3.1-CPImu;
(B) single digestion of pcDNA3.1-CPI2 with DpnI enzyme.
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NdeI/ XhoI digested pET29c and pET21b, respectively. Clones were confirmed by PCR
using T7 and T7 terminator primers. The plasmids of pcDNA3.1-ADDALT,
pDEC205-ADDALT, pcDNA3.1-CPI2, pcDNA3.1-CPImu, pDEC205-CPI2,
pDEC205-CPImu, pISO-ADDALT, pISO-CPI2, pISO-CPImu, pET29c-CPI2 and
pET21b-ALT were sent for sequencing and results showed that all plasmids were constructed
successfully.









Fig. 3.5 Agarose electrophoresis of double digestion of plasmids for construction of
vaccines in 0.5% TBE solution at 120 V for 40 minutes. (A) pDEC205-OVA and
pISO-OVA using NotI/XbaI. M, 1kb marker. 1, undigested pDEC205-OVA. 2, 3, digested
pDEC205-OVA. 4, undigested pISO-OVA. 5, 6, digested pISO-OVA; (B) pcDNA3.1-ALT
and pcDNA3.1-ADDALT. M, 100bp marker. 1, digested pcDNA3.1-ALT. 2, digested
pcDNA3.1-ADDALT with BamH I/ XbaI; (C) pcDNA3.1-CPI2 and pcDNA3.1-CPImu
using BamH I/ XbaI. M, 100bp marker. 1, digested pcDNA3.1-CPI2. 2, digested
pcDNA3.1-CPImu; (D) pDEC205-CPI2. M, 100bp marker. 1, empty pDEC205. 2,
NotI/XbaI digested pDEC205-CPI2; (E) pET29c-CPI2 double digestion with NdeI/XhoI.
M, 1000bp marker. 1, digested pET29c-CPI2. (F) pET21b-ALT double digestion with
NdeI/XhoI. M, 100bp marker. 1, undigested pET21b-ALT 2, digested pET21b-ALT.
M 1 2 M
500bp
300bp







Fig.3.6 Electrophoresis of PCR identification of plasmids in 0.5% TBE solution at 120
V for 40 minutes.. (A).pcDNA3.1-ADDALT and pcDNA3.1-ALT using T7/BGH primers.
M, 100bp marker; 1, pcDNA3.1-ADDALT; 2, pcDNA3.1-ALT (B) pcDNA3.1-CPI2 and
pcDNA3.1-CPImu using T7/BGH primers. M, 100bp marker. 1, pcDNA3.1-CPI2. 2, 3,
pcDNA3.1-CPImu; (C) pDEC205-ADDALT and pISO-ADDALT using T7/BGH primers.
M, 100bp marker. 1, pDEC205-ADDALT, 2, pISO-ADDALT; (D) pDEC205-CPImu and
pISO-CPI2 using T7/BGH primers. M, 100bp marker. 1, pDEC205-CPImu ,2, pISO-CPI2;
(E) pET29c-CPI2 using T7/T7 terminator primers. M, 100bp marker. 1, pET29c-CPI2; (F)
pET21b-ALT using T7/T7 terminator primers. M, 100bp marker. 1, pET21b-ALT.
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3.2.4 Protein expression in E. coli and purification of recombinant
antigen
To prepare antigens for ELISA, two genes, CPI2 and ALT, were sub-cloned into expression
vector pET29c and pET21b, respectively, in which the recombinant protein carries a poly
His tag. To determine the optimal expression, IPTG concentration (0.5 mM,1 mM, 2 mM),
host strain (competent cell BL21-DE3 and Rosseta-gami 2), and temperature (22°C, 25°C,
30°C, 37°C) were tested. Pellets and supernatant fluids on 1, 2, 3, 4, 5 hour after IPTG
induction were assessed by SDS-PAGE electrophoresis as shown in (Fig 3.7), which showed
that the protein of CPI2 was expressed best at 37°C, 5 hour after 0.5 mM IPTG induction
while ALT was expressed best at 37°C, 4 hour after 1 mM IPTG induction and the pellet
contained most of the expressed proteins. The concentration of purified protein measured by
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Fig. 3.7 SDS-PAGE electrophoresis of recombinant CPI2 and ALT at 200 V for 1 hour.
(A). Protein expression of pET29c-CPI2 at 37℃ on different time points. M, See Blue plus
2 prestained standard( Invitrogen, UK). 1, uninduced empty pET29c. 2, uninduced
pET29c-CPI2. 3, pET29c-CPI2 2 hour after 0.5mM IPTG induction. 4, pET29c-CPI2 3 hour
after 0.5mM IPTG induction. 5, pET29c-CPI2 4 hour after 0.5mM IPTG induction. 6,
pET29c-CPI2 5 hour after 0.5mM IPTG induction. 7, pET29c-CPI2 overnight after 0.5mM
IPTG induction. (B). CPI2 protein eluted from His-binding column in the fractions. M, See
Blue plus 2 prestained standard( Invitrogen, UK). 1-9: puritied fractions. (C). Protein
expression of pET21b-ALT at 37℃ on different time points. M, See Blue plus 2 prestained
standard( Invitrogen, UK). 1, uninduced empty pET21b. 2, uninduced pET21b-ALT. 3,
pET21b- ALT 2 hour after 0.5mM IPTG induction. 4, pET21b-ALT 3 hour after 0.5mM
IPTG induction. 5, pET21b-ALT 4 hour after 0.5mM IPTG induction. 6, pET21b-ALT 5
hour after 0.5mM IPTG induction. 7, pET21b-ALT overnight after 0.5mM IPTG induction.
(D). ALT protein eluted from His-bounding column in the fractions. M, See Blue plus 2
prestained standard (Invitrogen, UK). 1-6: puritied fractions. Molecular Weight
CPI2:11KDa; ALT: 14KDa











3.2.5 Identification of ALT and CPI2 by Western blotting
The ALT and CPI2 proteins expressed in E. coli were identified using Western blotting.
Results showed that ALT / CPI2 protein from the pET21b / pET29C vector expressed in E.
coli were recognized by the sera from mice immunized with plasmid pcDNA3.1-ALT and
pcDNA3.1-CPI2, respectively (Fig 3.8).
3.2.6 Protein expression in COS7 cell and identification
1.25 g DNA of each plasmid (pcDNA3.1-ALT, pcDNA3.1-ADDALT, pDEC-ADDALT,
pISO-ADDALT which expressed an irrelevant antibody that did not bind to DCs,
pcDNA3.1-CPI2, pcDNA3.1-CPImu, pDEC-CPI2, pDEC-CPImu, pISO-CPI2 and
pISO-CPImu) was transfected into COS7 cells. Transfection remained for 48 hours, and
supernatants for secreted protein and /or lysed cells were collected for protein harvesting.
Reverse transcription PCR and Western blotting were carried out to identify whether the
plasmid expressed in COS7 cell, or not. Results showed the transcripts of all plasmids were
detected using ALT- or CPI2-specific primers (Fig. 3.9) and all proteins expressed in COS7
cell could be recognized strongly by the serum from the ALT- or CPI2 DNA immunized mice
(Fig. 3.10).
Fig. 3.8 Electrophoresis of Western blotting of ALT (A) and CPI2 (B) protein against
sera from immunized mice with pcDNA3.1-ALT and pcDNA3.1-CPI2 vaccine,
respectively at 30 V for 1 hour. Protein was separated under reducing conditions on a
10-12% acrylamide gel. Gel was probed with sera from immunized mice with






3.2.7 Tissue distribution of ALT / CPI2 plasmids in mice
In order to test the efficiency and distribution of plasmids of ALT, ADDALT, OVA, CPI2 and
CPImu in mice following the intramuscular injection and electroporation, two doses of




Fig. 3.9 Electrophoresis of RT-PCR amplification of gene expression in COS7 cells in
0.5% TBE solution at 120 V for 40 minutes. Plasmids of ALT, CPI2 and CPImu were
transfected into COS7 cells in vitro, then cells were harvested and ultrasonicated, mRNA
was extracted to for RT-PCR. M: 100bp DNA ladder; 1, 2: pcDNACPI2; 3: pcDNACPImu;
4: pDECCPI2; 5: pDECCPImu; 6: pISOCPI2; 7: pISOCPImu; 8: pcDNAALT; 9:
pcDNAADDALT; 10: pDECADDALT; 11: pISOADDALT.
Fig. 3.10 Elctrophoresis of Western blotting of proteins expression in COS7 cells
under reducing conditions on a 10-12% acrylamide gel at 30 V for 1 hour. Plasmids of
ALT, CPI2 and CPImu were transfected into COS7 cells in vitro, then cells were harvested
and ultrasonicated, and the supernatant fluids were used to perform the Western blotting
against the serum from the ALT and CPI2 DNA vaccinated mice. (A). Western blotting of
CPI2 and CPImu; 1, pcDNACPImu; 2, pDECCPImu; 3, pISOCPImu; (B). Western blotting of
CPI2 and CPImu; 1, pcDNACPI2; 2, pDECCPI2; 3, pISOCPI2; (C). Western blotting of ALT
and ADDALT; 1, pcDNAALT; 2, pcDNAADDALT; 3, pDECADDALT; 4, pISOADDALT.
11KDa
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plasmid were given at 2 weeks intervals and necropsy was performed at 28 days after final
immunization. Murine tissue was collected at the point of injection together with spleen,
liver and lung and prepared for mRNA extractions. Reverse transcription PCRs with
ADDALT- and CPI2-specific primers and T7 /BGH primers (which locate the flank of
inserted gene on the plasmids, implying the existence of plasmids in tissues) were carried out.
The results showed all genes were expressed in muscle, spleen, liver and lung when specific
primers were used, but the OVA gene was not expressed in liver. All the positive PCR
detections in muscle, spleen, liver and lung when T7/BGH primers were used showed the
evidence of presence of plasmids (Table 3.1). The ALT/ADDALT vaccines were intensively
distributed in muscle, spleen and lung, whereas most CPI2/ CPImu vaccines were expressed
strongly in muscle, spleen and liver (Table 3.1).
Real time PCR was applied to test the quantity of genes expressed in local muscle. All
vaccines were expressed in different levels, but the single chain DEC205- carried ADDALT
and CPI2 vaccines expressed at higher levels than the others.(Fig 3.12). Fig 3.11 shows four
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Fig.3.11 Electrophoresis of tissue distribution of ALT/CPI2 plasmids in mice in 0.5%
TBE solution at 120 V for 40 minutes. All plasmids of ALT, ADDALT, OVA, CPI2 and
CPImu were injected into muscle twice followed by the electroporation, 28 days later,
muscle, spleen, liver and lung were taken to detect the gene distribution by specific
primers and T7/ BGH primers by reverse transcriptional PCR. (A). ALT/ADDALT
distribution in spleen detected by ADDALT-specific primers. 1-5: pcDNA-ADDALT;
2-10: pDEC-ADDALT; 11-15: pISO-ADDALT; 16-17: pcDNA-ALT; (B). ALT/ADDALT
distribution in lung/liver detected by T7/BGH primers. 1-5; pcDNA-ALT in lung; 2-10:
pcDNA-ADDALT in lung; 11-16: pcDNA-ADDALT in liver; (C). CP2/CPImu
distribution in muscle detected by CPI2-specific primers.1-5: pcDNA-CPI2; 6-10:
pDEC-CPImu; 11: pcDNA-CPImu; (D). CP2/CPImu distribution in muscle detected by
T7/BGH primers.1-5: pcDNA-CPI2; 6-10: pcDNA-CPImu; 11-15; pDEC-CPImu; 16-17:
pcDNA-CPI2; (E). ADDALT distribution detected by ADDALT-specific primers. 1-3:
ADDALT; 4-6: OVA; 7-9: Naïve; (F). OVA distribution detected by OVA-specific
primers.1-3: ADDALT; 4-6: OVA; 7-9: Naïve (G). CP2/CPImu distribution detected by
CPI2-specific primers.1-3: CPI2; 4-6: CPImu; 7-9: OVA; 10-12: Naïve; (H). OVA
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Specific primers T7/BGH primers
plasmid Muscle spleen lung liver Muscle spleen lung liver
pcDNA-ADDALT +++ ++ ++ + + + ++ ++
pDEC-ADDALT +++ ++ ++ + + + ++ ++
pISO-ADDALT +++ ++ ++ + + + ++ ++
pDEC-OVA + ++ + - + + + +
pISO-OVA + ++ + - + + + +
pcDNA-ALT +++ ++ ++ + + + ++ ++
pcDNA-CPI2 +++ ++ + +++ + + + +
pDEC-CPI2 +++ ++ + +++ + + + +
pcDNA-CPImu +++ ++ + +++ + + + +
pDEC-CPImu +++ ++ + +++ + + + +
pISO-CPImu +++ ++ + +++ + + + +
pISO-CPI2 +++ ++ + +++ + + + +
Naïve - - - - - - - -
Table. 3.1 Summary of tissue distribution of ALT, ADDALT, OVA, CPI2 and CPImu
vaccines in mice detected by RT-PCR ( for detection of expressed sequence) and
standard PCR (for detection of existence of plasmids)
Fig 3.12 Relative quantification of ALT, ADDALT, CPI2 and CPImu vaccine in local
muscle. All DNA vaccines were injected by the intramuscular route. 28 days later, local
muscle was collected and real time PCR was applied to measure the quantification of each
































































































“+”represents Expression positive;“-“represents no expression
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3.2.8 Stronger antibody responses were induced by DEC-ADDALT
compared to control
In an attempt to enhance the immunogenicity of the ADDALT antigen, recombinant plasmid
with the gene encoding an antibody with specificity for the DEC205 surface protein of
dendritic cells was constructed. A fusion peptide consisting of a heavy and light chain of this
antibody with the ADDALT peptide was encoded by the plasmid. Single chain antibody
against DEC205 targets the antigen to the DCs via its surface receptor DEC205.
pcDNA3.1-ADDALT, which is based on the backbone of vector pcDNA3.1 without the
single chain antibody of DEC205, together with backbone plasmid alone (pempty) and
pISO-ADDALT were injected as controls. In addition, the plasmids encoding IL4, MIP1
and Flt3L gene, respectively were used to enhance the host immune responses. Mice were
given 3 inoculations at 14 days intervals. Challenge with 40 L3s was performed 28 days after
the final vaccination and necropsy was carried out 60 days after challenge.
As shown in Fig.3.13, both pcDNA3.1-ADDALT and pcDNA3.1-DEC-ADDALT
(designated as DEC-ADDALT) could induce much higher IgG1 antibody than the pempty
control, but the DEC-ADDALT induced more IgG1 than pcDNA3.1-ADDALT. The same
trend was seen with respect to IgG2a and IgE. In terms of cellular response, elevated levels
of cytokines were detected together with eosinophils, neutrophils, macrophages,
lymphocytes, monocytes and mast cells recruited into the pleural cavity compared to plasmid
controls. However, there were no differences between pcDNA3.1-ADDALT and




































































































Fig. 3.13 Stronger antibody responses were induced by DEC-ADDALT compared to
control. Antibody levels of IgG and IgE were compared between pcDNA3.1-ADDALT
and DEC-ADDALT by indirect ELISA. Results are shown as titers of IgG and the mean of
replicate samples (+/- S.E.M) for total IgE. 5 mice per group were tested. The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyze
differences between groups. Differences were considered significant for p < 0.05; p values
were not reported otherwise.
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3.2.9 DEC-ADDALT provoked stronger Th2 antibodies
In order to test if DEC-ADDALT can provoke and augment the immune responses, three
groups pISO-OVA, DEC-OVA and pISO-ADDALT were set up as controls for
DEC-ADDALT, among them, pISO-OVA and pISO-ADDALT were set as controls to
DEC-OVA and DEC-ADDALT, respectively. Mice were given 2 doses of DNA plasmid each
plus a plasmid encoding IL4 as adjuvant followed by electroporation, on D0 and D21, mice
were challenged with 40 L3s on Day 53. Blood was collected on D7, D14, D35 and D63 for
the antibody dynamics. Necropsy was carried out 10 days post challenge (D63). For IgG1,
there was a slight decline between D7 and D14 before an increase on D35 then was
increased in mice vaccinated with DEC-ADDALT. The pattern of IgG2a followed a similar
trend, although slightly higher levels of antibody against DEC-ADDALT were detected
against pISO-OVA group (Fig 3.14, A, B). When IgG1 and IgG2a were measured on D10
post challenge (when the L3s migrate into the pleural cavity and moult to L4s), both showed
an increased level. However, the titer of IgG1 was greater than that of IgG2a induced by
DEC-ADDALT (Fig 3.14, C, D). Meanwhile, the level of IgE showed a significant























































































































































































Fig 3.14 Stronger IgG1 and IgE level were elicited by ADDALT in BALB/c mice. 5 mice
each group were given 2 doses of DNA plasmid each (pISO-OVA, DEC-OVA, pISO-ADDALT
and DEC-ADDALT) with the adjuvant of IL4, at day 7, day 14 and day 35 post first injection,
sera were tested for the IgG1 and IgG2a level by ELISA. Plates were coated with recombinant
ALT protein. Mice were challenged 32 days after final immunization with L. sigmodontis L3,
necropsy was performed 10 days post infection. IgG and total IgE were measured. (A). (B) IgG1
and IgG2a levels elicited by ADDALT at day7, 14 and 35. (C).(D).(E). IgG1, IgG2a and IgE
level elicited by ADDALT 10 days post challenge. Results are shown as titer of IgG and the
mean of replicate samples (+/- S.E.M) for total IgE. The Kruskal-Wallis test followed by Dunn's
test for multiple comparisons were used to analyzed differences between groups. Differences
were considered significant for p < 0.05; p values were not reported otherwise.
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3.2.10 DEC-ADDALT elicited Th2-biased cytokines
To investigate the cytokine profile produced by DEC-ADDALT vaccine, a capture ELISA
was used to detect the expression of cytokines in the pleural cavity 10 days post challenge.
Th2 cytokines IL4, IL5, IL13, IL10 and Th1 cytokine IFN were measured. Low levels of
IL4 were detected in all samples with slightly greater amounts detected in the mice
immunized with DEC-ADDALT. Low levels of IL5 were also detected with no difference
between groups. However, IL13 levels were greatly increased in the group immunized with
DEC-ADDALT. IL10 was undetectable. The expression of IFN showed an opposite profile
to that of IL4 and IL13, only the controls not DEC-ADDALT induced high level of IFN
(Fig.3.15).
- 87 -
3.2.11 Recruitment of total cells and eosinophils were decreased
following vaccination with DEC-ADDALT
Cytospin analysis was used to investigate the type of cells recruited into pleural cavity 10



























































































































































Fig.3.15 Th2-biased cytokines were induced by DEC-ADDALT in pleural cavity lavage.
Supernatant fluids of pleural cavity lavage were harvested and the level of various cytokines
(IL4, IL5, IL13 and IFN) were measured by capture ELISA - see methods and materials.
Results are shown as the mean of replicate samples. 5 mice per group were tested. Standard
curves were prepared with recombinant cytokine. The Kruskal-Wallis test followed by
Dunn's test for multiple comparisons were used to analyze differences between groups.






















































following vaccination with DEC-ADDALT when compared with numbers recruited to the
pleural cavity with vaccination of pISO-ADDALT. Similarly, the number of eosinophils
recruited following DEC-ADDALT vaccination was decreased (not significantly) compared
to that in the pISO-ADDALT group (Fig.3.16). The major cells recruited were the














































A Total cells EosinophilsB
Fig. 3.16 Numbers of total cells and eosinophils decreased in pleural cavity following
vaccination with DEC-ADDALT. Pellets of pleural cavity lavage were used for total cell
counting on CASY model TT cell counter. Cells were used for the cytospin process and
eosinophils and other types of cells were counted under a microscope on fixed slides, 300 cells
minimum on each slide were counted. 5 mice per group were tested. The Kruskal-Wallis test
followed by Dunn's test for multiple comparisons were used to analyze differences between




































































































































3.2.12 Worm recovery was reduced but protection was not obtained
following vaccination with DEC-ADDALT
The numbers of filariae in the pleural cavity lavage fluids were counted to evaluate the
protective response provoked by the DEC-ADDALT vaccination. Mice were challenged with
40 L3s and at day 10 post challenge an average of 8 L3s was recovered in control groups
immunized with pISO-OVA or pISO- ADDALT. In contrast, an average of 6 worms was
recovered from the group immunized with DEC-OVA and an average of 4 worms was
recovered from the group vaccinated with DEC-ADDALT. Although the numbers recovered
from DEC-ADDALT vaccinated mice reduced compared to the controls of DEC-OVA and
pISO-ADDALT, the difference among them was non-significant (Fig.3.17).
3.2.13 Immune responses induced by CPI2 was reversed by CPImu
The second candidate molecule for the DNA vaccine is CPImu, which is a mutation of the
Fig.3.17 Worm recovery was reduced but protection was not obtained following
vaccination with DEC-ADDALT was obtained. Necropsy was performed 10 day post
challenge with 40 L3s, pleural cavity lavage fluids were harvested then filariae were counted
under a microscope. 5 mice per group were tested. The Kruskal-Wallis test followed by Dunn's
test for multiple comparisons were used to analyze differences between groups. Differences


























































CPI2 gene via the replacement of Asn66 (N) with Lys66 (K). To investigate the ability of
CPImu to elicit a host immune response, three negative control groups (naïve, primary
infection, pISO-OVA) were compared with BALB/c mice immunized with pDEC-CPI2 and
pDEC-CPImu separately. All groups were also simultaneously inoculated with plasmids
encoding IL4, MIP1 and Flt3L as adjuvants. Mice were given two inoculations with the
recombinant plasmids followed by electroporation after each injection. Mice were
challenged with 40 L3s 4 weeks post the final immunization which was performed 4 weeks
post the first immunization and necropsy was performed 60 days after the challenge. Sera
(blood), pleural cavity lavage and lymph nodes were collected. As shown in Fig. 3.18,
pcDNA3.1-CPImu induced much stronger (not significantly) levels of IgG1 and IgG2a than
pcDNA3.1-CPI2. Moreover, the IgG1level was enhanced greatly when pDEC-CPImu was
compared with the pcDNA3.1-CPImu group, although the level of IgG2a in pDEC-CPImu
was only slightly higher (not significantly) than pcDNA3.1-CPImu group. There was no
enhancement of either IgG1 or IgG2a on pDEC-CPI2 vaccination in contrast to
pcDNA3.1-CPI2 group, however, IgG1 level was significantly increased when
pDEC-CPImu group was compared with pcDNA3.1-CPI2 and pDEC-CPI2, respectively. As
for IgG2a, significant rise was only seen between pcDNA3.1-CPI2 and pDEC-CPImu. The
significant stronger IgE response was only seen between pDEC-CPImu and pcDNA3.1-CPI2
group. Although there was no big difference between pcDNA3.1-CPI2 and
pcDNA3.1-CPImu, much stronger IgE was produced by pcDNA3.1-CPImu immunization.
All data showed that the CPI2 gene either pcDNA3.1-CPI2 or pDEC-CPI2 could not induce
strong immune responses, but such responses were reversed by the vaccination of CPImu,











































































































































Fig. 3.18 Immune responses induced by CPI2 was reversed by CPImu. Antibody
levels of IgG and IgE were compared among pcDNA3.1-CPI2, pcDNA3.1-CPImu,
pDEC-CPI2 and pDEC-CPImu by indirect ELISA using recombinant CPI2 protein as the
target (see methods and materials). All test groups were also inoculated with plasmids
encoding IL4, Flt3L and MIP1 as adjuvants. Results are shown as titer of IgG and the
mean of replicate samples (+/- S.E.M) for total IgE. The Kruskal-Wallis test followed by
Dunn's test for multiple comparisons were used to analyze differences between groups.
Differences were considered significant for p < 0.05; p values were not reported
otherwise.
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3.2.14 DEC-CPImu vaccination induced a Th2 bias
IL4, IL5, IL10, IL13 and IFN were measured in pleural lavage fluid by the capture ELISA
to evaluate the cellular immune effect of pDEC-CPImu vaccination. Results showed that
high levels of IL4 could not be induced by the immunization of pcDNA3.1-CPI2 and
pDEC-CPI2, but it could be elicited by pDEC-CPImu vaccination with a significantly
stronger enhancement. Although the pcDNA3.1-CPImu and pDEC-CPI2 induced higher
levels of IL5 than pcDNA3.1-CPI2, significant enhancement was seen on pDEC-CPImu
vaccination with comparison to pcDNA3.1-CPI2. IL13 showed a similar profile to IL4 and
significant greater production of IL13 was evoked by pDEC-CPImu immunization. However
the profile of IL10 and IFN showed opposite trends. Only CPI2 (either pcDNA3.1-CPI2 or
pDEC-CPI2) could induce high levels of IL10 and IFN, whereas the CPImu (both

















































































































































































































Fig.3.19. Th2-associated cytokines were induced by DEC-CPImu immunization.
Supernatant of pleural cavity lavage were harvested and the level of various cytokines
(IL4, IL5, IL13, IL10 and IFN) were measured by sandwich ELISA- (see methods and
materials). Results are shown as the mean of replicate samples. The Kruskal-Wallis test
followed by Dunn's test for multiple comparisons were used to analyze differences
between groups. Differences were considered significant for p < 0.05; p values were not
























































3.2.15 CPImu restored the responses induced by CPI2 on the
proliferation of lymph node cells in vitro
The ability of CPI2 and CPImu, with and without adjuvants (IL4, MIP1 and Flt3L), to
stimulate proliferation of T cells was tested using isolated lymph node cells cultured with
Ls-Ag and anti-CD3. RPMI 1640 medium was used as a negative control. As presented in
Fig. 3.20, the pcDNA3.1-CPI2 could not stimulate the proliferation of lymph node cells after
the Ls-Ag-specific stimulation ex vivo compared to pcDNA3.1-CPImu which demonstrated
an augment of proliferation. Similar impacts were seen in medium and anti-CD3 stimulation.
However, the adjuvants IL4, MIP1 and Flt3L only assisted both pcDNA3.1-CPI2 and
pcDNA3.1-CPImu to enhance the proliferation with stimulation of medium and anti-CD3,
not the Ls-Ag antigen, whereas slightly inhibited the ability of pcDNA3.1-CPImu on cell















































Fig. 3.20 CPImu removed inhibition of CPI2 on the proliferation of lymph node cells in
vitro. Lymph node cells were cultured in 5% CO2 incubator at 37℃ for 48 hours followed
by the addition of Alamar blue reagent to measure the cell proliferation in 24 hours. Media
of RPMI 1640 and Anti-CD3 were set as controls and L. sigmodontis excretory/secretory
antigen (Ls-Ag) was added to stimulate cells. Adjuvant plasmids encoding IL4, Flt3L and
MIP1 were added with CPI2 and CPImu to test their impacts on enhancement of
proliferation. 5 mice per group were used. The Kruskal-Wallis test followed by Dunn's test
for multiple comparisons were used to analyze differences between groups. Differences






























































































3.2.16 Combination of ADDALT and CPImu upregulated the levels of
Th2 type antibodies
Although both ADDALT and CPImu candidates could evoke stronger host immune
responses, especially when they targeted dendritic cells via the recognition of single chain
antibody scDEC205 to the surface receptor DEC205, protection was not achieved. It was
therefore decided to test the ability of a combination vaccine of pDEC-ADDALT and
pDEC-CPImu to induce protection. The experiment comprised the following: 7 groups were
tested including 3 control groups [naïve, primary infection and pcDNA3.1 backbone
(pempty)] and pDEC-ADDALT alone, pDEC-CPImu alone and pDEC-ADDALT plus
pDEC-CPImu were the test groups. Mice were given 2 doses of immunizations at 2 week
intervals simultaneously with adjuvant plasmids encoding IL4, Flt3L and MIP1. Vaccinated
mice were challenged with 30 L3s 4 weeks after the final immunization. Sera (blood),
pleural cavity lavage, and lymph nodes were collected after necropsy which was performed
60 days post challenge. Antibody levels were measured by indirect ELISA coated by the L.
sigmodontis excretory/secretory protein rather than the recombinant ALT and/ or CPI2
protein.
As shown in Fig. 3.21. A, IgG1 levels were increased by the combination immunization
compared to the vaccination of pDEC-ADDALT alone, or pDEC-CPImu alone. Thus,
antibody titers more than 1×107 in log10 were induced by the combined vaccine which was
about 10-fold higher than the titers induced by pDEC-ADDALT alone, or pDEC-CPImu
alone.
However, the IgG2a level displayed a decreasing trend following immunization with the
combination in contrast to the vaccination of pDEC-ADDALT alone and pDEC-CPImu
alone. The titers of IgG2a for all groups were lower than IgG1 (Fig.3.21. B). Total IgE levels
were also measured. As shown in Fig.3.21. C, the combined vaccination induced greater IgE
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than the vaccination of pDEC-ADDALT alone or pDEC-CPImu alone, although there was no










































































































































































Fig.3.21. Combination of ADDALT and CPImu unregulated the levels of Th2
antibodies. Antibody levels of IgG and IgE were compared among pDEC-ADDALT alone,
pDEC-CPImu alone and the combination of pDEC-ADDALT and pDEC-CPImu by indirect
ELISA coated with L. sigmodontis excretory/secretory protein (see methods and materials).
All test groups were co-immunized with the adjuvants IL4, Flt3L and MIP1. Results are
shown as titer of IgG and the mean of replicate samples (+/- S.E.M) for total IgE. 5 mice per
group were used. The Kruskal-Wallis test followed by Dunn's test for multiple comparisons
were used to analyze differences between groups. Differences were considered significant
for p < 0.05; p values were not reported otherwise.
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3.2.17 IL5 and IL13 levels increased following combined vaccination
The impact of combination vaccination on cytokine production in the pleural cavity and the
supernatants of lymph node culture were measured by the capture ELISA. In the pleural
cavity, although the level of cytokines remained low, IL5 and IL13 showed a slight increase
over control levels. However, the Th1 cytokine IFNγ was never detected either following
vaccination with pDEC-ADDALT alone, pDEC-CPImu alone or the combination of
pDEC-ADDALT and pDEC-CPImu (Fig.3.22). In lymph node cultures with Ls-Ag, IL13
levels were increased slightly following the combination vaccine compared to immunization
with the single vaccines. Other cytokines including IL4, IL5 and IFNγ were undetectable




































































































































































Fig. 3.22 Increased IL5, IL13 were induced by combined vaccination. Supernatant
of pleural cavity lavage were harvested and the level of various cytokines (IL5, IL13
and IFN) were measured by capture ELISA against the recombinant antigen CPI2 (see
methods and materials). Results are shown as the mean of replicate samples. 5 mice per
group were used. Mann-Whitney test was used as statistical method. Differences were
considered significant for p < 0.05; p values were not reported otherwise.
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3.2.18. Eosinophil numbers increased in the pleural cavity following
combined immunization
The cells from the pleural cavity of mice from each of the control and experimental group
were concentrated using a cytospin and numbers were counted under a microscope. The
pDEC-ADDALT alone, pDEC-CPImu alone and combined vaccinations caused an increase
level of total cell recruitment compared to controls, and the combined vaccination induced
higher number of cells than pDEC-ADDALT alone, and pDEC-CPImu alone, although
no statistically significant difference was found between groups. Regarding eosinophils, a
significant increase in combined vaccination was recorded when compared to primary
infection and naïve controls. Eosinophil numbers were also raised by immunization with
pDEC-ADDALT alone or pDEC-CPImu alone. Numbers of other cell types were also
counted, both the macrophages and neutrophils increased in combined vaccination compared
to [pempty] control, but the number of macrophages on combined vaccination group was


























































Fig.3.23 Eosinophil numbers in pleural cavity increased following combined
immunization. Total cell numbers were determined using the CASY model TT cell counter
system. Eosinophil, neutrophils and macrophage numbers were determined following
concentration by cytospin and enumerated by microscopy on fixed slides (300 cells at
minimum each slide were counted). The Kruskal-Wallis test followed by Dunn's test for
multiple comparisons were used to analyze differences between groups. Differences were



































































































































































3.2.19. Significant reduction of worm burden was achieved by combined
vaccination
To evaluate the protection elicited by the combined vaccination, adult worms in the pleural
cavity and Mf in the blood stream were counted. Mice were challenged with 30 L3s.
Protection was recorded as a reduction in worm numbers in test animals compared to those
in control groups (Fig.3.24). The mean worm recovery of unvaccinated control mice was 16.
The mean recovery of worms from the combined vaccination was 3, which represents about
an 82.3% reduction in worm burden. The numbers of worms recovered from mice
immunized with pDEC-ADDALT alone or pDEC-CPImu alone were reduced by 38.7% and
50%, respectively. However only the 82.3% reduction observed with the combined vaccine
was statistically significant.
As for the number of Mf recovered in the blood, there was an apparent reduction in numbers
following vaccination with the pDEC-ADDALT alone, pDEC-CPImu alone or the combined
vaccine, and the combined vaccination resulted in a statistically significant reduction of
microfilariaemia.
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3.2.20 Immune determinants of protective immunity
In order to identify the main immune determinants of protection, a principal component
analysis was performed on all the immunological read-outs that lead to significant reductions
of parasite survival (Fig 3.24). 31 variables (Appendix 7) were examined in each mouse and
then reduced to 4 principal components that exceeded the explanatory power expected by
chance alone, and that represented 51.6% of the variation present in our sampling (Appendix
6, 7; Fig 3.25). Subsequent components were rejected for lack of explanatory power. The
first component (PC1) comprised mainly in vitro Th2 cytokine responses; PC2 comprised
whole worm-specific IgG1, and pleural eosinophils, neutrophils, macrophages but not
lymphocytes; PC3 comprised substantial effects of Ls-ALT- and Ls-CPI2-specific IgG1 and
IgG2a opposed to equally strong effects of pleural lymphocytes; Finally, PC4 contained
































































































































Fig. 3.24. Significant reduction of worm burden was achieved by combined vaccination.
Adult worms and microfilariae were counted at 60 day post challenge. Adult worms were
recovered in the pleural cavity lavage while microfilaraie were counted in 30 μl blood. The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyze
differences between groups. Differences were considered significant for p < 0.05; p values
were not reported otherwise. 5 mice per group were used.
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power of the resulting components on parasite survival was assessed by a generalized linear
model (GLM). Only the second principal component was significantly correlated with
parasite survival (r = -0.72, P < 0.0001, Fig 3.26). The relative contribution of each antibody
class (IgE, IgG1 and IgG2a) to parasite killing was determined. Only IgG1 was found to
have a significant effect on parasite killing (P = 0.026 with interactions between IgG1 and
IgG2a accounted for) whereas IgE and IgG2a had none (P= 0.7 and PGLM = 0.6,
respectively). Likewise, the analysis of respective roles for pleural cell types in protection
revealed that parasite killing was attributable to macrophages and neutrophils (P = 0.02, P =
0.003, and P = 0.002), respectively once interactions were accounted for), but not to
eosinophils (P =0.5)
31302928272625242322212019181716151413121110987654321
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Fig. 3.25. Scree plot of principal component assay. 31 variables (Appendix 7) for each
mouse were used in this analysis. The break point was determined to be between 4 and 5
based on the total extraction of the sums of squares loading value (3.163).
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3.3 Discussion
3.3.1 Ls-ALT and Ls-CPI2 can be expressed in the adult stage of L.
sigmodontis
The data showed that Ls-ALT-1 and Ls-CPI2 genes had been successfully cloned and
identified by enzyme digestion, DNA sequencing, protein expression (in E. coli and in COS
7 cell) and Western blotting with sera from mice immunized with Ls-ALT-1/CPI2 DNA
vaccines. The ALT gene has been described as L3-specific and highly expressed in B. malayi
and W. bancrofti and it has been suggested that the corresponding protein is involved in
survival of filarial nematodes in immunocompetent hosts (Ramachandran S et al., 2004;
Thirugnanam S et al., 2007).
In the case of L. sigmodontis, the Ls-ALT gene was previously identified from an L3 cDNA
Fig. 3.26. Correlation between worm survival and PC2. Worm numbers recovered
and all cells recruited to the pleural cavity (including eosinophils, macrophages,
neutrophils but not lymphocytes) and worm specific IgG1 were analyzed. The figure
was created by SPSS 13.0.



























library by using an EST strategy (Allen JE et al., 2000), however, the Ls-ALT-1 gene used in
this work was cloned from adult worm mRNA, demonstrating that Ls-ALT-1 is not only
expressed in the L3 stage but also the adult stage. This is the same as reported for O. volvulus
where the ALT gene has been found to be stage-specific (Joseph DT et al., 1998), but can
also be expressed restrictly in L2 and L3 stages (Wu Y et al, 2004). It should be noted,
however, that in this investigation no attempt was made to confirm the presence of the
Ls-ALT-1 transcripts in the L3 or L4 stage.
As for Ls-CPI2 gene, the data presented indicated expression of the protein by adult worms
which is consistent with the analysis of differential expression of Bm-CPI2 cystatin (Gregory
WF et al., 2008), although in this study no attempt was made to determine whether the gene
was expressed at all stages. The Ov-CPI2 derived from O. volvulus is highly expressed in the
cuticle of moulting larvae (Johnstone IL, Barry JD, 1996) but there is no detectable increase
in CPI2 transcription around the moulting events in C. elegans (Johnstone IL, Barry JD,
1996).
Therefore, Ls-ALT-1 and Ls-CPI2 used in the present experiments were successfully cloned
from the adult stage, suggesting that both genes play a role in the parasite-host interaction
and may be used as candidates for vaccine development.
3.3.2 Extensive distribution and long time persistence of foreign DNA in
host tissue
The distribution of plasmids after immunization is associated with the ability of induction
and longevity of immune responses following stimulation by DNA vaccination. To evaluate
the gene expression patterns in mice after DNA vaccination, mRNAs from muscle, liver,
lung and spleen were extracted and followed by the gene-specific-primer RT-PCR detections.
Data presented indicated that Ls-ADDALT was most abundantly expressed in muscle around
the tibialis followed by spleen, lung and liver. Ls-CPI2/ CPImu was abundantly expressed in
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both muscle and spleen followed by in liver and lung. These data suggest that
Ls-ALT/ADDALT and Ls-CPI2/CPImu were extensively distributed in mouse tissue after
DNA vaccination. The extensive stimuli of DNA vaccines lead to an interaction between the
antigen and the host immune system, thereby inducing subsequent humoral and/or cellular
responses. Furthermore, DNA was extracted and detected by PCR using T7/ BGH primers
(which indicate the existence of carry plasmids after immunization) instead of specific
primers, results showed that all carried plasmids of Ls-ALT/ ADDALT, Ls-CPI2/ CPImu
were detectable in muscle, spleen, liver and lung, indicating that genes carried by plasmids
were still existed in tissues and might be released to stimulate host immune responses in
subsequent time courses. These findings are consistent with the previous reports which have
shown that uptake and expression of foreign DNA by muscle cells as well as other tissues
such as liver and lung can be maintained after direct injection (Bonifaz LC et al., 2004;
Demangel C et al., 2005; Trumpfheller C et al., 2006).
Another important point is the longevity of foreign DNA in mouse tissue. The data presented
showed that even 28 days after the final immunization genes were still detectable. Marc D et
al (2000) using fluorescence-labeled plasmid DNA detected plasmid 24 hours after
inoculation in muscle and draining lymph nodes albeit at low level. A comparison with our
data suggests present protocols of DNA immunization and delivery have improved
persistence of foreign DNA in tissues. This can provide a long term stimulus to the host
immune system and consequently lead to the longevity of humoral and cellular responses.
3.3.3 Removal of immunomodulatory properties of Ls-ALT and Ls-CPI2
results in the enhancement of immune responses
The immunomodulatory properties of Ls-ALT-1 and Ls-CPI2 have been mapped according
to their amino acid sequences. Bm-ALT-1, which contains one acidic domain (46 aa), is
involved in the modulatory function (Maizels RM et al., 2008). The corresponding acid
domain of L. sigmondontis has also been shown to possess similar immunomodulatory
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activity (Ls-ALT and Ls-ADDALT based on backbone plasmid pcDNA3.1 had been tested
by Simon Babayan, unpublished data). Consequently, DNA plasmids encoding Ls-ALT-1
deleted acidic domain (ADD) were used to immunize BALB/c mice against L. sigmondontis
L3 challenge. Results showed that the Ls-ADDALT vaccine induced stronger immune
responses including IgG1, IgE and Th2 cytokines than Ls-ALT-1without deletion of acidic
domain which inhibited host immune responses (data not shown). This observation
suggested that the acidic domain prevents Ls-ALT from eliciting protection.
Works presented here have shown that DNA vaccination in BALB/c mice using
pcDNA3.1-ADDALT plasmid induced increased IgG1 and IgE antibodies, but not IgG2a,
when compared to control plasmids. On the other hand, no predominant cytokine profiles
and protection were obtained 10 days after the challenge with 40 L3s. After analysis, it was
concluded that the efficiency of DNA uptake and expression might impact the
vaccine-mediated immune responses and the 10 days interval between challenge and
necropsy might not be long enough to detect resultant cytokine responses. Consequently, a
novel DNA vaccine targeting dendritic cells via specific binding to its surface receptor,
DEC205, by the single chain Fv monoclonal antibody scDEC205 (encoded by the plasmid
vector) was constructed. Immunization with this DEC-ADDALT plasmid increased the
IgG2a level and a marginal elevation of IgG1 and IgE. However, immunization with
DEC-ADDALT alone did not induce protection.
Analysis of Ls-CPI2 showed it contains the conserved amino acid motifs of QVVAG, PW
and SND. The SND motif is responsible for the immunomodulatory properties of Bm-CPI2
(Murray J et al (2005). This immunomodulatory property is associated with inhibition of
multiple cysteine protease activities found in human B cells and inhibition of the hydrolysis
of synthetic substrates. In addition, evidence showed that inhibition of presentation of
selected T cell epitopes by antigen-presenting cells existed (Manoury B et al., 2001). These
findings provided a good example of a product from a eukaryotic parasite that can directly
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interfere with antigen presentation, which may suggest how filarial parasites modulate the
host immune response to a helminth invader. More importantly, Murray J et al (2005)
showed a 10-fold diminished and ablated activity of AEP inhibition, respectively, through
site-directed mutagenesis of Bm-CPI2 at Asn-77 (mutated to Asp and Lys).
To remove the AEP inhibition thoroughly, a similar site-directed mutagenesis of Ls-CPI2
gene (substitution of Asn66 with Lys66) was performed. The presented data demonstrated
that immunization with Ls-CPI2 DNA vaccine based on pcDNA3.1 backbone inhibited the
immune responses with down-regulated IgG1, IgG2a and IgE, and Th2 cytokines IL4, IL5
and IL13, but up-regulated IL10. However, whether the AEP inhibition has been removed
thoroughly has not been tested in current study and was not the first concern in this study.
T cell proliferation stimulated by the whole L. sigmondontis antigens in vitro was suppressed
by Ls-CPI2. All these findings are generally consistent with the observations of Schierack P
et al (2003). However, the cystatin used in their experiment induced an up-regulation of
nitric oxide production by IFN stimulated murine macrophages. Such a response was not
seen in the experiments with Ls-CPI2 and Ls-CPImu. Similar results to Schierack P et al
(2003) have been reported by Hartmann S et al (1997). However, all these
immunosuppressions caused by Ls-CPI2 were reversed by vaccination using its mutant
Ls-CPImu with significant enhancement, which proved that the strategy of removal of
immunosuppressive motifs in Ls-CPI2 can circumvent the parasite immunomodulation and
thereby enhance the host immune responses.
Both Ls-ALT-1 and Ls-CPI2 have the immunomodulatory properties that may play a crucial
role on the establishment and persistence of filarial infection. However, these
immunomodulatory characteristics have been removed from modified sequences and both
Ls-ADDALT and Ls-CPImu have been shown to evoke Th2 immune responses which can
kill the parasites.
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3.3.4 DCs are essential to the enhancement of DNA vaccination
Besides the circumvention of parasite immunomodulation strategy, it was presumed that the
effects of vaccination may depend on DNA antigen uptake efficiency. A fundamental initial
step in vaccination is that the proteins need to be taken up, processed, and presented by DCs.
Following intradermal injection of a plasmid DNA vaccine into mice, the encoded gene is
expressed in transfected keratinocytes and myocytes at the site of inoculation (Wolff JA et al.,
1990) as well as a small number of DCs (Akbari O et al., 1999a; Bot A et al., 2000).
Keratinocytes and myocytes lack MHC II and co-stimulatory molecules, which renders them
poorly effective at presenting antigen and priming naïve immune cells (Wiendl H et al.,
2005), and they do not have ready access to T cells in lymphoid tissues, as is the case for
DCs (Granelli-Piperno A et al., 2005; Lindquist RL et al., 2004). Therefore, it is thought that
immune priming begins a few transduced DCs then boosts immunity (Cho JH et al., 2001;
Corr M et al., 1999). Consequently, uptake of DNA vaccines could be enhanced by directly
targeting the encoded protein to DCs.
Works by other researchers demonstrated that antigens can be targeted selectively to DCs in
vivo when they are fused into antibody against DEC205 (Hawiger D et al., 2001), this
interaction can lead to high efficient antigen processing and presentation on MHC I and II
products and strong protective T cell immunity (Bonifaz LC et al., 2004; Trumpfheller C et
al., 2006). Therefore, plasmids based on the scDEC205 backbone plasmids (which were
kindly made available by Dr. Ralph Steinmann) were constructed to enhance DNA
vaccine-induced immune responses by targeting DCs. Results showed that immunization
with DEC-ADDALT plasmid induced stronger IgG2a, IgG1 and IgE immune responses
compared with pcDNA-ADDALT vaccination which was not targeting DCs directly in
BALB/c mice. Significant increases were seen with DEC-CPImu vaccination. In contrast to
the low level of immune responses elicited by pcDNA-CPImu, statistically significant
increases in IgG1, IgG2a and IgE as well as Th2 cytokines including IL4, IL5 and IL13 were
produced by DEC-CPImu immunization, suggesting targeting DCs via its surface receptor
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DEC205 enhanced the efficacy of DNA vaccination. This is consistent with the experiment
reported by Demangel C et al (2005) on the capacity of a single-chain antibody,
anti-DEC205. Results showed targeting DNA vaccine antigens in mice resulted in a roughly
2-fold increase in B and T cell responses to a mycobacterial antigen. Furthermore, these
findings are supported by Nchinda G et al (2008), they generated a DNA vaccine encoding a
fusion protein HIV gag p41 and a single-chain Fv antibody (scFv) which was specific for the
DC-restricted antigen-uptake receptor DEC205. Results showed immune responses were
enhanced greatly by DEC205 targeting.
3.3.5 Th2-bias induced by Ls-ADDALT and Ls-CPImu DNA
vaccinations
The presented data showed that, when DNA vaccinations were performed in BALB/c mice,
Ls-ADDALT and Ls-CPImu DNA vaccinations significantly enhanced the levels of IgG1,
IgE, IL4, IL5, and IL13 and significantly decreased the level of IFN when compared to the
immunization with CPI2 (presented as pcDNACPI2 or DEC-CPI2). These findings are
similar in profile to the protective immunity induced by the irradiated L3 immunization in
mice, cats and dogs (Jian X et al., 2006; Le Goff L et al., 1997; Le Goff L et al., 2000;
Babayan SA et al., 2006; Ricardo T, 2006). However, some differences between presented
data and vaccinations of irradiated L3s were found. First, both Ls-ADD ALT and Ls-CPImu
DNA vaccinations mainly induced IgG1 antibody not both IgG1 and IgG2 or IgM (IgM was
not measured in present studies). Second, the cytokine IL13 was elevated by DNA
vaccinations in present studies and seldom detected following irradiated L3 vaccination.
Though differences exist between present findings and irradiated L3 vaccinations, one
agreement has been reached that vaccination success depends on Th2-biased immune
responses especially IL5, IL4, IgE and IgG1 and /or eosinophils (Martin C et al., 2000;
Martin C et al., 2001; Abraham D et al., 2004).
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3.3.6 IL10 produced by DNA vaccine did not induce inhibition of
Th2-mediated protective immunity
Production of IL10 has been reported to be associated with the downregulatory pathway.
IL10 produced by CD4+CD25+ Tregs is associated with the inhibition of Th1 and Th2
response (Hesse M et al., 2004; McKee AS, Pearce EJ, 2004). Similarly, IL10 deficiency has
been found to enhance the Th1-mediated killing of muscle larvae of T. spiralis (Helmby H,
Grencis RK., 2003). Although IL10 might play a role on regulation of L. sigmodontis
infection, Taylor MD et al (2005) believed that it was not the key role or sole mechanism for
CD4+CD25+ Treg action in light of the fact that neutralization of IL10R did not restore T cell
responsiveness in vitro and failed to restore protective immunity in vivo. However, IL10 is
required to promote Th2 responses and it has been shown that IL10 deficient mice fail to
induce protective Th2 responses against Trichuris muris (Schopf et al., 2002).
As for presented data, Ls-CPI2 vaccination induced elevated IL10 toward L3 challenge,
which is consistent with the report that CPI proteins elicited an IL10 response against
A.viteae (Hartmann S et al., 1997). However, IL10 production by Ls-CPImu vaccinated mice
decreased significantly following L3 challenge and was undetectable after dual vaccinations
with Ls-ADDALT and Ls-CPImu. Nevertheless, a cocktail of Ls-CPImu and Ls-ADDALT
did induce a protective immunity. It is possible that the induction and regulation role of IL10
are performed in a dose dependent manner, with low levels promoting Th2 and protection
and high levels drive regulation.
3.3.7 Worm specific IgG1 and neutrophils, macrophages are correlated
with worm killing
Present data showed that neither DEC-ADDALT alone nor DEC-CPImu alone could induce
protection while dual vaccination (combination of DEC-ADDALT and DEC-CPImu)
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significantly reduced the number of worms (Fig. 3.24). This protective immunity appears to
be associated with worm specific IgG1, neutrophils and macrophages.
The mechanism of parasite killing is not fully understood. Classically, it is associated with
the antibody-dependent cell-mediated cytotoxicity (ADCC, Chandrashekar R et al, 1990), in
which a large amount of Th2 type antibodies are involved including IgG1 and IgE. The
present data showed high levels of IgG1 following combination vaccination, suggesting it
plays a protective role. However, as mentioned previous, IgG2a might be responsible to the
adult worm killing based on the fact that Th1 and Th2 responses might synergize to donate to
protective responses. According to present findings, it appears to be more biased toward
IgG1 rather than IgG2a, and this might be because the vaccine design strategy in the present
study was mainly aimed at enhancing Th2 rather than Th1 responses; However, it does not
mean the IgG2a does not contribute to the protection in general.
The present study did not determine whether antibody is involved in Mf killing. Earlier
studies showed that the MT mice prolonged survival of B. malayi Mf which is due to a
detection of antibody, not the lack of B cells (Gray CA, Lawrence RA, 2002). Mf killing in
this study might be the consequence of adult worm killing, which may be expected to reduce
the number of circulating Mf. A reduced Mf would be expected to reduce morbidity and
severe disease. However, in most lymphatic filariasis, where Mf is in the blood, the disease
is associated with the adult worms. So again, killing Mf instead of adult worms is not the
main target to design vaccines.
Besides IgG1, in the present study, cells including macrophages and neutrophils recruited
into the pleural cavity contributed to worm killing. Macrophages are not only innate immune
cells in the primary response to filarial infection, but also play a role on coordination of the
adaptive immune response, inflammation, resolution and tissue repairs (Delavary BM et al,
2011). The classic macrophage activation is required to kill intracellular pathogen while
alternatively activated macrophages driven by IL4 and IL13 are a different phenotype that is
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important for the immune response to parasites (Gordon S, Martinez FO, 2010).
Combination vaccine immunization in the present study induced increased IL13, which may
trigger the macrophage activation and worm killing. This activation may be dependent on the
up-regulation of arginase, Fizz-1 and Ym-1. However, the phenotypes of macrophages
recruited to the pleural cavity 60 days post challenge were not investigated because the aim
of present experiment was to measure the effect not the causes of vaccination. It was
assumed that both types of macrophage might be involved in the worm killing but dominant
one might be alternatively activated macrophage which are however to be part of Th2
responses on parasite killings (Gordon S, Martinez FO, 2010).
Neutrophils are reported to be the first cells recruited in response to a helminth infection, and
have been suggested to play a protective role during L. sigmodontis infection (Saeftel M et
al., 2001; Saeftel M et al., 2003). In the present findings, neutrophils increased in the pleural
cavity 60 days post infection when worms develop to the adult stage and live in the pleural
cavity. The increased neutrophils may kill worms by forming nodules around the worms. In
addition, the increased IL5 might enhance worm killing as well as the IgG1 antibody, which
was also described to play a crucial role in Strongyloides sp worm killing by cooperation
with neutrophils through ADCC mechanisms (Brigandi RA et al., 1996).
However, eosinophils, which are well-documented to be effector cells in human helminth
infection, did not appear to correlate with worm killing in the present study. This might relate
to the eosinophil activation state, not the number of cells, and the infection stage. As
documented, eosinophils are capable of degranulation and selective release of granule
proteins in a process mediated by eosinophil vesicles (Melo RCN et al., 2008; Walsh GM,
2001). Degranulation is triggered by FcRs recognizing antibody-bound antigen. Several
cytokines including IL3, IL5, granulocyte macrophage colony stimulating factor (GM-CSF),
TNF, IFN, and platelet activating factor (PAF) can enhance or directly trigger this process.
Human eosinophils express FccRΙ, FccRIIα, FccRIIβ, FccRⅢ, FcεRII and FcαR, however,
mouse eosinophils do not express the high-affinity IgE FcεRI, and therefore do not
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deregulate as readily. Thus, despite of significantly elevated eosinophils in the present
combination vaccination, effective activation might not be triggered and consequently the
cells may not be involved in worm killing in this system.
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Chapter 4-Immune responses against filarial infection
were enhanced by single VAH or TPX vaccination
4.1 Introduction
Vaccination with antigens derived from iL3 are of particular interest, because L3s are
important for the establishment of infection and represent key targets of protective immunity
(Gregory WF et al., 2000). It has been proposed that antigens secreted from L3 that are
recognized by putative immune individuals may make suitable targets for vaccine
development. One such antigen, VAH, a homologue of insect venom allergen identified
earlier from B. malayi, had been shown to be a promising vaccine candidate in experimental
animal models (Murray J et al., 2001; MacDonald AJ et al., 2004). One study also suggested
that VAH is a potent adjuvant for other antigens (MacDonald AJ et al., 2004).
An alternative rationale is to target molecules that are known to assist the parasite in its long
survival in an immuno-competent host. One such molecule is the thioredoxin peroxidase
(TPX) that is highly expressed by all filarial life cycle stages. TPXs are a new class of
antioxidant molecules identified from nematode B. malayi, although the family was
previously described from yeast (Kim IH et al., 1989; Kim K et al., 1988). Works on the
yeast TPX showed that this antioxidant is capable of reducing H2O2 and alkyl
hydroperoxides (Chae H et al., 1994). It is known that cytotoxic molecules such as oxygen
radicals and nitric oxide released from the immune system can damage filariae. It has
become clear that helminths do produce enzymes with antioxidant capabilities, With
example of both extracellular and cytoplasmic forms of Cu/ Zn superoxide dismutase (SOD)
(Henkle KJ et al., 1991; Hong Z et al., 1991; James ER et al., 1994; Rhoads ML, 1983; Tang
L et al., 1994). Moreover, a glutathione peroxidase has been shown to be one of the major
surface-associated molecules on filarial nematodes (Cookson E et al., 1992). Such
considerations identify TPX as a potential vaccine candidate.
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The works presented below focus on immune responses to the L. sigmodontis genes,
Ls-VAH and Ls-TPX, and their use as DNA vaccines. Again, the potential of targeting
DEC205 on the surface of DCs and thereby enhance immunogenicity was tested.
4.2 Results
4.2.1 Isolation of Ls-VAH and Ls-TPX genes
VAH is a member of venom allergen like protein (VAL) family related to the Ancylostoma
secreted protein (ASP) antigen, and has been identified to be a protective vaccine candidate
and be associated with angiogenesis. The VAH gene sequence derived from L. sigmodontis
was downloaded from Genebank (http://www.ncbi.nlm.nih.gov/). The full ORF (504 bp) was
isolated from adult worms and cloned into the pcDNA3.1 expression vector (Fig. 4.1 A) and
sequenced and analyzed by the BLASTn and BLASTp programs at the NCBI website.
Results showed the isolated gene shares 82% identity with W. bancrofti vespid allergen
antigen homolog (AF109794) at the gene level and with 84% identity at protein level with
venom allergen antigen-like protein 1 (XP-001894273). Alignments with W. bancrofti
VAH-1(AF109794), D. immitis VAL (AF001100) and O. volvulus ASP-1 (AF020586)
revealed that the Ls-VAH gene possesses almost all the conserved domains except the
N-glycosylation site (Fig. 4.3).
The Ls-TPX gene sequence recorded in Genebank contains an ORF of 645 bp, however, the
gene cloned for this work contained a 723bp ORF (Fig. 4.1.B). An alignment of Ls-TPX
with members of TPX/ TSA family described from B. malayi (Bm-TPX-1, -2; U34251,
U47100), D. immitis (Di-TPX; AF001007), F. hepatica (Fu-TPX; U88577), Mus musculus
Mer 5 (Mu-TPX; M28723), O. volvulus (Ov-TPX; R95400), Saccharomyces cerevisiae
(Sc-TPX; L14640) is presented in Fig. 4.2. The overall level of identity and similarity
between Ls-TPX and the other TPX proteins ranged from 45% to 90% (Fig. 4.2. A, B). The
amino acid sequence of Ls-TPX showed a high identity of 89.4% to Bm-TPX1. For all the
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members of TPX/ TSA family proteins, there is a high degree of sequence identity upstream
and downstream from the conserved amino-terminal Cys with the consensus of Motif 1. The
level of sequence conservation surrounding the carboxy-terminal Cys was notably lower




Fig. 4.1 Agarose gel electrophoresis of PCR amplification of VAH and TPX in 0.5%
TBE at 120 V for 40 minutes. PCR was performed to amplify the full ORF of VAH and
TPX. mRNAs derived from adult worms were used as the templates. (A) PCR products of










Fig.4.2. Comparison of L. sigmodontis TPX and other TPX sequences . (A).Alignment
of the deduced amino acid sequence of L. sigmodontis Ls-TPX with TPX/TSA proteins.
Alignment of L. sigmodontis Ls-TPX with TPX/TSA proteins reported from B.malayi
(Bm-TPX-1 U34251; Bm-TPX-2 U47100), D.immitis (Di-TPX; AF001007), F.hepatica
(Fu-TPX; U88577), Mus musculus Mer 5 (Mu-TPX; M28723), O.volvulus (Ov-TPX2;
R95400), S. cerevisiae (Sc-TPX; L14640) using Clustal W method. Regions shaded in
black designate residues identical to Ls-TPX. The conserved TPX motifs were boxed and
labled. (B). Outline of the percent identity and divergence between the TPX proteins
based on the alignment outcomes. (C). Outline of the phylogenetic trees of the TPX



















4.2.2 Construction of plasmids
PCR products of VAH and TPX for pcDNA3.1- constructs were ligated into pcDNATM3.1
Directional TOPO expression vector according to the kit instructions. The pDEC205-
plasmids contain the single chain antibody (scDEC205), which targets to the DEC205
receptor on the surface of DCs, or a single chained antibody with irrelevant specificity
(sc-ISO) as the control. Before the ligation into vectors, pDEC205-OVA and pISO-OVA
were double digested with NotI/ XbaI enzymes (Figure.3.5 A). Then, NotI/ XbaI-digested
PCR products of VAH and TPX were ligated into digested pDEC205- and pISO- to replace
the OVA gene on the vector, respectively. Clones were confirmed by PCR using T7 and BGH
primers, respectively (Fig. 4.4). Expression plasmids of pET24a-VAH and pET29c-TPX
Fig. 4.3. Comparison of L. sigmodontis VAH and other VAH sequences . (A). Alignment
of L. sigmodontis VAH proteins with B. malayi, W. bancrofti, O. volvulus and D. immitis.
Alignments were prepared using the ClustalW facility on Lasergene Suite 5.0. All cysteine
residues are displayed in red. Arrows identify the two potential N-glycosylation sites, one of
which is shared with W. bancrofti, one of which is defect. Rhombus denote condos found to
show synonymous nucleotide polymorphisms (AAC/AAT, both Ask; and ACC/ACG, both
Thr), red rectangle denoting conservation within the nematode sequences shown. Accession
numbers of the sequences presented are as follows: W. bancrofti VAH-1, AF109794; D.
immitis VAL, AF001100; O. volvulus ASP-1, AF020586; Hc24 (derives from H. contortus),
AAC03562; A. Caninum, AAD31839; L. sigmodontis VAH. (B) Sequence distance result of
alignment of VAH proteins. Clustal W in MegAlign program was used to construct
alignment. W. bancrofti VAH-1, AF109794; D. immitis VAL, AF001100; O. volulus
ASP-1, AF020586; Hc24, AAC03562; A. caninum, AAD31839; L. sigmodontis VAH were
applied to process; Solonepsis invicta (fire ant) allergen, SOLI3, AF012919. (C). Outline of
the phylogenetic trees of the VAH proteins based on the alignment outcomes.
C
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were constructed by the ligation of the NdeI/XhoI digested PCR product of VAH and TPX
with NdeI/ XhoI digested pET24a and pET29c, respectively. Clones were confirmed by PCR
using T7 and T7 terminator primers (Fig. 4.5). The plasmids of pcDNA3.1-VAH,
pDEC205-VAH, pcDNA3.1-TPX, pDEC205-TPX, pISO-VAH, pISO-TPX, pET24a-VAH











Fig. 4.4 Agarose gel electrophoresis of PCR identification of plasmids in 0.5% TBE at 120
V for 40 minutes. (A).pcDNA3.1-VAH using T7/BGH primers. M, 100bp marker;
1, pcDNA3.1-VAH; (B) pDEC205/ pISO-VAH using T7/ BGH primers. M, 100bp marker.
1, pDEC205-VAH. 2, pISO-VAH. (C) pcDNA3.1-TPX using T7/ BGH primers. M, 100bp
marker; 1, pcDNA3.1-TPX; (D) pDEC205-TPX and pISO-TPX using T7/ BGH primers .
M, 100bp marker. 1, pDEC205-TPX ,2, pISO-TPX;
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4.2.3 Protein expression in E. coli and purification
To prepare antigens for ELISA, VAH and TPX genes were sub-cloned into the expression
vector pET24a and pET29c, respectively which produce recombinant protein containing a
poly His tag. To determine the optimal expression conditions, IPTG concentration (0.5 mM,1
mM, 2 mM), host strain (competent cell BL21-DE3 and Rosseta-gami 2), and temperature
(22°C, 25°C, 30°C, 37°C) were tested. Pellets and supernatant fluids were collected at 1, 2, 3,
and 4 hours after IPTG induction and assayed by SDS-PAGE electrophoresis. As shown in
Figure 4.6 the protein of VAH was expressed best at 37°C 3 hour after 0.5mM IPTG
induction while TPX was expressed best at 37°C 4 hour after 1 mM IPTG induction and the
pellet contained most of both of the expressed proteins. The concentration of purified protein
detected by Coomassie (Bradford) Protein Assay was 1.26 mg/ml for VAH and 0.47 mg/ml
for TPX.
Fig. 4.5 Agarose gel electrophoresis of PCR identification of expression plasmids in
0.5% TBE at 120 V for 40 minutes. (A) pET24a-VAH using T7/ T7 terminator primers.
M, 100bp marker. 1, pET24a-VAH; (B) pET29c-TPX using T7/ T7 terminator primers. M,






Fig. 4.6 SDS-PAGE electrophoresis of VAH and TPX at 200 V for 1 hour. (A). Protein
expression of pET24a-VAH at 37℃ on different time points. M, See Blue plus 2
prestained standard (Invitrogen, UK). 1, uninduced empty pET24a. 2, pET24a-VAH 2
hour after 0.5 mM IPTG induction 3, pET24a-VAH 3 hour after 0.5 mM IPTG induction.
4, pET24a-VAH 4 hour after 0.5 mM IPTG induction. (B). Protein expression of
pET29c-TPX at 37℃ on different time points. M, See Blue plus 2 prestained standard
(Invitrogen, UK). 1, pET29c- TPX 1 hour after 1 mM IPTG induction. 2, pET29c-TPX 2
hour after 1 mM IPTG induction. 3, pET29c-TPX 3 hour after 1 mM IPTG induction. 4,
pET29c-TPX 4 hour after 1 mM IPTG induction. (C) VAH protein eluted from
His-binding column in the fractions. M, See Blue plus 2 prestained standard (Invitrogen,
UK). 1-6: purified fractions. (D). TPX protein eluted from His-bounding column in the
fractions. M, See Blue plus 2 prestained standard (Invitrogen, UK). 1-6: purified fractions.
Molecular weight for VAH: 18.6 KDa; TPX: 26.4 KDa.
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4.2.4 Identification of VAH and TPX by Western blotting
The VAH and TPX proteins were analyzed by Western blot using a mouse monoclonal
anti-His antibody and sera from mice immunized with plasmids of pcDNA3.1-VAH and
pcDNA3.1-TPX. Bound antibodies were detected with horseradish peroxidase-conjugated
goat anti-rabbit IgG as the secondary antibody. The proteins were visualized using Chemi
Glow (1:1) reagents, and the membranes were exposed on a Fluor ChemTMSP image machine.
As shown in Fig 4.7, the VAH and TPX recombinant proteins were recognized by the sera
from mice immunized with plasmids of pcDNA3.1-VAH or pcDNA3.1-TPX, respectively.
4.2.5 Protein expression in COS7 cell and identification
1.25 g DNA for each plasmid (pcDNA3.1-VAH, pcDNA3.1-TPX, pDEC-VAH, pISO-VAH,
pDEC-TPX and pISO-TPX) was transferred into COS7 cells. Transfection lasted for 48
hours, then supernatants for secreted proteins and /or lysed cells for protein content were
collected. Reverse transcription PCR and Western blotting were carried out to identify
whether the plasmid expressed in COS7 cell or not. Results showed that transcripts of all
plasmids were detected using VAH- or TPX-specific primers (Fig. 4.8) and all proteins
expressed in COS7 cells could be recognized strongly by the serum from the VAH- or TPX




Fig. 4.7 Western blotting of VAH (A) and TPX (B) protein against sera from mice
with immunized pcDNA3.1-VAH and pcDNA3.1-TPX vaccine, respectively. Protein
was separated under reducing conditions on a 10-12% acrylamide gel. Gel was probed
with sera from mice immunized with pcDNA3.1-VAH or pcDNA3.1-TPX vaccine with a
dilution of 1:500.
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4.2.6 Tissue distribution of VAH / TPX plasmids in mice
To determine the distribution of plasmids of VAH and TPX in mice following i.m injection
and electroporation, two doses of plasmid were given at 2-week interval and necropsy was
M 1 2 3A
504 bp
M 1 2 3B
723bp
Fig. 4.8 Agarose gel electrophoresis of RT-PCR identification of gene expression in
COS7 cells in 0.5% TBE at 120 V for 40 minutes. Plasmids of VAH, and TPX were
transfected into COS7 cells in vitro, then cells were harvested and ultrasonicated, mRNA
were extracted to carry out the RT-PCR. (A). M: 100bp DNA ladder; 1, pcDNA-VAH; 2:








Fig. 4.9 Western blotting identification of proteins expression in COS7 cells under
reducing conditions on a 10-12% acrylamide gel at 30 V for 1 hour. Plasmids of VAH
and TPX were transfected into COS7 cells in vitro, then cells were harvested and
ultrasonicated, the supernatants were used to perform the Western blotting against the serum
from the VAH TPX DNA vaccinated mice. (A).Western blotting of VAH; 1, pcDNAVAH; 2,
pDECVAH; 3, pISOVAH; (B).Western blotting of TPX; 1, pcDNATPX; 2, pDECTPX; 3,
pISOTPX.
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performed at 28 days after the final immunization. Mouse tissues were collected from
muscle at the point of inoculation, spleen, liver and lung and prepared for mRNA extraction.
Reverse transcription PCR with VAH- and TPX-specific primers and T7/ BGH primers
(which locate the flank of inserted gene on the plasmids, implying the existence of plasmids
in tissues). The results showed that when using the specific antigen primers all genes were
expressed in muscle, spleen, liver and lung. In addition, all genes were detected in muscle,
spleen, liver and lung when the T7/ BGH plasmid specific primers were used (Table 4.1).
VAH appeared to be expressed more intensively in lung, spleen and liver than in in muscle
while TPX was expressed equally by muscle, spleen, lung and liver. The presence of the
carrier plasmids was detected more easily in spleen, lung and liver rather than in muscle. Fig
4.10 represents four examples for the tissue distribution in vivo. The overall tissue
distributions of VAH/ TPX vaccines are listed in (Table 4.1).
M 1 16
600bp









Fig.4.10 Agarose gel electrophoresis of examples of tissue distribution of VAH/TPX
plasmids in mice in COS7 cells in 0.5% TBE at 120 V for 40 minutes. All plasmids of
VAH and TPX were injected into muscle twice followed by the electroporation; 28 days
later, muscle, spleen, liver and lung were assayed to detect the gene distribution by specific
primers and T7/BGH primers by reverse transcriptional PCR. (A). pcDNAVAH distribution
in spleen and muscle detected by VAH-specific primers. (B). pDECVAH distribution in lung
detected by T7/BGH primers. (C). pcDNATPX distribution in muscle detected by
TPX-specific primers. (D). pDECTPX distribution in muscle and spleen detected by
T7/BGH primers. (E) VAH distribution in muscle detected by VAH-specific primers; 1-3:
VAH; 4-6: OVA ; 7-9: Naïve; (F) OVA distribution in muscle detected by OVA-specific
primers; 1-3: VAH; 4-6: OVA ; 7-9: Naïve; (G) TPX distribution in muscle detected by
TPX-specific primers; 1-3: TPX; 4-6: OVA ; 7-9: Naïve;(H) OVA distribution in muscle
detected by OVA-specific primers; 1-3: TPX; 4-6: OVA ; 7-9: Naïve;
M 1 2 3 4 5 6 7 8 9
532bp
E
M 1 2 3 4 5 6 7 8 9
603bp
F
M 1 2 3 4 5 6 7 8 9
751bp
G




Specific primers T7/BGH primersplasmid
Muscle spleen lung liver Muscle spleen lung liver
pcDNAVAH2 + ++ +++ ++ + + + +
pDECVAH2 + ++ +++ ++ + + + +
pISOVAH2 + ++ +++ ++ + + + +
pcDNATPX4 + + + + + +++ ++ ++
pDECTPX4 + + + + + +++ ++ ++
pISOTPX4 + + + + + +++ ++ ++
Naïve - - - - - - - -
4.2.7 Higher levels of Th1 and Th2 antibodies were evoked by
DEC-VAH compared to control
In order to compare the capability of DEC-VAH and pcDNA-VAH to provoke and enhance
immune responses, five experimental mouse groups were tested. These comprised: naïve,
primary infection, pempty, pcDNA-VAH and pcDNA-DEC-VAH. Naïve, primary infection
and pempty groups were the negative controls to pcDNA-VAH and DEC-VAH. On D0 and
D14, mice were given two doses of vaccine in addition of the plasmids encoding IL4, Flt3L
and MIP1αas adjuvants. The electroporation procedure was performed following each
injection. Mice were challenged with 40 L3s 35 days post the final immunization followed
by necropsy 60 days post challenge. Blood (for sera preparation and Mf counting), pleural
cavity lavage (for cell counting, cytospin, and cytokine detection) and lymph node (for cell
stimulation in vitro and cytokine detection) were collected.
ELISA analysis showed that high levels of IgG1 with a titer of over 100,000 (in Log10) were
induced by pcDNA-VAH and DEC-VAH. Significantly stronger IgG1 responses were
produced by both pcDNA-VAH and DEC-VAH in contrast to primary infection (p=0.04,
0.01, respectively, see Fig. 4.11 A). However, although there was no significant difference
“+”represents Expression positive; “-”represents no expression
Table. 4.1 Summary of tissue distribution of VAH and TPX vaccines in mice detected
by RT-PCR ( for detection of expressed sequence) and standard PCR (for detection
of existence of plasmids)
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between pcDNA-VAH and DEC-VAH groups, DEC-VAH induced more IgG1 than
pcDNA-VAH.
Levels of IgG2a were nearly equal to those of IgG1 (100,000) following vaccination with
both pcDNA-VAH and DEC-VAH. More importantly, pcDNA-VAH and DEC-VAH induced
significant higher IgG2a in contrast to primary infection (Fig. 4.11 B).
DEC-VAH induced higher levels of IgE compared to primary infection and pcDNA-VAH
groups but pcDNA-VAH failed to induce greater levels of IgE than controls (Fig. 4.11C).
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4.2.8 DEC-VAH induced significant quantities of IL 4, IL5 and IL13 in
pleural cavity fluid
To investigate the cytokine profile produced by DEC-VAH vaccination, a capture ELISA




















































































Fig. 4.11 DEC-VAH evoked higher levels of antibodies than VAH. Antibody levels of IgG
and IgE were compared between pcDNA3.1-VAH and DEC-VAH by indirect ELISA. All test
groups were co-administrated the plasmids encoding IL4, Flt3L and MIP1αas adjuvants.
Results are shown as titer of IgG and the mean of replicate samples (+/- S.E.M) for total IgE.
The Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to
analyze differences between groups. Differences were considered significant for p < 0.05; p








































Various cytokines including IL4, IL5, and IL13 were measured. Significantly higher IL4 was
induced by DEC-VAH vaccination in contrast to the primary infection (p=0.013) and pempty
(p=0.03) groups. Although the level of IL4 induced by pcDNA-VAH decreased compared to
DEC-VAH, it was still stronger than the controls (Fig. 4.11 A). For IL5, the same trend as
IL4 was seen and a significant difference (p=0.04) between DEC-VAH and primary infection
but not pempty group was demonstrated (Fig. 4.11 B). The IL13 expression profile was also
similar to IL4 and IL5, with significantly higher production by DEC-VAH than primary








































































































Fig.4.11. DEC-VAH induced significant quantities of IL 4, IL5 and IL13 in the
pleural cavity fluid. Supernatants of pleural cavity lavage were harvested and the level
of various cytokines (IL4, IL5, IL13) were measured by sandwich ELISA-(see methods
and materials). Results are shown as the mean of replicate samples. Kruskal –Wallis and
Mann-Whitney tests were used as statistical methods. Differences were considered
significant for p < 0.05; p values were not reported otherwise. 5 mice were tested in
each group.
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4.2.9 Vaccination with DEC-VAH resulted in decreased levels of IFN in
the pleural cavity and decreased IL10 production by lymph nodes
The Th1 cytokine IFN and Treg/ Th2 cytokine IL10 were also measured to assess the
cellular immune effect of pDEC-VAH vaccination. The production of IFN displayed a
decreased trend. Both pcDNA-VAH and DEC-VAH induced quite low levels of IFN with
the lowest after DEC-VAH vaccination. However, primary infection produced the most IFN
(Fig.4.12 A). Both pcDNA-VAH and DEC-VAH failed to produce IL10 in the pleural cavity
lavage. However, in lymph node culture, significantly lower IL10 was induced by DEC-VAH




































































Fig.4.12. Vaccination with DEC-VAH resulted in reduced IFN in the pleural
cavity and decreased IL10 in lymph node culture. Supernatants of pleural cavity
lavage and lymph node culture were harvested and the levels of IFNγand IL10 were
measured by capture ELISA-(see methods and materials). The Kruskal-Wallis test
followed by Dunn's test for multiple comparisons were used to analyze differences
between groups. Differences were considered significant for p < 0.05; p values were not
reported otherwise. Results are shown as the mean of replicate samples (+/- S.E.M). 5
mice were tested in each group.
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4.2.10 Increased Th2 cytokines and IFN were induced with stimulation
of Ls-Ag in vitro by DEC-VAH immunization
Cytokine profiles in supernatants of lymph node cell culture following stimulation with
Ls-Ag were measured. Cytokines in medium were measured as background controls. Results
showed that in medium, IL4 production after vaccination with VAH was higher than after
immunization with DEC-VAH and controls. In contrast, the level of IL5 induced by
vaccination with VAH decreased compared to immunization with DEC-VAH. However, IL13
and IFN were poorly produced by the vaccinations. In contrast, cytokines in supernatants of
lymph node culture following stimulation with Ls-Ag showed that IL4 production in
response to Ls-Ag decreased in the VAH group compared to in mice immunized against
DEC-VAH, but the quantity decreased when compared to that in medium. The level of IL5
showed similar trends to that in medium but quantities in both groups of VAH and
DEC-VAH were reduced. Levels of IL13 in both groups of VAH and DEC-VAH increased
compared that in medium. There was no increase in production of IFN in both groups of
VAH and DEC-VAH compared to that in medium, although the levels of IFN increased a














































































































































































Fig. 4.13 Increased Th2 cytokines and IFN were induced by DEC-VAH vaccination with
stimulation of Ls-Ag in vitro. Supernatants of lymph node cell cultures were harvested 24 hours
post stimulation with L. sigmodontis secretary antigen. The level of IL4, IL5, IL13 and IFN were
measured by sandwich ELISA- (see methods and materials). Results are shown as the mean of
replicate samples (+/- S.E.M). The Kruskal-Wallis test followed by Dunn's test for multiple
comparisons were used to analyze differences between groups. Differences were considered





































































































4.2.11 Elevated numbers of eosinophils, but not macrophages and
neutrophils, were detected following vaccination with DEC-VAH
Numbers and types of cells from pleural cavity were recorded following concentration using
a cytospin assay. The numbers of all cells recovered from the pleural cavity following a
primary infection, or vaccination with the carrier plasmid, or recombinant vaccines, were
similar but all were elevated compared to naïve controls. Eosinophil numbers in all
experimental groups were higher than measured in the naïve control group. Mice immunized
with pcDNA-VAH and DEC-VAH had the highest number of eosinophils but these levels
were not significantly different from those recorded for the primary infection and control
group immunized with the carrier plasmid. A similar situation was seen with respect to
neutrophil numbers.
In the case of macrophages, again, the numbers in all experimental groups were higher than
naïve controls but in this case those mice immunized with pcDNA-VAH or DEC-VAH had
lower numbers than seen in the primary infection or the group immunized with the carrier
















































































































































Total cells in PCL
Fig. 4.14 Elevated numbers of eosinophils, but not macrophages nor neutrophils, were
induced by DEC-VAH vaccination. Total cell numbers were determined using the CASY
model TT cell counter system. Eosinophil, neutrophil and macrophage numbers were
determined following concentration by cytospin and enumerated by microscopy on fixed
slides (300 cells, at minimum on each slide were counted). 5 mice were tested in each group.
The Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to
analyze differences between groups. Differences were considered significant for p < 0.05; p
values were not reported otherwise.
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4.2.12 Vaccination with DEC-VAH resulted in reduced worm burdens
To assess the protection elicited by the DEC-VAH vaccination, worms in the pleural cavity
and Mf in blood were counted. Each mouse had been challenged with 40 L3s. Protection was
recorded as a reduction in worm numbers in test animals compared to those in the control
groups. As presented in Fig.4.15. A, the number of worms recovered from DEC-VAH
immunization decreased when compared to that of primary infection group, although similar
number of worms was recovered from pcDNA-VAH group. As far as the number of Mf
recovered in the blood was concerned, a low level of recovery was displayed in all tested
groups except the pempty group in which only one mouse carried a high microfilaraemia

















































































Fig. 4.15. Vaccination with DEC-VAH resulted in reduced worm burden. Necropsy was
performed 60 day post challenge, pleural cavity lavage was collected and worms were fixed
with 70% hot ethanol; 30 l blood were added into 270 l FACS lysing solution then
microfilariae were counted under microscope as well as adult worms. Results are shown as
the mean of replicate samples (+/- S.E.M). 5 mice were tested in each group. Mann-Whitney
test was used as a statistical method. Differences were considered significant for p < 0.05; p
values were not reported otherwise.
- 142 -
4.2.13 Th2-dominant antibodies were produced by DEC-TPX
vaccination
To compare the ability of DEC-TPX and pcDNA-TPX to evoke and enhance the immune
responses, six groups of mice were investigated: naïve, primary infection, pempty,
pISO-TPX, pcDNA-TPX and DEC-TPX. Naïve, primary infection pempty and pISO-TPX
were used as negative controls to pcDNA-TPX and DEC-TPX. Mice were immunized twice
on D0 and D14 with DNA vaccine candidates together with plasmids encoding IL4, Flt3L
and MIP1 as adjuvants. Electroporation was performed at the site of inoculation following
each injection. Mice were challenged with 25 L3s on D28 after the final immunization and
the necropsy was carried out 60 days post challenge. Blood (for sera preparation and Mf
counting), pleural cavity lavage (for cell counting, cytospin and cytokine detection) and
lymph node (for cell stimulation in vitro and cytokine detection) were collected.
The levels of IgG1 induced by pcDNA-TPX and DEC-TPX were higher than naïve control.
However, the DEC-TPX showed a stronger ability to enhance IgG1 production compared to
pcDNA-TPX which induced only half the level of IgG1 of DEC-TPX (Fig.4.16 A).
As far as IgG2a was concerned, it was induced by DEC-TPX but not by pcDNA-TPX.
However, IgG2a levels induced by DEC-TPX were lower than those induced by pISO-TPX
and pempty (Fig.4.16 B).
For total IgE level, there was an upward trend among groups as shown in Fig.4.16 C. Both
pcDNA-TPX and DEC-TPX induced greater levels of total IgE than controls, and DEC-VAH
group induced significant increase of total IgE in contrast to the primary infection group














































































Fig.4.16. Th2-dominant antibodies were produced by DEC-TPX vaccination. Antibody
levels of IgG and IgE were compared among pDEC-TPX and the pcDNA-TPX by indirect
ELISA coated with recombinant TPX protein (see methods and materials). All test groups
were immunized with the adjuvants IL4, Flt3L and MIP1α.Results are shown as titer of IgG
and the mean of replicate samples (+/- S.E.M) for total IgE. Kruskal-Wallis and
Mann-Whitney tests were used as statistical methods. 5 mice were tested in each group.







































4.2.14 IL5 and IL13 rather than IL4 in the pleural cavity fluid were
enhanced by DEC-TPX immunization
To assess the impact of DEC-TPX vaccination on the production of cytokines, the cytokines
in the pleural cavity were detected by capture ELISA. In the pleural cavity, an up-regulation
of IL5 and IL13 was demonstrated in mice immunized with DEC-TPX in contrast to
pcDNA-TPX. IL4 was undetectable when immunized with DEC-TPX (only one mouse


















































































C IL4 in PCL
Fig. 4.17 IL5 and IL13 rather than IL4 were enhanced by DEC-TPX immunization.
Supernatants of the pleural cavity lavage were harvested and the levels of various cytokines
(IL5, IL13 and IL4) we re measured by capture ELISA- (see methods and materials). Results are
shown as the mean of replicate samples (+/- S.E.M). 5 mice were tested in each group. . The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyze







































4.2.15 Increased IFN in the pleural cavity fluid was induced by TPX
DNA vaccination
The level of IFN was measured by the capture ELISA to evaluate the Th1 cellular immune
effect of TPX DNA vaccination. In the pleural cavity lavage, increased levels of IFN were
induced by DEC-TPX compared to the pcDNA-TPX group but all were elevated compared
with control groups including the primary infection. The expression of IFN was sharply
increased on DEC-TPX with comparison to pempty (p=0.08) and the primary infection
group (p=0.016) (Fig. 4.18).
4.2.16 Levels of IL10 were no difference between primary infections and
mice vaccinated with DEC-TPX
The level of IL10 was measured by capture ELISA to evaluate the Th2/Treg cellular immune








































Fig. 4.18 Increased IFN in the pleural cavity fluid was induced by TPX DNA
vaccination. Supernatants of pleural cavity lavage were harvested and the level of IFNγ
was measured by sandwich ELISA- (see methods and materials). Results are shown as the
mean of replicate samples (+/- S.E.M). The Kruskal-Wallis test followed by Dunn's test
for multiple comparisons were used to analyze differences between groups. Differences
were considered significant for p < 0.05; p values were not reported otherwise. 5 mice per
group were tested.
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immunized with pcDNA-TPX and DEC-TPX were no significant difference (Fig.4.19).
4.2.17. Lymph nodes cells produced more IL5, IL13 and IFN than IL4
and IL10 following stimulation with Ls-Ag in vitro
Cytokine profiles of supernatant fluids collected from lymph node culture following
stimulation of Ls-Ag were measured. IL4 production was increased over control levels in all
test groups although there was no difference in the amount of cytokine induced by DEC-TPX,
TPX and pempty vaccinations. The induction of antigen-specific IL4 by the pempty group
was unexpected and this apparent abnormality has not been explained. When IL5 and IL13
levels were measured, again enhanced responses were seen in the experimental groups but in
this case, levels measured in mice immunized with DEC-TPX showed a considerable
increase over primary infection and naïve groups. However, statistical analysis revealed that






































Fig. 4.19 Levels of IL10 were no significant difference between primary infections and
mice vaccinated with DEC-TPX. Supernatants of pleural cavity lavage were harvested and
the level of IL10 was measured by sandwich ELISA- (see methods and materials). Results are
shown as the mean of replicate samples (+/- S.E.M). 5 mice were tested in each group. The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyze
differences between groups. Differences were considered significant for p < 0.05; p values
were not reported otherwise.
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The induction of antigen-specific IL10 levels by the DEC-TPX and TPX were lower than
that induced by pISO-TPX. Enhanced IFN responses were seen in experimental groups of
DEC-TPX compared to TPX, primary infection and pempty groups. However, stimulation of



































































































































































































































































































Fig. 4.20 IL5, IL13 and IFN rather than IL4 and IL10 were unregulated following
stimulation of Ls-Ag in vitro by DEC-TPX vaccination. Supernatants of lymph nodes
culture were harvested 24 hours post stimulation of L.sigmodontis secretory antigen. The level
of IL4, IL5, IL10, IL13 and IFN were measured by sandwich ELISA- (see methods and
materials). Results are shown as the mean of replicate samples (+/- S.E.M). 5 mice were tested
in each group. The Kruskal-Wallis test followed by Dunn's test for multiple comparisons were
used to analyze differences between groups. Differences were considered significant for p <













































































4.2.18 Lower numbers of eosinophils, macrophages and neutrophils were
recruited in the pleural cavity with DEC-TPX immunization
The types and numbers of cells recovered from the pleural cavity of experimental mice were
determined. Vaccination with pcDNA-TPX and DEC-TPX was associated with a decrease of
total cell recruitment compared to primary infection. Regarding number of eosinophils, the
number recovered from DEC-TPX immunized animals was significantly decreased when
compared to the primary infection control, and it was decreased when compared to the
pcDNA-TPX group. The neutrophils showed a different profile, with higher levels in
pcDNA-TPX immunized mice than in either DEC-TPX vaccinated mice or a primary
infection. The number of macrophages was significantly decreased in DEC-TPX vaccinated














































































D Total cells in PLC
Fig. 4.21 Eosinophil, macrophage and neutrophil numbers were reduced following
immunization with DEC-TPX when compared to levels recorded in a primary
infection. Total cell numbers were determined using the CASY model TT cell counter
system. Eosinophil, neutrophils and macrophage numbers were determined following
concentration by cytospin and enumerated by microscopy on fixed slides (300 cells at a
minimum on each slide were counted). 5 mice were tested in each group. The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to
analyze differences between groups. Differences were considered significant for p <






















































































4.2.19 Adult worm recovery was significantly decreased in mice
vaccinated with DEC-TPX when compared to a primary infection
To evaluate the efficacy of the DEC-TPX vaccination, the number of worms recovered from
the pleural cavity, and Mf in blood were determined on day 60 post challenge with 25 L3
larvae. Protection is defined as a reduction in worm number in test animals compared to
those in control groups. As presented in Fig.4.22, the number of worms recovered from
DEC-TPX vaccination was significantly lower than that recovered from mice with a primary
infection (p=0.0061).
However, there was no difference between the numbers of worms recovered from mice
vaccinated with DEC-TPX and those immunized with the pempty plasmid, and the
pISO-TPX control and TPX alone.
As for the number of Mf recovered in the blood, there was an apparent reduction in numbers
following vaccination with pcDNA-TPX and DEC-TPX, and DEC-TPX vaccination resulted
in a statistically significant reduction of microfilariaemia.
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4.3 Discussion
4.3.1 Ls-VAH and Ls-TPX as candidates for a filarial DNA vaccine
VAH was originally described as an abundantly expressed transcript of the L3 stage of
filariae (B. malayi, Murray J et al., 2001). The present work with L. sigmodontis showed that
Ls-VAH is expressed by adult worms. Moreover, works by others (Schallig HD, van
Leeuwen MA, 1997; Ghosh K et al., 1996; Sen L et al., 2000) have shown that mice can be
protected from challenge infection with other parasitic nematodes by immunization with a
recombinant VAH protein. For this reason, this molecule was chosen as a candidate for an
experimental DNA vaccine.
Fig.4.22. Adult worm recovery was significantly decreased in mice vaccinated with
DEC-TPX when compared to a primary infection. Necropsy was performed 60 day post
challenge, pleural cavity lavage was collected and worms were fixed with 70% hot ethanol;
30l blood were added into 270l FACS lysing solution then microfilariae were counted
under microscope as well as the adult worms. The Mann-Whitney test was used as statistical
method. P<0.05 represents a significant difference. Results are shown as the mean of




























































































In the case of Ls-TPX, the presented data revealed that it is expressed in the adult stage,
although precisely how much is produced is not yet known. Interestingly, work with
Ov-TPX2, suggested that expression of the gene declined with age and might reflect the
decline in growth, basal metabolic rate and embryogenesis in adult worms (Karam M et al.,
1987; Strote G et al., 1993). This may reflect the relative invulnerability of mature adults to
immune attacks. TPX may be considered as primarily a housekeeping antioxidant and has
been adapted to play a role in defense against the host immune response by protecting the
parasites from damage by host-generated oxidative stress. For this reason, this molecule is
considered a vaccine candidate.
4.3.2 Immunization with Ls-VAH and Ls-TPX induces a predominant
antibody response
Human studies by Anand SB et al (2007) showed that the predominant antibody response of
EN individuals against W. bancrofti-VAH was of the IgG1 and IgG2 isotypes with IgG3
being expressed at a lower level. However in infected individuals (Mf and chronic patients)
this order was reversed with IgG3 antibodies being the predominant response followed by
IgG2 and IgG1 isotypes. These observations were different with the previously reported
isotype profiles seen with either Bm-VAH or Ov-VAH (Murray J et al., 2001; MacDonald
AJ et al., 2004) in which the most predominant isotype in protective individuals were IgG3
followed by IgG4 with very little IgG1 or IgG2 isotype.
Vaccination of unexposed adult volunteers with recombinant Ancylostoma secreted protein-2
(Na-ASP-2), a homologue of VAH, resulted in a predominant IgG1 response followed by
IgG4 and IgE. However, no IgG2a or IgG3 antibodies were produced (Bethonya JM et al.,
2008).
These various observations suggest a strong Th2 response following natural infection and
vaccination. The results presented with respect to L. sigmodontis showed the same trend,
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although Ls-TPX stimulated a predominant IgG1 and IgE response, while Ls-VAH also
induced IgG2a indicating a Th1 component in the response.
4.3.3 Vaccination with Ls-VAH not Ls-TPX induces a Th2-bias in
cytokine responses
One of the aims of present study was to enhance the Th2-biased cytokines because of the
association with the reduction in the number of worms recovered. Presented data showed
DEC-VAH immunization significantly improved the expression of IL4, IL5 and IL13 in the
pleural cavity 60 days post the L. sigmodontis challenge. DEC-TPX vaccination induced a
similar trend of cytokines, as despite of the lack of IL4 production for DEC-TPX vaccination,
IL5 and IL13 were much higher than controls but the IFN was also significant higher than
TPX. These findings are important for present DNA vaccines because of the high similarities
with responses to irradiated L3 vaccinations. This is important because irradiated L3
vaccines would not be acceptable for human use and DNA vaccines may provide an
acceptable alternative.
4.3.4 IL10 should be taken into consideration when develop a DNA
vaccine
One of the most important developments in the field of filarial immunity has been the
recognition of regulatory networks in which Treg cells and IL10 play a predominant role. In
humans, it has been shown that reduced levels of IL10 can, in part, explain the different
clinical and parasitological manifestation of filarial infections (Specht S et al, 2010; Simons
JE et al, 2010). This indicates that very careful attention should be paid to the production of
IL10 by a vaccine: A low level of IL10 induction following vaccination may help to increase
the protective response because of the lack of suppression associated with IL10.
Presented data showed that levels of IL10 were decreased in DEC-VAH vaccination with a
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significant decrease following immunization with DEC-VAH compared to primary infection
and pempty groups. This may be an indication that suppression induced by IL10 does not
impact the protective responses induced by DEC-VAH immunization, and provide an
explanation of enhanced immune responses with immunization of DEC-VAH. This
speculation is supported by result of undetectable IL10 in mice immunized with combination
vaccine (DEC-ADDLAT and DEC-CPImu, chapter 3), which eventually achieved a high
protection.
4.3.5 Factors associated with protective responses induced by single
DEC-VAH or DEC-TPX vaccination
Presented data showed that the number of worms recovered after DEC-VAH immunization
was lower than that of the primary infection group, while the number of worms recovered
after DEC-TPX vaccination was significantly lower than that of primary infection (p=0.011).
However, in the case of DEC-TPX vaccination, when the worm burden of mice immunized
in control DNA vaccines was measured, there was no difference between control and test
groups. This result must be investigated further. It should be remembered that the number of
worms recovered from immunized mice and the number of challenge L3 given are small.
This makes identification of statistical significantly differences very difficult. Much larger
experimental groups of mice must be used to overcome this problem.
A second consideration may be the complicated life cycle of filarial nematode. The
possibility must be considered that the effective vaccination may require one or more
antigens must be targeted to different life stages. To take VAH as an example, Bethony JM
et al ( 2008) found that vaccination with recombinant Na-ASP-2 (a homologue of VAH)
could not prevent L3 from reaching the gastrointestinal tract and developing into
blood-feeding adult worms.
Additionally, attention must be paid to a possible role for Th1 responses in protection. One
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of the major advantages of DNA vaccines is that they can induce Th1 as well as Th2
responses. Indeed, research in experimental parasite systems suggests a role of Th1 in
protective responses (Saeftel M et al., 2001; Turaga PS et al., 2000; Anand SB et al., 2007;
MacDonald AJ et al.,2004; Dabir P et al., 2006). This indicates that a Th1 response might be
important for VAH vaccination to induce protection. In W. bancrofti, the Wb-VAH primarily
induced a Th1 type response on EN individuals. Similar responses occurred to Bm-VAH-1.
In the case of DEC-VAH, it induced high levels of IgG2a and decreased IFN, which might
imply that for this VAH, Th1-biased responses might be more important than Th2 responses.
However, this speculation has not been investigated in the present work.
Although it is clear that protein vaccines can induce protection (Schallig HD et al., 1997;
Ghosh K et al., 1996; Sen L et al., 2000), it is difficult to conclude that protein vaccines are
better than DNA vaccines. Rather, it is still necessary to conduct detailed investigation of
both approaches. Nevertheless, the work presented with the L. sigmodontis model and
immunization with a combination DNA vaccine (chapter 3) did show a good protective
response.
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Chapter 5-Partial protection has been achieved by ADDALT,
CPImu and VAH or TPX cocktail vaccination
5.1 Introduction
DNA vaccine has been shown to be an effective way to produce protective immune
responses against a wide range of viral and bacterial pathogens (Chang SW et al., 1998;
Fynan EF et al., 1993; Lowrie DB et al., 1999; Strugnell RA et al., 1997) and more recently
in eukaryotes including malaria (Hill AV et al., 2010) and gastrointestinal parasites (Rothel
JS et al., 1997). However, the complex parasite life cycles, involving the stage-specific
antigens expession, numbers of different anatomical and immunological compartments in
their hosts, and the abilities of modulation of their host’s immune responses, suggest an
effective vaccine may necessarily comprise a number of different antigens.
The possibility of combining a number of plasmids in a cocktail vaccine could be very
attractive. This possibility has been explored by Zhang YB et al (2002) using a cocktail
DNA vaccine comprising 4 DNA plasmids which encode 4 different S. japonicum antigens,
Sj62, Sj28, Sj23 and Sj14-3-3, respectively. A significant cellular response with a high
production of IFN in splenocytes was induced by recombinant antigens stimulation in vitro
following three i.m injections of the cocktail DNA vaccine. Significant resistance (34-37 for
single DNA vaccine and 44-45% for cocktail vaccine, respectively) against S. japonicum
cercarial challenge has also been reported. Fachado A et al (2003) described a long-lasting
protection induced by a DNA cocktail immunization against a lethal challenge infection with
the virulent T. gondii RH strain, whereas low doses of single vaccine were not protective.
Finally, Anand SB et al (2008) evaluated the protective efficacy and cell-mediated immune
response a cocktail vaccine encoding Bm-ALT-2 and Bm-TPX in mice. Results showed that
mice treated with a cocktail vaccine induced 78% of cytotoxicity against B. malayi Mf, but
the single vaccine induced only 37%. Taken together, the combination of two or more
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antigens may be an effective vaccine development strategy to improve protection and
immunogenicity against filariasis.
The results presented in chapter 3 & 4 showed that co-vaccination with ADDALT and
CPImu (in association with single chain antibody DEC205 targeting to the surface receptor
DEC205 of DCs) can achieve significant reduction of worm and Mf burden, whereas the
immunization of ADDALT alone or CPImu alone could not induce protection. The other two
antigens, VAH and TPX, could induce Th2-biased immune responses with DEC205,
however they did not afford any protection. These results suggested an opportunity to test the
hypothesis that a combination of antigens/ plasmids in a single vaccine may potentiate
responses against individual components. In addition, the observation that the DEC205
antibody was crucial for stimulation of enhanced responses also indicated that the choice of
adjuvant will also be critical.
The work demonstrated below aims to induce high immunities with variable combinations of
ADDALT, CPImu, VAH and/ or TPX with adjuvants of IL4 or IL4 plus MIP1 and Flt3L.
5.2 Results
5.2.1 Bi- and Tri- rather than Tetra-vaccine induced higher production of
IgG1 compared to backbone plasmid
Four vaccines comprising DEC-ADDALT alone (designated Single-vaccine),
DEC-ADDALT plus DEC-CPImu (designated Bi-vaccine), DEC-ADDALT plus
DEC-CPImu plus DEC-VAH (designated Tri-vaccine), and DEC-ADDALT plus
DEC-CPImu plus DEC-VAH plus DEC-TPX (designated Tetra-vaccine) were compared to a
primary infection. As a control, a group of mice was also immunized with the carrier plasmid
(pempty) that did not contain any parasite gene. All mice were given the same total volume
and concentration of total DNA irrespective of whether they were immunized with a
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recombinant alone or with a plasmid encoding IL4 as adjuvant. Mice were given two
immunizations separated by two weeks and challenged with 25 L3s one month after the final
immunization. Necropsy was performed and sera, pleural cavity lavage, blood for Mf and
lymph nodes were harvested 60 days after challenge. As displayed in Fig. 5.1, the
Tri-vaccine stimulated the strongest Th2 response with the highest levels of IgG1 and IgE.
This together with the Bi-vaccine revealed that significant elevation of IgG1 levels over the
control groups. The Single-vaccine did however stimulate a stronger and statistically
significant IgG2a [Th1] response than pempty and primary infection. The apparent enhanced
Th2 biased response by Bi- and Tri-vaccines was however sharply reversed by the results
obtained with the Tetra-vaccine, which failed to induce any responses over and above those



























































































































































































































































Fig. 5.1 Antibody responses induced by cocktail vaccinations. Antibody levels of IgG
and IgE were compared between Single-, Bi-, Tri- and Tetra-vaccine by indirect ELISA.
All test groups were included adjuvants IL4. Results are shown as titer of IgG and the
mean of replicate samples (+/- S.E.M) for total IgE. Mann-Whitney test was used as
statistical method. Differences were considered significant for p < 0.05; p values were not
reported otherwise. 5 mice per group were tested.
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5.2.2 No significant difference on cytokine production by vaccinations
To determine the cellular responses provoked by cocktail vaccinations, the levels of cytokine
in the pleural cavity were measured by capture ELISA. As shown in Fig.5.2. D, slightly
higher IL13 was induced by Single- and Bi-vaccines compared to backbone control. An
increased level of IL13 was induced by Tri-vaccination in contrast to the Single- and
Bi-vaccines. Although a significant increase in IL13 was produced by Tri-vaccination when
compared to primary infection, there was no significant difference between Tri-, Bi-, and
Single-vaccine. Further, the Tetra-vaccine did not induce IL13 production. Although it was
possible to detect IL4, IL5 and IL10, there was no statistically significant difference between



































































































































































































































































































































































































































Fig.5.2 Cytokine production in pleural cavity lavage induced by cocktail vaccinations.
Supernatant of pleural cavity lavage were harvested and the levels of various cytokines (IL4,
IL5, IL13, IL10 and IFN) were measured by sandwich ELISA-(see methods and materials).
Results are shown as the mean of replicate samples. 5 mice per group were tested. . The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyze
differences between groups. Differences were considered significant for p < 0.05; p values
were not reported otherwise
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5.2.3 Significantly higher numbers of eosinophils were recruited in the
pleural cavity by Tri- and Tetra-vaccinations
To determine the numbers and types of cells recruited in the pleural cavity where adult
worms live, the pleural cavity was lavaged and cells recruited were counted via the cytospin
assay. Cell numbers were counted under a microscope. As shown in Fig. 5.3 A, compared to
pempty control, eosinophil numbers were significantly elevated by vaccination with Tri- and
Tetra-vaccines compared to the primary infection group, although the number in the
Tetra-vaccine group was lower than that in the Tri-vaccine group.
5.2.4 Cocktail vaccines induced significantly higher number of
macrophages but not neutrophils compared to the Single-vaccine
Since macrophages and neutrophils are primary defense against pathogens in the innate
immune system, the numbers of these cells were measured in vaccinated mice following L3
challenge. Neutrophil numbers were significantly increased in mice receiving the
Single-vaccine over and above those measured in control groups. Although apparent
numbers of neutrophils were also seen following immunization with Bi-, Tri- and
Tetra-vaccine, the numbers were lower than the Single-vaccine and there was no statistical
difference between these groups and controls (Fig. 5.3).
Interestingly, macrophage numbers in mice immunized with pempty and in the animals with
a primary infection were significantly higher than in naïve mice, Bi-, Tri- and Tetra-vaccine.






























































































































































































































































































































Total cells in PLC
C
Fig.5.3 Cells recruited in pleural cavity by cocktail vaccinations. Total cell numbers were
determined using the CASY model TT cell counter system. Eosinophil, neutrophils and
macrophage numbers were determined following concentration by cytospin and enumerated
by microscopy on fixed slides (300 cells at a minimum on each slide were counted). The
Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to analyse
differences between groups. Differences were considered significant for p < 0.05; p values
were not reported otherwise. 5 mice per group were tested
- 165 -
5.2.5 Significant reduction of worm burden but not microfilariae
numbers was achieved by the Tri-vaccine immunization
To evaluate the protective response elicited by the cocktail vaccinations, worms in the
pleural cavity and Mf in the blood stream were counted. A challenge of 25 L3s were given to
each mouse, and worms recovered at day 60 post challenge were counted. Protection was
recorded as a reduction in worm numbers in test animals compared to those in control groups.
As presented in Fig.5.4. A, the number of worms recovered from Tri-vaccine immunization
was significantly lower than that in the primary infection group, showing that protection was
obtained by the Tri-vaccine. However, the Tetra-vaccine did not provide protection. The
Single-and Bi-vaccine did not result in the reduction of worm burden. As for the recovery of
Mf, the number varied among groups and no significant differences were found between test
groups and controls.
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5.2.6 Both Tri-VAH and Tri-TPX induced protective responses
Results in chapter 3 together with the presented IgG in Fig 5.1 and Fig. 5.5, suggested that
ADDALT and CPImu may provide a core component of a vaccine where immunogenicity
and protective responses can be enhanced by addition of other antigens such as VAH and
TPX. To test this idea further, several experiments were designed to compare VAH and TPX
as vaccines in their own right and in company with ADDALT and CPImu. Six vaccination
strategies comprising of DEC-VAH alone, DEC-TPX alone, DEC-VAH plus
DEC-ADDALT plus DEC-CPImu (designated Tri-VAH), DEC-TPX plus DEC-ADDALT
plus DEC-CPImu (designated Tri-TPX), backbone plasmid (pempty) and primary infection



















































































Fig.5.4 A significant reduction in adult worm rather than microfilariae was achieved
by Tri-vaccine immunization. Necropsy was performed 60 day post challenge, pleural
cavity lavage was collected and worms were fixed with 70% hot ethanol; 30 μl blood was
added into 270μl FACS lysing solution then microfilariae were counted under a microscope
as well as adult worms. Mann-Whitney test was used as a statistical method. Differences

















































































amounts of DNA irrespective of the recombinant formulation. Mice were also inoculated
with plasmids encoding IL4, MIP1 and Flt3L as adjuvants. Mice were given two
immunizations separated by two weeks and challenged with 30 L3s one month after the final
immunization. Necropsy was performed and sera, pleural cavity lavage, blood for Mf and
lymph nodes were harvested 60 days after challenge.
As shown in Fig 5.5, the Tri-VAH vaccine again induced significantly higher levels of IgG1
when compared to control groups. Similarly, the Tri-TPX in which TPX replaced VAH, also
induced significantly levels of IgG1. However, VAH or TPX alone did not stimulate any
responses over and above controls.
Although levels of IgE and IgG2a were detected, there was no significant difference between
test groups and controls.
When IL4, IL5, IL13, IL10 and IFN were measured, no significant differences were
detected between test and control groups (Fig. 5.6). Nor there was any difference in
recruitment of eosinophils, neutrophils and macrophages in the pleural cavity in mice (Fig.
5.7).
However, as shown in Fig. 5.8, vaccination with Tri-VAH and Tri-TPX did result in
significant reductions in worm burden (55.7% and 41.6%, respectively). In addition,
vaccination with Tri-TPX also resulted in a significant reduction in Mf.
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Fig. 5. 5 Antibody responses induced by cocktail vaccinations. Antibody levels of IgG
and IgE were compared by indirect ELISA. All test groups included the adjuvants IL4, Flt3L
and MIP1. Results are shown as titer of IgG and the mean of replicate samples (+/- S.E.M)
for total IgE. The Kruskal-Wallis test followed by Dunn's test for multiple comparisons were
used to analyse differences between groups. Differences were considered significant for p <


































































































































































































































































































































































































































































































































































Fig.5.6 Cytokine production induced by cocktail vaccinations in the pleural cavity
lavage fluid. Supernatant of pleural cavity lavage were harvested and the level of various
cytokines (IL4, IL5, IL13, IL10 and IFN) were measured by capture ELISA- (see methods
and materials). Results are shown as the mean of replicate samples. 5 mice per group were
used. The Kruskal-Wallis test followed by Dunn's test for multiple comparisons were used to
analyse differences between groups. Differences were considered significant for p < 0.05; p






































































































































































































D Total cells in PCL
Fig.5.7 Cells recruited by cocktail vaccinations in the pleural cavity. Total cell
numbers were determined using the CASY model TT cell counter system. Eosinophil,
neutrophil and macrophage numbers were determined following concentration by cytospin
and enumerated by microscopy on fixed slides (300 cells at a minimum on each slide were
counted). 5 mice per group were used. The Kruskal-Wallis test followed by Dunn's test for
multiple comparisons were used to analyse differences between groups. Differences were

































































5.3.1 Cocktail vaccination is a promising approach for a more
efficacious vaccine against filarial infection
The goal of immunization is the induction of a protective immune response against the
pathogen. In the case of filarial nematodes, the complex life cycle presents a plurality of
antigenic epitopes whose expression can vary widely between each developmental stage. In
this situation, a broad immunity targeting several different antigens may be required to
produce a more efficacious vaccine. Presented data showed that partial protection can be



























































































































































Fig.5.8 Significant reduction of adult worm and microfilariae burden were achieved
by cocktail immunizations. Necropsy was performed 60 day post challenge, pleural
cavity lavage was collected and worms were fixed with 70% hot ethanol; 30 μl blood were
added into 270μl FACS lysing solution then microfilariae were counted under a
microscope as well as adult worms. Mann-Whitney test was used as a statistical method.
Differences were considered significant for p < 0.05; p values were not reported
otherwise.5 mice per group were used.
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(41.6%), while the single vaccines DEC-VAH and DEC-TPX obtained no protections,
suggesting cocktail vaccines might be the better strategy to stimulate the host immune
system to fight against filarial infection. This was also supported by the findings in chapter 3
in which the combination of DEC-ADDALT and DEC-CPImu induced stronger humoral and
cellular immune responses as well as a significantly lower worm burden than the single
DEC-ADDALT or DEC-CPImu vaccines. Similar reduction of worm burden has been
judged on vaccination with four S. japonicum antigens (Zhang Y et al, 2001). In this sense, it
appears that DNA cocktail can induce more efficacious protective responses than a single
recombinant plasmid, although present work needs more investigation.
5.3.2 Ratio and quantity of components in cocktail vaccine may impact
protective responses
DNA cocktail vaccines can induce stronger protective responses than a single vaccine
(Anand SB et al., 2008; Jongert E et al., 2007; Ahmed SB et al., 2009; Park SU et al., 2008;
Williamson ED et al., 2002). Presented data suggested that the immune responses and the
protection were associated with the relative amount of an individual component. Results
from the experiment that designed to compare the effects of Single-, Bi-, Tri- and
Tetra-vaccines showed that the best immune response and significant reduction of worm
burden were only observed with the Tri-vaccine but not the Single-, Bi- nor Tetra-vaccines.
The reason might be the lower amount of an individual ingredient in the Tetra-vaccine
compared with the others. The best ratio of individual components in a cocktail vaccine
might be 1:1:1. This was supported by a subsequent experiment in which the cocktail
vaccines were composed only by three individual ingredients (the ratio was 1:1:1) with the
same amount of each component. This immunization led to the protective responses with
Tri-TPX vaccination, in which the amount of TPX had been increased in contrast to the
previous lower amount of TPX in Tetra-vaccination.
However, what has not yet been tested is whether variation of the amount of individual
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components (ie. a dose response) may influence responses with respect to the determinant
responses and protective immunity. Second, the optimal quantity of individual component
must be investigated. Because, Fachado A et al (2003) showed that injection of 25 and 50 g
of DNA cocktail vaccine against T. gondii infection (containing 12.5 or 25 g per plasmid)
can induce both humoral and cellular immune responses which cannot be elicited by
equivalent doses of a single vaccine, respectively. Third, the quantity of adjuvant requires
more investigation. This experiment has used DEC205 to target DCs, but more conventional
adjuvants, such as alum, may also influence responses against the target antigens.
5.3.3 Cytokine production of cocktail vaccination
Presented data showed that levels of cytokines were rarely enhanced following cocktail
immunization, only increased IL13 (but not IL4, IL5 and IL10) was induced by the
Tri-vaccine (but not Bi- nor Tetra-vaccine). Interestingly, significantly increased IL13 was
found in mice immunized with a combined vaccine (chapter 3) which may be an indication
that individual components can be critical to cytokine production. Again, this relates to
formulation of the vaccine, but also important was the absence of induction of IL10 which
has the potential to modulate vaccine-mediated protective immunity (discussed in chapter 3,
4).
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Chapter 6- General discussion
6.1 Summary of experimental results
Four candidates (ADDALT, CPImu, VAH and TPX) as DNA vaccines against filarial
infection were tested in L. sigmodontis-BALB/c mouse model. ADDALT and CPImu were
engineered variants of ALT and CPI from which sequences encoding peptides that have
immunosuppressive functions have been removed. In an attempt to enhance protective
responses, the ability to target antigen presentation cell (DCs) was used. For this purpose,
combinations of plasmids encoding single chain antibody with specificity of DEC205 were
tested. Humoral responses (IgG1, IgG2a, IgE), cellular responses (cytokines IL4, IL5, IL10,
IL13 and IFN), cells recruited in pleural cavity (eosinophils, neutrophils, macrophages,
lymphocytes/ monocytes) and protection (adult worms and Mf recovery) have been
investigated to assess the effects of vaccinations.
Immunization with these individual plasmids enhanced production of IgG1 and IgE, Th2
cytokines and increased eosinophils while levels of IgG2a and IFN were decreased.
However, this bias towards a Th2 response did not result in any significant reduction of
worm burden or microfilariaemia.
When a cocktail vaccine comprising ADDALT plus CPImu was used, both humoral and
cellular responses were enhanced in contrast to the single antigen plasmid vaccines. More
important, vaccination resulted in a significant reduction of worm burden (82.3%).
Subsequently, cocktail vaccinations composed of ADDALT, CPImu and VAH or TPX had
demonstrated that Tri-VAH (ADDALT, CPImu and VAH) achieved 55.7% protection while
Tri-TPX (ADDALT, CPImu and TPX) only obtained 41.6% reduction of worm burden.
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6.2 Discussion
There are two ways of thinking about vaccination: 1), to mimic and enhance a response that
is known to be protective following a natural infection; and 2), to design a vaccine that
stimulates a protective response that is novel and not found following a natural infection, or
may reverse or circumvent a response that would normally interfere or block a protective
response.
The rationale design of a vaccine requires a thorough understanding of immune responses
evoked by natural infection, both with respect to protection and possible pathology (allergic
responses). In the case of filariae, the role of Th2 in protection against filarial infection was
demonstrated by experiments with iL3s (Le Goff L et al., 2000; Babayan SA et al., 2006;
Hübner MP et al., 2010). Nevertheless, the core strategy of present vaccines is to enhance
Th2-biased immune responses, which presents as an increased production of IgG1, IL4, IL5,
IL13, and decreased IgG2a and IFN, although there is another voice that the synergism of
both Th1 and Th2 responses might contribute to the successful protection (Saeftel M et al.,
2001). The experiments reported demonstrated significant reduction of worm burden
following vaccination with a cocktail of DEC-ADDALT and DEC-CPImu. This vaccine
induced high levels of IgG1, increased IL5 and IL13, the characteristic of a Th2 response.
Although allergy can associate with Th2 response, it was not demonstrated in present study.
The protection afforded by ADDALT plus CPImu cocktail was produced through use of
recombinant plasmid in DNA delivery system. It should be remembered that DNA vaccines
can also stimulate a Th1 response. In the present study, strong Th1 responses were not
demonstrated. At this stage, a contribution towards protection by Th1 responses cannot be
ruled out.
For a successful vaccine, the most important inspection item is the high protection against
infection. Current data indicated that the dual vaccine comprising ADDALT and CPImu
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candidates resulted in 82.3% reduction of worm burden and the cocktail vaccine comprising
ADDALT, CPImu and VAH achieved 55.7% protection against L.sigmodontis infection in
BALB/c mouse model, suggesting current DNA vaccine formulas were successfully tested
and might be a promising logical feasible way against filarial nematodes. For vaccine
development against filarial nematodes including onchocerciasis, W. bancrofti and B. malayi,
various strategies such as epitope, protein, radiation-attenuated L3, recombinant engineering
vaccines have been investigated previously, but none of them (except iL3, some can reach
100% protection) obtained as high protection as present DNA vaccination did so far. For
instance, two B epitopes from the antioxidant thioredoxin of B. malayi were synthesized to
produce a single peptide conjugate (PC1) vaccine and this vaccine can produce a
significantly high protection (75.14%) in experimental filariasis (Madhumathi J et al., 2010).
A mean protection of 75.86% was achieved by vaccination with Setaria cervi 175 kDa
collagenase against B. malayi infection in jirds (Pokharel DR et al., 2006). Immunization
with iL3 against L. sigmodontis in mice obtained a long-term protection (54-58%) against
the L3 larvae (Babayan SA et al., 2006). Roughly 61% protection was achieved against a B.
malayi when a recombinant GST from W. Bancroft was immunized in a jird model
(Veerapathran A et al., 2009) and a 50% reduction in larvae survival was obtained when
recombinant O. volvulus glycolytic enzyme fructose-1,6-bisphosphate aldolase was tested in
a mouse chamber model (McCarthy JS et al., 2002). However, present works have been
demonstrated to be profound with comparison to previous vaccines, even the same vaccine
type (DNA vaccine) against filarial nematodes. Immunization with Bm-ALT DNA vaccine in
jirds produced 57% protection (Thirugnanam S et al., 2007), while DNA immunization with
O. volvulus chitinase produced 53% protection against challenge infection with L3 larvae in
mice (Makepeace BL et al., 2009) and the cocktail vaccine comprising Bm-ALT2 and
Bm-TPX induced only 78% of cytotoxicity against B. malayi Mf. In this sense, current dual
vaccine might be the highest protection obtained by DNA vaccine against filarial nematodes
so far. One might argue that it is the different natures of candidates that results in the diverse
protections. General speaking, it is true that the characteristics of candidate antigens are
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essential for vaccine development, which is the main reason why scientists keep seeking
promising antigens to investigate the protective effects they may induce, however, it is not
the only factor that have to be considered when develop a successful vaccine. Many factors
are involved, for instance, the pre-dominant responses the vaccine should elicit, the main
killing cells that vaccine should promote, the adaptive adjuvant that vaccine should use, and
so on. Four antigens for vaccine development against filarial nematodes, ALT, CPI2, VAH
and TPX have been suggested to be promise as vaccines candidates. However, seldom DNA
vaccines comprising all these four antigens so far have been proved to be success, despite the
protein vaccine of Bm-ALT2 conferred about 75% protection (Thirugnanam S et al., 2007)
and Bm-TPX in jirds exhibited 69% protection (Vanam U et al., 2009). Present works
selected all these four antigens to develop cocktail vaccines instead of single vaccine, results
showed that high protection was obtained by dual vaccination, suggesting single antigen
might not be enough to induce strong protective immune responses. In this sense, the
individual nature of single antigen might not be the only important factor when developing
cocktail vaccine, the importance might be the co-reaction of each antigen in cocktail vaccine
regimen. Current works were carried out on the L. sigmodontis/ mouse model, not jirds,
gerbil nor cattle, which might be one of the reasons that high protection could be achieved. L.
sigmodontis/ mouse model provides an excellent model system to investigate the immune
mechanisms and vaccine development because of the advantage of allowing the observation
of the full life cycle of the parasite, including the development of L3 moulting to L4 and
adult worms and the Mf stage circulating in the bloodstream in susceptible BALB/c mice.
All these merits provided for filarial vaccine development by L. sigmodontis/ mouse model
cannot be offered by other models such as B. malayi/ mouse/ jird, O. volvulus/ cattle.
The core strategy to design present vaccines is to enhance Th2-biased immune responses
characterized by the increased IgG1, IL4, IL5, IL13 and decreased IgG2a as well as IFN
(see chapter 1 and 3). Although the synergism of both Th1 and Th2 responses might
contribute to the successful protection, the Th2-biased immune responses have been shown
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to be the pre-dominant responses donated to the reduction of worm burden by massive
researches (see section 1.2). Current experiments tried to increase Th2 responses by the
application of adjuvants of IL4, MIP1 and Flt3L, which had been proved to augment the
immune responses individually or synergistically by Simon Babayan in our previous works.
Results showed their combination assisted the enhancement of Th2 responses following
current vaccinations, which is why these adjuvants were used in all experiments in the same
amounts. Besides, a new exploration to test a new cytokine adjuvant IL33 had been
performed (data not shown) based on the observation that IL33 recombinant protein
increases the survival of eosinophils by foreign administration. However, the exploration
failed. Even so, more works are worth of investigating on IL33 as cytokine adjuvant in future
works.
Regardding dual vaccine comprising DECADDALT and DECCPImu, the main contributors
to the protective immunity were the high level of IgG1, increased IL5 and IL13 instead of
IgG2a and eosinophils. For the tri-vaccine, Tri-VAH and Tri-TPX, the protective immunity
attributed to high level of IgG1, increased IL5 or IL13 (not all Th2 cytokines), eosinophils
and decreased IgG2a as well as IFN. IgG1 is the antibody represents Th2 response in mouse
immune responses and it has been described relates to the ADCC mechanism and is vital to
the worm killing (discussed in chapter3), thus the high level of IgG1 in current experimental
mice, with no doubts, attributed to the high protective immunity. However, one might argue
the quite high level of IgG1, more than 105, might result in hyper-responses and increase the
possibility that exacerbates host health. It cannot be denied that the IgG1 level was high on
dual vaccine, but it was also high on controls, thus comparatively, the IgG1 on dual vaccine
was normal. Another explanation might be the difference of coating protein. When IgG in
single vaccine was measured, the relative recombinant protein was used, it only recognizes
specific protein. However, the whole raw proteins secreted from L. sigmodontis adults were
used when dual vaccine was measured considering the dual vaccine contains two different
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candidates which need to recognize two different proteins. In the whole raw proteins, there
were many other unknown proteins which might interact with antigens, consequently
promoted the level of IgG1, similar phenomenon had been demonstrated in cocktail vaccine
experiments (see chapter 5). However, the specific reasons have not been investigated yet.
Th2 cytokines have been described to be essential to worm or Mf killing (discussed in
chapter 3). However, present data from single vaccine of DECADDALT and DECCPImu in
chapter 3 indicated that despite IL4, IL5, and IL13 were significantly increased, the worm
burden was not decreased significantly. In surprise, in dual and cocktail vaccines, despite the
IL5 and/ or IL13 increased but not significantly, the worm burden was decreased
significantly, suggesting that one or two factors are not fully contributed to final protection,
the key might be the co-reaction among all factors. In addition, the decreased IFN was
produced in dual and cocktail vaccine accompanied with the increased Th2 cytokines,
(although it increased in single vaccine of TPX), suggesting the Th2-biased responses were
successfully induced as designed.
Another phenomenon worth mentioning is the cytokine productions, which were strong in
single and dual vaccine experiments, were quite week even none in cocktail vaccine
experiments. The reasons are unknown so far. However, besides the experimental errors and
long interval (longer than 3 months) between the second immunization and challenge, the
most possible factor might be the effects of mixture of antigens on host immune system, in
other words, the antigens interactions might result in the weak production of cytokines, but it
has not been investigated yet.
The success of the ADDALT and CPImu vaccination is clearly associated with the removal
of a sequence expressing a “regulatory”or “suppressive”domain, 46 aa domain in the case
of ADDALT and a single site mutation (Asn66 to Lys66) for CPImu, which abolish any
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stimulation of host modulatory responses. The combination of DECADDALT and
DECCPImu increased such power of properties than single immunization (chapter 3) and
resulted in the final high protection, suggesting the removed suppression of single antigen
might not enough to augment the immune responses and the combined deletion of inhibitions
might be the base for further vaccine development. Therefore, subsequent cocktail
vaccinations based on ADDALT and CPImu candidates had been shown that this
combination could assist other candidates such as VAH or TPX to elevate the immune
responses and eventually achieved protections. This had been supported by present single
vaccine of VAH or TPX, which could not achieve protection whereas strong Th2-biased
responses were induced respectively. One might be curious that whether the Treg responses
were involved in or not during the removal of immunosuppression of ALT and CPI2. It
cannot be denied that the key role of Tregs during filarial infection. The severe bias of the
balance among Tregs, Th1, Th2 and Th17 might lead to the disorders of immune system.
Although current candidates achieved the similar effects to the effects that Tregs being
moved, these candidates are not involved in the airway of Tregs, in other words, these
removals of suppression just circumvented the immune responses. If wants to depress the
Tregs, the way by targeting the key gene in its airway such as Eos or RUNX3 might work
(see 1. 2).
Present results illustrate the fine depth to which analysis of antigens must be taken to identify
epitopes that drive protection. This implies that a great deal more effort should be applied to
the exploration of the immunogenicity of pathogens. Fortunately, new knowledge that can
provide information on genomes and transcriptsomes of pathogens can now be used
combined with new methods in bioinformatics. It should be possible to identify new and
additional vaccine targets.
Present data exhibited that DECADDALT, which targets DEC205 receptor on the surface of
DCs by the encoded ADDALT gene on DEC205 mAb that can specific recognize DEC205
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receptor, elicited higher level of IgG1, Th2 cytokines IL4, IL5, IL13 as well as reduced
worm burden with comparison to the pcDNAADDALT, which backbone carried on DEC205
mAb hereby cannot recognize DEC205 receptor, suggesting that the immune responses had
been augmented by targeting to DCs via DEC205 receptor recognition. This is consistent to
the report from Nchinda G and colleagues (Nchinda G et al., 2010; Nchinda G et al., 2008)
that the DNA vaccine which encodes HIV gag p41-scFv DEC205 fusion protein generated
10-fold higher antibody and the mice were protected. In addition, subsequent findings on
DECCPImu, DECVAH and DECTPX had provided more supports. For instance,
DECCPImu induced remarkable higher IgG1, IL4, IL5, IL13 and increased IgE, IgG2a as
well as decreased IL10, IFN in contrast to pcDNACPImu, despite of the lack of protections.
However, the combination of DECADDALT and DECCPImu finally obtained significant
reduction of worm burden. Moreover, both DECVAH and DECTPX evoked stronger
immune responses than pcDNAVAH and pcDNATPX, respectively. All above results showed
consistence with previous report from Demangel C et al.(2005) that the use of scDEC205
could improve DNA vaccination. DCs are known to express several receptors with the
potential to enhance antigen uptake (Figdor CG et al., 2002), the DEC205 receptor has been
shown to deliver many different proteins for antigen presentation on both MHC I and II
products (Boscardin SB et al., 2006; Soares H et al., 2007). In contrast, other antigen uptake
receptors are preferentially expressed on different DC subsets with distinct
antigen-presenting properties. In addition, DEC205 targeting may has unique merits that the
subset of DCs targeted by DEC205 in mice is specialized to process antigens on MHC I.
Moreover, DEC205 targeting can mediate immunization of MHC II-restricted CD4+ helper T
cells (Bonifaz LC et al., 2004; Boscardin SB et al., 2006; Trumpfheller C et al., 2006). This
has been also proved by Nchinda G and colleagues (Nchinda G et al., 2010) that
DEC-targeted protein vaccine could enhance antigen specific CD4+ helper T cells. Regarding
to present works, despite the change of CD4+ helper cells post DNA vaccination was not
measured, the profiles of Th2 cytokines during this process might provide some clues which
might reflect the functions of CD4+ helper cells.
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The cells recruited in pleural cavity 60 days after the challenge infection have been analyzed,
as discussed in Chapter 3, macrophages and neutrophils were involved in the worm killing
correspond to the dual vaccination. These cells have been well-recorded to be responsible to
host defense against invading pathogens (see section 3.3). Likewise, numbers of neutrophils
recruited by the single vaccine of DECVAH, DECTPX and cocktail vaccine of Tri-vaccine
and Tri-VAH showed similar trends to dual vaccine, but they were not significantly increased
after vaccinations. However, numbers of macrophages in these experiments showed inverse
trends when compared to dual vaccine. Whether this opposite phenomenon impacted the
worm killing negatively has not been investigated. For now it cannot be answered. The
possibility might be the different natures of antigens and the co-reactions among different
antigens which may lead to inverse of bio-functions. However, whether these cells are
associated with the Mf killing has not been answered clearly in present experiments. Data
showed that all vaccines except the single vaccine of DECVAH and DECTPX resulted in the
significant reduction of Mf in the blood in mice, but analysis in present study showed no
correlation between these cells and the Mf killing. This is not consistent with studies about
onchocerciasis. In untreated generalized infection with onchocerciasis (GEO), macrophages,
eosinophils are correlated with the dead Mf (Büttner DW, Racz P, 1983) and the presence of
Mf increased the accumulation of eosinophils in nodules (Wildenburg G et al., 1996). Besides,
the neutrophils have also been reported to participate the immune attack to Mf
(Gutierrez-Pena EJ et al., 1996). Several in vitro researches have also demonstrated that the
eosinophils and neutrophils have the capability to mediate the Mf killing in infective
individuals (Greene BM et al.,1981; Johnson EH et al., 1994). Apart from immune cells, the
reasons associated with the Mf reduction in current study were assumed to be the
consequence of sub-lethal effects on reproduction of the adults (Babayan SA et al., 2005), but
the damage of embryogenesis in female worms has not been examed in current experiments.
However, experiments on onchocerciasis using bovine model indicated this effects might not
be simply a consequence of decreased adult female worms, because in the vaccinated cattle
the Mf numbers increase was associated with the female density (TchakoutéVL et al., 2006).
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This might be the result of antigenic cross-reactivity of antigens from distinct life cycle
stages base on the observation that successful anti-Mf immunity against O. lienalis was
induced by iL3 vaccination in mice (Townson S et al., 1984). However, all antigens used in
present study mainly derive from adult or L3 stages, even there is cross-reactivity from Mf,
that effects are presumed to be marginal. Therefore, the specific answers have to be made
after the further investigated in future works.
In designing vaccines against filarial infection, it will be extremely important to remember
that pathology associated with filarial infection is also a Th2 driven hypersensitivity (King
CL et al., 1993; Maizels RM et al., 1995) in which IgE may play a critical role. The
ADDALT plus CPImu cocktail vaccine induced production of IgE over and above controls.
However, no evidence of hypersensitivity was detected. While this is said, the L. sigmodontis
BALB/c mouse model is probably not appropriate, as even in heavy infection, pathology is
not observed. To answer questions about the possibility of CPImu and ALT being associated
with hypersensitivity reactions, it will be useful to test reactivity of sera collected from
human presenting with or without such responses. At an experimental level, the ability of
these antigens to evoke specific anaphylactic (passive) responses in rats may be considered.
Taking the DNA vaccine strategy further, the biological differences of filarial nematodes and
their hosts have to be considered more seriously. Attempts to circumvent the
immunosuppression caused by the molecules secreted or derived from parasites during their
development in hosts have been tried in present works (chapter3, by deleting the acid domain
of ALT and site direct mutation of CPI2). However, the immuno-modulation in host
immunity during chronic filarial infection has also been well documented. The hypothesis is
that the filariae-drived molecules attribute to the regulation of host immune response against
antigens which derived from filariae, resulting in the increase of parasite survival and
chronic infections (Maizels RM et al., 2001). To inhibit the Tregs in host immunity in vivo
might be a possible way to avoid such parasite-inducible regulation. This is based on the
findings that removal of regulatory T cell activity reversed the hyporesponsiveness and
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resulted in the filarial parasite clearance in vivo (Taylor MD, et al., 2005). Present work had
been designed to inhibit Tregs by suppressing the Eos gene which is associated with the
Tregs activity, results showed there were no impacts on suppression of Tregs in mice (data
not shown), however, it was only tested once and this regimen had not been optimized.
Besides, the success suppression of Tregs leads to the increase of Th2 cells has been
observed previously by other researchers (see 1.2). Thus it cannot be ignored simply.
Another biological feature noteworthy is the intracellular bacteria Wolbachia in filarial
nematodes. Abundant evidences have showed that this kind of bacterial impacts the growth,
biology and immunity of filarial nematodes and has already been proved in gene level by
genomic sequencing (Fenn K, et al., 2004). The molecules involved in the parasite- Wolbachia
interactions such as heme-dependent enzymes, which are essential for energy metabolism,
(Rao RU, et al., 2002) might be potential targets to develop novel DNA vaccines. The
comprehensive system biology approachs may provide a chance to define such molecules
and point the biochemical and physiological dependences that can be used to control
filariasis.
In formulating vaccines, it will be important to consider the commercial manufacture
processes including quality control and material resource requirements. For experimental
purposes, this work has used cocktails of recombinant plasmids. This allows investigation of
the contribution of individual components to the induction of immune responses. However,
for commercial production, a single construction [plasmid] would be preferred, because it is
a key issue for validation of process that evaluating the quality of the eventual plasmid
preparation in light of its purity, safety and potency (Schleef M, 1999). The more components
raise more chances to disorder the quality control process. Although the proof-of principle
researches of DNA vaccine have been demonstrated in various animal models, as an instance
of present dual vaccine and cocktail vaccine, to date, only few commercial DNA vaccines
are licensed. The barriers to commercialization include ease way of delivery, transfection
efficacy, cost of production and safety (BělákováJ et al., 2007). Although the adverse impacts
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on safety by plasmid in vivo are quite low, the irrational concerns about societal or ethical
aspects of DNA products may discourage firms to make the commercialized products. In
addition, the complicate judgment processes and multiple patents of a DNA vaccine may
increase the costs, consequently discourage companies to register a novel DNA vaccine.
Finally, an easier delivery system, which can increase the efficacy of DNA vaccine directly
in target cells, is not now available for livestock use, although such devices have been used
in mice in lab (Babiuk LA et al., 2000). Thus, measures must be taken to overcome such
barriers. Apart from the techniques required to enhance the efficacy and delivery methods
(see 1.3), intensive and extensive publicity might be essential to put forward, which makes
public understanding of the nature of DNA vaccine correctly and can be accepted rationally.
Also the government policy- makers might put more concerns on the managements of
patents and encouragement of firms, which may reduce the costs and processes that a DNA
vaccine can finally be brought into markets, consequently leads to the rebound of registration
for DNA vaccine products.
6.3 Future work
The results of this study are of significance because of the successful protection achieved by
vaccination with the ADDALT plus CPImu resulting in more than 80% reduction of worm
burden. It is a demonstration of the feasibility of use of a DNA vaccine against filarial
infection.
This present study demonstrates the great amenability of the L. sigmodontis-BALB/c mouse
model in development of a DNA vaccine against filarial infection. However, as is the case in
most helminth models of infection, difficulties and constraints arise with measurement and
assessment of worm burden. The use of just 25 or 30 infective larvae is a “challenge”for
delivery and statistical analysis. Recovery of adult worms and arrestment of Mf are also very
difficult to measure and irrespective of adult worm number which relates to the Mf numbers
vary. Despite of these limitations, protective responses have been demonstrated.
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The present study is only a preliminary stage of DNA vaccine against filarial infections.
Commercial use of the ADDALT and CPImu is a long way off. There are a number of
aspects that require investigation including: 1) Possible toxicity of the recombinant plasmid
at a local and systemic level; 2) The exact tissue distribution of vaccine, the storage life of
vaccine in host cells, the expression time and strength of vaccine. 3) The research of genetic
toxicity, mainly focus on the detection of whether the plasmid DNA insertion may result in
the integration into the host genome, and the consequences of DNA plasmid and its
expression products on the target or non-target organs. 4) In addition, it might be necessary
to determine whether the DNA vaccines can cause reproductive toxicity, which raises the
need to measure samples in both male and female mice.
Furthermore, the present work measured immune responses in mice that were only given one
challenge, but under field conditions, there will be multiple challenges, and it will be
necessary to investigate challenge that may occur under such antigenic pressure. This work
will be carried out using the O. ochengi-bovine model. Finally, it will be important to
improve and simplify the formulation of present vaccines and DNA adjuvants and indeed
consider whether use of recombinant protein of CPImu and ADDALT may not afford better
protection and less manifestation of pathology.
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Appendix
Appendix 1. Bacterial host strains and related plasmid vectors used in experiments
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Δ( ara–leu)7697 ΔlacX74 ΔphoA PvuII
phoR araD139 ahpC galE galK
rpsLF'[lac+ lacI q pro] gor522::Tn10







( ara–leu)7697 ΔlacX74 ΔphoA PvuII 
phoR araD139 ahpC galE galK rpL
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Appendix 2.1 Designed primers used in experiments














LsCPImu F: 5'-GAT AAT CAA CAG TCA AAA GAT GCG TAT
CAC CTT ATG CC-3'
R: 5'-GG CAT AAG GTG ATA CGC ATC TTT TGA




























Appendix 2.2. Designed primers used in experiments (continued)
























































Appendix 3. Plasmid constructions used in experiments. Double-digested insert fragment
was ligated into a backbone plasmid which was double-digested with the same enzymes, and
the ligation reaction was performed with T4 DNA ligase at 16°C overnight. CACC sequence is
a linker in backbone plasmid of pcDNA3.1 through which the inserted fragment carried it can be













pcDNA3.1 ALT ( with CACC)
ADDALT( with CACC)
CPI2 ( with CACC)
CPImu ( with CACC)
VAH ( with CACC)































NdeI and Xho I)







NdeI and Xho I)







NdeI and Xho I)







NdeI and Xho I)
ALT, CPI2, VAH, TPX Nde I and Xho I
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Appendix 4. Schematic of pSilencer 4.1-CMV neo vector. msEOS and msEOSsc (see
appendix 1) were inserted into pSilencer 4.1-CMV neo vector between Hind III and
BamHI to construct pSiEOS and pSiEOSSC plasmids.
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Appendix 5. Schematic of pET29c vector. In the multi-cloning site (MCS), XhoI and NotI
were chosen as enzymes and the fragment double digested by both XhoI and NotI was
insected in MCS. T7 tag is at the N terminus and His tag is at the C terminus. pET21b,
pET24a and pET30a have simlar structure in the MCS region and N/ C terminus to
pET29c.
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Appendix 6. Output of the total variance of the principal component assay.
Initial Eigenvalues Extraction Sums of
Squared Loadings
















1 6.306 20.342 20.342 6.306 20.342 20.342 4.930 15.904 15.904
2 4.343 14.010 34.351 4.343 14.010 34.351 4.239 13.675 29.579
3 3.703 11.947 46.298 3.703 11.947 46.298 3.671 11.843 41.422
4 3.163 10.204 56.502 3.163 10.204 56.502 3.156 10.182 51.604
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Appendix 7. Output of the rotated component matrix of the principal component
PC1 PC2 PC3 PC4
IgE 0.064 0.011 -0.162 -0.067
anti.worm.IgG1 0.029 0.305 -0.063 -0.076
anti.ALT.IgG1 0.177 -0.060 -0.362 0.171
anti.CPI.IgG1 0.173 -0.069 -0.366 0.187
anti.worm.IgG2a 0.050 0.019 0.038 -0.012
anti.ALT.IgG2a 0.171 0.149 -0.360 -0.144
anti.CPI.IgG2a 0.162 0.153 -0.330 -0.162
IL4.PL -0.031 -0.087 -0.119 -0.213
IL5.PL 0.055 0.126 0.255 -0.243
IL13.PL 0.061 0.170 0.143 -0.326
IFNgPL -0.066 -0.052 0.056 -0.241
IL4.M.LN 0.213 -0.151 0.040 0.319
IL4.LsAg.LN 0.200 -0.043 0.167 0.029
IL4.aCD3.LN 0.117 0.051 0.177 0.238
IL5.M.LN 0.306 -0.093 0.157 0.116
IL5.LsAg.LN 0.308 0.079 -0.012 -0.165
IL5.aCD3.LN 0.313 -0.025 0.105 -0.092
IL13.M.LN 0.231 -0.020 0.120 0.059
IL13.LsAg.LN 0.330 0.036 0.139 -0.189
IL13.aCD3.LN 0.321 -0.029 0.013 -0.102
IFNg.M.LN 0.230 -0.078 0.211 0.207
IFNg.LsAg.LN 0.074 0.011 0.199 -0.170
IFNg.aCD3.LN 0.157 -0.132 -0.164 0.244
EosNx 0.086 0.425 -0.032 0.083
NeuNx -0.041 0.399 0.049 0.162
MacNx 0.085 0.422 -0.108 0.068
LyMoNx -0.113 0.118 0.252 0.347
PleCNx 0.018 0.428 0.059 0.211
Prol.M 0.232 -0.057 -0.003 0.053
Prol.LsAg 0.184 -0.002 0.158 -0.108
Prol.aCD3 0.114 -0.103 -0.109 -0.059
